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ABSTRACT 
Sarah Claire Rogan: REMOTE CONTROL OF NEURONAL SIGNALING IN VIVO 
(Under the direction of Bryan L. Roth) 
 
A significant challenge for neuroscientists is to determine how both electrical 
and chemical signals affect the activity of cells and circuits and how the nervous 
system subsequently translates that activity into behavior. Remote, bidirectional 
manipulation of those signals with high spatiotemporal precision is an ideal approach 
to addressing that challenge. Recently, neuroscientists have developed a diverse set 
of tools that permit such experimental manipulation with varying degrees of spatial, 
temporal, and directional control. These tools use light, peptides, and small 
molecules to primarily activate ion channels and G protein-coupled receptors 
(GPCRs) that in turn activate or inhibit neuronal firing. By monitoring the 
electrophysiological, biochemical, and behavioral effects of such activation/inhibition, 
researchers can better understand the links between brain activity and behavior. 
The research in this thesis centers on using a class of designer GPCRs, 
termed Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), to 
remotely and non-invasively control the activity of particular neuronal populations. 
DREADDs are evolved muscarinic receptors that selectively respond to the 
otherwise inert compound clozapine-N-oxide (CNO) and not to their native ligand, 
acetylcholine. Using a chemical-genetic approach, I demonstrate that the Gq-
 iv 
coupled DREADD (hM3Dq), which is derived from the human muscarinic M3 
receptor, can be used to activate neuronal firing selectively in the cortex and 
hippocampus of mice expressing hM3Dq. The neuronal activation subsequently 
results in behavioral and electrophysiological changes. Then, I use those behavioral 
changes as a readout to examine the underlying neurocircuitry and discuss the 
findings in the context of psychosis. 
The tools for remote control of neuronal activity, including DREADDs, differ in 
the direction of their effect (activation/inhibition, hyperpolarization/depolarization), 
their onset and offset kinetics (milliseconds/minutes/hours), the degree of spatial 
resolution they afford, and their invasiveness. While none of these tools is perfect, 
they each have advantages and disadvantages, which I describe, and they are all 
still works-in-progress. I conclude with a discussion of the clinical and translational 
applications of these technologies and provide suggestions for improving upon the 
existing tools. 
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CHAPTER 1: TOOLS FOR REMOTE CONTROL OF NEURONAL SIGNALING 
 
 
*Portions of this chapter are adapted from Rogan and Roth, 2011. 
 
Over the past few decades, scientific understanding of neurobiology and of 
the links between brain function and behavior has increased exponentially. For 
example, we know now how light can be transduced from a photon into a chemical 
signal that the brain can interpret (Kristiansen, 2004; Sung and Chuang, 2010). We 
understand the specific cellular loss that contributes to Parkinson’s Disease 
(Przedborski, 2005). Additionally, we know how the cranial nerves and descending 
spinal tracts stimulate the neuromuscular junction to elicit muscle contraction and 
movement. Despite these advances, knowledge of how neuronal signals encode 
complex behaviors remains vague and incomplete. For example, addictive drugs 
induce dopamine release in the striatum, although the populations of cells – and the 
particular signaling pathways within those cells – responsible for drug seeking and 
reward are incompletely identified. The brains of psychotic patients, for instance, 
show evidence of decreased cortical inhibition, but how such lowering of inhibitory 
interneuron activity relates to the symptoms of schizophrenia is unknown. Also, we 
do not understand, for example, how and to what extent specific interneuronal 
populations (e.g., parvalbumin- or calcretin-expressing) might be involved in the 
pathogenesis of diseases such as schizophrenia. 
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Elucidating the cellular and molecular substrates of behavior remains a ‘grand 
challenge’ for neuroscientists and for the neuroscience field in general. Historically, 
neuroscientists have administered a variety of drugs to laboratory animals and have 
observed how those drugs have subsequently affected behavior. Thus, any 
conclusions regarding the links between drug action, drug targets, and behavioral 
outcomes were indirect and equivocal. Mouse genetic technology has permitted 
study of loss- or gain-of-function phenotypes, but does not allow for control of 
receptors or pathways over a range of activity levels, with finely tuned temporal 
resolution, or for the bidirectional or reversible control of receptor activity. To 
conclusively define the neuronal pathways and networks involved in normal 
behaviors – and by extension, abnormal behaviors – it would be useful to have a tool 
that enables the direct linkage of neuronal events (e.g., membrane hyper- or 
depolarization, action potential firing, neurotransmitter release), activation of a 
specific receptor, second-messenger-induced signaling, and a behavioral outcome. 
Additionally, such a tool should be suitable for use in vivo in awake, freely mobile 
animals. 
Recently, researchers have developed a variety of techniques that aim to 
achieve that goal, with varying degrees of success. From these approaches, two 
classes of technology have emerged at the forefront of tools for controlling neuronal 
signaling. First, several microbial light-gated receptors (opsins) can be functionally 
expressed in mammalian tissue and, in response to light, alter cell membrane 
potential to either hyperpolarize or depolarize neurons and thus control precisely the 
intensity, frequency, and pattern of neuronal firing. Individual opsins respond to 
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specific wavelengths of light so that bi-directional modulation of a single cell is 
feasible in an intact animal. Second, a class of designer GPCRs that selectively 
responds to small molecule ligands enables the manipulation of Gq, Gi, and Gs G 
protein signal transduction pathways. Receptors Activated Solely by Synthetic 
Ligand (RASSLs) and Designer Receptors Exclusively Activated by Designer Drug 
(DREADDs) constitute the first- and second-generations, respectively, of 
orthologous GPCR-ligand pairs [for review, see (Conklin et al., 2008; Pei et al., 
2008; Nichols and Roth, 2009; Dong et al., 2010a)]. In addition to these two 
approaches to manipulating neuronal signaling, several non-native or peptide 
receptors, such as the TRPV1 ligand-gated ion channel and the Drosophila 
allatostatin receptor (AlstR), can provide control over neuronal activity. Ideally, each 
of these tools should confer a high degree of spatial, temporal, and directional 
control over neuronal signaling – a goal they all achieve to varying degrees. 
 
1.1 Technical considerations of the tools 
 
Many technical challenges hinder the ability of researchers to manipulate 
neuronal signaling pathways. To precisely correlate a neuronal activity pattern with a 
resulting biochemical, cellular, or behavioral change, one must tightly control the 
location (e.g., subcellular compartment, cell type or brain region), the timing, and the 
direction (i.e., increasing or decreasing) of that activity. While such control is 
relatively simple in vitro in cultured cells, whole-animal studies in vivo introduce 
additional obstacles. Current methods of addressing these challenges are described 
here. 
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1.1.1 Transgenic systems and approaches to spatial control 
 Spatial control of neural activity, by definition, enables a researcher to 
selectively modulate a particular cell type (e.g., parvalbumin-expressing 
interneurons) or a particular anatomical brain region (e.g., hippocampal CA1 
pyramidal neurons). Each tool described in this chapter requires expression of an 
exogenous receptor, either for light (opsins) or for small molecules (RASSLs, 
DREADDs, TRPV1, etc.). Controlling either the location of receptor expression or 
the availability of their cognate ligands (i.e., photons or small molecules) confers the 
necessary spatial resolution for defining neuronal pathways. 
 To date, researchers have either developed transgenic mouse lines or have 
locally infused viruses with cell-type-specific promoters to achieve the necessary 
spatially regulated pattern of exogenous receptor expression (Figure 1.1). For both 
techniques, tissue-specific promoters convey a large degree of spatial specificity. 
For example, the parvalbumin, calcium/calmodulin kinase IIα (CaMKIIα), and glial 
fibrillary astrocytic (GFAP) promoters drive transgene expression in basket cell 
interneurons, forebrain pyramidal neurons, and astrocytes, respectively (Mayford et 
al., 1996; Hippenmeyer et al., 2005; Sweger et al., 2007). These promoters can 
drive transgene expression directly, as in the case of traditional transgenic mice, or 
indirectly through tet-on/off or Cre-lox systems. The indirect systems are 
advantageous because they can be inducible; the tet system has some advantages 
in that it is also reversible. In this system, a tissue-specific promoter drives 
expression of a transcription factor, either the tetracycline transactivator (tTA) or the 
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reverse tetracycline transactivator (rtTA) (Figure 1.1A, top). A tetracycline response 
element (TRE) promoter then drives expression of the transgene of interest (Figure 
1.1A, bottom). The tTA or rtTA transcription factor is required to initiate transcription 
at the TRE promoter, thus the tissue-specific promoter driving tTA or rtTA 
expression determines where TRE is active. The antibiotic tetracycline (tet) or its 
analog doxycycline (dox) regulates activity of tTA and rtTA. Tetracycline inhibits the 
former transcription factor to prevent transgene expression (tet-off; Figure 1.1A, left) 
while it activates the latter transcription factor to enable transgene expression (tet-
on; Figure 1.1A, right). Expression using the tet system is reversible, in that 
administering or removing tet/dox will turn expression on or off. In vivo, mice 
consume either food or water that contains dox to control the timing of receptor 
expression. This system is particularly useful when exogenous receptor expression 
per se induces pathology because the timing of dox administration determines the 
timing and duration of receptor expression. 
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Figure 1.1. Genetic approaches to achieving spatially regulated transgene 
expression 
In the tet-regulated expression system (A), a tissue specific-promoter drives 
expression of the tTA (tet-off, left panel) or rtTA (tet-on, right panel) transgene to 
produce the tTA or rtTA transcription factor, respectively, in a driver mouse line. That 
line is crossed to a responsive mouse line in which the TRE promoter drives 
expression of the exogenous transgene of interest. The tTA or rtTA transcription 
factor binds to the promoter to initiate transcription of the endogenous transgene. In 
the tet-off system, dox inhibits tTA binding to the TRE promoter. In the tet-on 
system, doxycycline is required for rtTA binding to the promoter. In the Cre-lox 
system (B), a tissue-specific promoter controls expression of Cre recombinase in a 
driver line. In the responsive line, loxP recognition sequences flank a stop sequence 
5’ of the exogenous transgene of interest. Cre recombinase excises the stop site to 
allow the ubiquitous Rosa26 promoter to drive transgene expression. For virally 
mediated recombination (C), virus is infused into the Cre driver line. The virus 
carries a plasmid with a doubly-floxed, inverted open reading frame. Cre mediates 
recombination at one of the two sets of recognition sites to cause inversion of the 
open reading frame and to allow the synapsin-1 promoter to drive transgene 
expression in neurons. The remaining lox sites are incompatible, thereby preventing 
re-inversion. 
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 The Cre-lox system functions in a similar manner, requiring two transgenes. A 
tissue-specific promoter controls expression of Cre recombinase, an enzyme from 
bacteriophage that recombines DNA at specific recognition sequences termed loxP 
sites (Figure 1.1B, top left). Typically, Cre recombinase will excise DNA that is 
‘flanked by loxP sites,’ or ‘floxed’. Most often, floxed-stop constructs are knocked-in 
via homologous recombination to a housekeeping locus such as Rosa26 (Figure 
1.1B, bottom left). In the presence of Cre, the stop signal is excised and the Rosa26 
promoter drives transgene expression (Figure 1.1B, right). This technique is cell-type 
specific because Cre-mediated recombination only occurs in cells expressing Cre, 
and only cells in which the tissue specific promoter is active are expressing Cre. This 
system is useful in that it is spatially regulated and inducible, but is not reversible. 
Once recombination occurs, the user has no control over the timing of transgene 
expression as the Rosa26 promoter will continue to drive expression of the 
transgene. 
Viral transgene delivery is advantageous in that it does not require the 
development of a novel transgenic mouse line, and thus it can be less time-
consuming. Virally-mediated gene delivery is an effective method of expressing 
exogenous genes in rats and even primates – species in which traditional transgenic 
approaches are unfeasible. Viruses can directly encode the transgene of interest 
downstream of a tissue specific promoter, or they can supply a component of the 
Cre-lox system. Recently, several groups have developed viral constructs that are 
now widely used for this purpose. Alternatively called flip-excision (FLEX) 
(Schnutgen et al., 2003; Atasoy et al., 2008) or doubly-floxed, inverted open reading 
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frame (DIO) (Cardin et al., 2009; Cardin et al., 2010) constructs, these viruses 
encode a transgene that is doubly floxed by variants of the canonical loxP site so 
that Cre does not excise the transgene but instead non-reversibly inverts it (Figure 
1.1C). The transgene is then cloned into the construct in a 3’ to 5’ orientation (Figure 
1.1C, bottom left), and Cre recombines the DNA so that the transgene is in a 5’ to 3’ 
orientation, and transcription and translation of the transgene can proceed (Figure 
1.1C, right). This viral construct is locally infused into particular brain regions of a 
Cre mouse driver line to ensure tissue-specific expression. This approach yields the 
same end result as the traditional Cre-lox double-transgenic approach, but does not 
require the development nor maintenance of novel transgenic lines, allows for 
temporal control over the recombination process, and provides additional spatial 
control as viral diffusion is limited so the localization of the viral infusion enhances 
the spatial resolution. 
 
1.1.2 Temporal and directional control 
In addition to a high degree of spatial resolution, temporal resolution and 
directional modulation of signaling are important characteristics of tools for remotely 
controlling neuronal signaling. Temporal control enables one to determine when a 
receptor or pathway is active or inactive, and for what duration. Temporal resolution 
can range from milliseconds (e.g., opsins) to minutes (e.g., TRPV1, DREADDs) to 
hours (e.g., DREADDs), and includes both “onset” kinetics (time between the 
experimental manipulation and the initiation of signaling) and “offset” kinetics (time 
between the initiation of signaling and the termination of signaling). Directional 
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control refers to the net effect of the tool on neuronal activity (i.e., activation versus 
inhibition); bi-directional modulation is ideal. Determining the effect of both turning on 
and turning off the same cell population would yield the most information regarding 
the role of that cell in a particular network or behavior.  
Temporal resolution is critical for directly linking activation of particular targets 
or cell types to subsequent molecular, cellular, electrophysiological, and behavioral 
outcomes. Here the term ‘temporal resolution’ describes the temporal characteristics 
of receptor activity – how long it takes for the experimenter to effect a change, and 
how long those changes last. Several techniques confer temporal control. Microbial 
opsins are photon receptors that respond rapidly (within milliseconds) to photons of 
a particular wavelength. While the duration of activity varies for each opsin, both the 
onset and offset kinetics are fast relative to other techniques, as described in detail 
below. On the other hand, DREADDs and RASSLs respond to small-molecule 
ligands, signal through G proteins, and induce responses that can last many hours 
(Alexander et al., 2009). The pharmacokinetic properties of the individual ligands 
determine how quickly neuronal signaling changes, but for systemically administered 
ligands, responses generally occur approximately 15 min after drug administration. 
Local administration (i.e., stereotactic infusion) of the ligand increases the temporal 
resolution of the techniques requiring small molecule ligands, but responses still 
occur on the order of minutes. Additional techniques such as using photoactivatable 
or caged ligands can yield a higher degree of spatial and temporal control, but that 
control does not enter the millisecond time range. 
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Finally, directional control over system activity is important. The techniques 
described herein elicit neuronal depolarization and hyperpolarization, which lead to 
neuronal firing and silencing. It is beneficial to bi-directionally modulate the same cell 
or population of cells in order to more thoroughly characterize the effects of 
activating particular pathways. Both designer GPCRs (through Gi versus Gq or Gs 
signaling partners) and opsins (through anion versus cation selectivity) can inhibit 
and activate neuronal firing. However, only some of these tools permit near-
simultaneous bi-directional manipulation of the same cells in vivo. 
 
1.1.3 In vivo considerations 
 Applications of these techniques in vivo require a few special considerations 
above and beyond those for a system in vitro. First, the complexity of the nervous 
system and its similarity to that of humans varies by species. Invertebrate models 
(e.g., Drosophila, Caenorhabditis elegans) are relatively simple and enable the 
complete dissection of particular signaling networks, but those networks do not 
necessarily translate to vertebrate nervous systems. In contrast, vertebrate models 
(e.g., mice, rats) have more in common with humans, and while it is much more 
complicated to map networks in vertebrate brains, understanding those networks is 
more likely to increase knowledge of the human nervous system. 
Second, genetic versatility varies by species according to the length of 
gestation and mating tendencies. The Drosophila, Caenorhabditis elegans (C. 
elegans), and Danio rerio (zebrafish) systems are highly conducive to genetic 
modulation. In fact, Zhu et al. (Zhu et al., 2009) recently adapted the tet on/off 
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system to zebrafish. Among the vertebrate models, mice afford the greatest degree 
of genetic manipulation as they have a short gestation, and transgenic, knock-in, 
and knock-out mice are now standard tools. To express exogenous genes in rats 
and primates, viral delivery methods are currently necessary. 
Third, the route, feasibility, and precision of local delivery of virus, light, and 
small molecule ligands differ across species. The larger the brain region, the easier 
it is to precisely target a particular population of cells. Thus, stereotaxic surgery is 
more precise in rats than in mice, for example. In Drosophila, the cuticle diffuses the 
light needed to activate the opsins, thereby introducing an additional technical 
difficulty. Aerosolized compounds are useful for Drosophila studies; for example, 
scented compounds are useful as attractive or aversive stimuli. In rodents, aversive 
and attractive stimuli are easily distinguishable in self-administration paradigms. 
Additionally, metabolic processes differ across species. For example, clozapine-N-
oxide (CNO), the ligand for DREADDs, undergoes extensive back-metabolism to 
clozapine in humans (Chang et al., 1998), but not in mice (Guettier et al., 2009). 
Thus, the particular animal model determines the ideal formulation of a ligand. 
Fourth, the invasiveness of the tools varies by technology. The optical 
approaches all require precise delivery of high-intensity light. In vertebrates, 
experimenters must surgically implant fiber-optic or other devices to deliver that light. 
On the other hand, the RASSL and DREADD ligands are systemically bioavailable, 
thus their delivery is less invasive than delivery of light. Moreover, non-invasive 
approaches are more conducive to facile studies on awake, freely-mobile animals, 
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which more reliably reflect native signaling in vivo. Thus, non-invasive approaches 
are optimal, especially when considering translating these techniques to humans. 
Finally, as these techniques require significant spatial resolution, visualization 
of the exogenous receptors is critical for verifying their localization. Fluorescent or 
epitope tags are particularly useful in vivo for the localization of transgene 
expression. Epitope tags such as hemaglutinnin (HA) tags are small and generally 
do not alter receptor expression, trafficking, or signaling, and antibodies against the 
epitopes are readily available. Fluorescent tags (directly fused to the receptor) are 
easier to detect and can localize receptors during live imaging, but these tags 
sometimes affect receptor trafficking and signaling; endoplasmic reticulum (ER) 
export sequences and signal peptides can improve trafficking (Zhao et al., 2008; 
Dong et al., 2010a; Gradinaru et al., 2010). Alternatively, internal ribosomal entry 
sequences (IRESs) enable expression of bicistronic constructs, so that the same 
cells express both the receptor and the fluorescent molecule as distinct proteins [for 
review, see (Martinez-Salas, 1999)]. This approach allows for facile identification of 
cells that express the transgene but does not inform on the level of receptor 
expression or the subcellular localization of that expression. Another disadvantage 
of using IRESs can be that expression of the gene downstream of the IRES is 
significantly less than expression of the upstream gene (Douin et al., 2004). While 
differences in expression are permissible when the downstream gene is merely a 
reporter, such differences become problematic when the activity of the downstream 
gene is important. For example, if one wishes to express proteins that induce 
opposite changes in membrane potential (e.g., channelrhodopsin-2 and 
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halorhodopsin, see below) and to compare their effects on neuronal activity, ideally 
they should express at equal levels (Han et al., 2009). Conveniently, foot-and-
mouth-disease virus and other picornaviridae express a short sequence of 18 
residues that promotes ribosomal skipping between a glycine and a proline residue, 
resulting in proportional translation of two separate peptides from a single mRNA 
molecule (Ryan et al., 1991; Ryan and Drew, 1994). Several groups have adapted 
this approach – variously termed a 2A sequence, self-cleaving peptide, or cis-acting 
hydrolase element – for expression of multiple transgenes, including distinct opsins 
(Tang et al., 2009; Zimmermann et al., 2009). 
Clearly, a variety of species-specific differences affect the utility of the tools 
for particular applications. Thus far, these techniques have been employed in vivo in 
Drosophila, C. elegans, zebrafish, mice, rats, and non-human primates.  
 
1.2 Early approaches to neuronal manipulation 
 
In one of the first attempts at ‘remote control’ of neuronal signaling, and, in 
fact, coining that phrase (Wisden et al., 2009), Zemelman et al. used photo-caged 
capsaicin and ATP to activate the TRPV1 vanilloid nociceptive receptor and the 
P2X2 purinergic receptor, respectively (Zemelman et al., 2003). Since then, several 
other groups have used TRPV1 (and less notably, P2X2) to manipulate neuronal 
events (see below). Additionally, neuroscientists have used caged ligands, 
dominant-negative presynaptic proteins, light-gated ionotropic glutamate receptors, 
and ligand-gated heterologous chloride channels, among others, to manipulate 
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neuronal activity. Here (see Table 1.1), these techniques and some of their 
advantages and shortcomings are described. 
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Table 1.1. Methods of activating and silencing neuronal activity 
 Tool Approach References 
ChARGe 
Consists of Drosophila Arrestin, Rhodopsin, 
and G protein; application of light activates 
rhodopsin and initiates a G protein signaling 
cascade that results in action potential firing; 
binding of arrestin to activated rhodopsin 
stops the signaling cascade; frequency and 
timing of action potential firing are 
inconsistent and unpredictable; not feasible 
for in vivo applications 
(Zemelman et al., 
2002) 
FMRF-
amide 
channel 
Phe-Met-Arg-Phe-amide (FMRFamide) -
gated sodium channel from Helix aspersa 
(HaFaNaC) is activated by FMRFamide; 
mammals express homologous acid-sensing 
ion channels (ASICs) but not the ligand 
FMRFamide; while FMRFamide activates 
HaFaNaC at lower concentrations than 
ASICs, extent of cross-reactivity is unknown, 
as is ability of endogenous mammalian 
amidated peptides to activate HaFaNaC 
(Schanuel et al., 2008) 
Caged 
glutamate 
Variety of caged glutamate compounds 
enable neuronal activation with fast kinetics 
and single-cell spatial resolution 
(Canepari et al., 2001; 
Matsuzaki et al., 2001; 
Nikolenko et al., 2007; 
Fino et al., 2009) 
A
ct
iv
at
io
n 
Light-gated 
glutamate 
receptor 
A photo-isomerizing glutamate molecule is 
covalently attached to the outer surface of 
the binding pocket of an ionotropic 
glutamate receptor; application of light 
causes isomerization, brings the glutamate 
into position in the binding pocket, and 
opens the cation-selective channel 
(Volgraf et al., 2006; 
Gorostiza et al., 2007; 
Szobota et al., 2007; 
Volgraf et al., 2007; 
Wang et al., 2007b) 
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Ivermectin-
gated 
chloride 
channel 
System relies on expression of a modified 
glutamate- and ivermectin-gated chloride 
channel from C. elegans, GluClαβ; point 
mutations reduce sensitivity to glutamate; 
slow onset (4 to 6 h) and time to peak (12 h) 
of silencing and prolonged recovery (4 days) 
with systemic administration; cells must 
express both α and β subunits (which allows 
for additional spatial resolution through 
intersectional expression strategies) 
(Li et al., 2002; Slimko 
et al., 2002; Slimko 
and Lester, 2003; 
Lerchner et al., 2007) 
 
Shibirets1 
Temperature-sensitive Drosophila dynamin 
mutant gene shibirets1; expression is induced 
by changes in temperature; expression 
causes reversible paralysis due to depletion 
of synaptic vesicles at nerve terminals; 
specific to Drosophila 
(Kitamoto, 2001; 
Kitamoto, 2002; 
Kasuya et al., 2009) 
Tetanus 
toxin light 
chain 
Tetanus toxin light chain TNT cleaves the 
synaptic vesicle protein 
VAMP2/synaptobrevin; TNT expression is 
inducible; slow recovery (14 days) occurs 
with VAMP2 resynthesis 
(Yamamoto et al., 
2003; Yu et al., 2004; 
Kobayashi et al., 
2008; Nakashiba et 
al., 2008) 
Kir2.1 
Strongly rectifying potassium channel; no 
cytotoxic potassium leak; channel is 
constitutively active so reversibility is only 
achieved through transcriptional control 
(Nitabach et al., 2002; 
Yu et al., 2004) 
Membrane-
tethered 
toxins 
Peptide neurotoxins specific for various ion 
channels can be tethered to the membrane 
to inactivate ion channels; only reversible 
through transcriptional regulation 
(Ibanez-Tallon et al., 
2004; Auer and 
Ibanez-Tallon, 2010; 
Auer et al., 2010; 
Sturzebecher et al., 
2010) 
5-HT1A 
8-OH-DPAT is a systemically administrable 
ligand that selectively activates the Gi-
coupled 5-HT1A receptor to activate GIRK 
and hyperpolarize neuronal membranes; 
requires 5-HT1A-/- background 
(Tsetsenis et al., 
2007) 
Si
le
nc
in
g 
GABAA-
Zolpidem 
Positive allosteric GABAA agonists bind 
benzodiazepine site at interface of α and γ2 
subunits; an F77I mutation of γ2 abolishes 
zolpidem binding; conditional expression of 
wild-type γ2 on a γ2F77I background enables 
selective neuronal silencing with zolpidem; 
the F77I mutation also abolishes binding of 
an inverse allosteric agonist, suggesting this 
same method could be used for neuronal 
activation 
(Cope et al., 2004; 
Ogris et al., 2004; 
Cope et al., 2005; 
Wulff et al., 2007; 
Wisden et al., 2009) 
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1.2.1 Tools for activation 
 The TRPV1 vanilloid receptor is a non-selective ligand-gated cation channel. 
Normally, TRPV1 is expressed in nociceptive (pain-sensing) neurons of the 
peripheral nervous system and causes membrane depolarization in the presence of 
its ligand, capsaicin (Caterina et al., 1997). Zemelman et al. first showed in cultured 
hippocampal neurons that they could use light to uncage a caged capsaicin 
derivative (4,5-dimethoxy-2-nitrobenzyl-capsaicin), thereby generating action 
potentials in a reliable and temporally precise manner. Depolarization occurred 
approximately 5 s after a 1-s light pulse, lasted for 2 to 3 s, and did not attenuate 
with multiple light pulses. No off-target effects of the caged ligand were evident 
(Zemelman et al., 2003). This demonstration was the first of precise experimental 
control over the on- and off- kinetics of neuronal activity. Subsequently, Lima et al. 
used TRPV1 and P2X2, along with their respective photocaged ligands, to control 
behavior and map neural circuits in Drosophila (Lima and Miesenbock, 2005). In an 
extreme example, they expressed P2X2 in a population of thoracic neurons, 
decapitated Drosophila, and successfully used light to make the headless bodies fly. 
The Ehlers group (Arenkiel et al., 2008) subsequently used TRPV1 to achieve 
remote control of neuronal signaling in vertebrates, although they did not photocage 
capsaicin. As the TRPV1 channel is not normally present in the mouse brain, and 
capsaicin is highly selective for it, this system provides high specificity. However, 
capsaicin activates peripheral pain receptors and is not blood-brain barrier-
permeable, so their approach required local infusion of capsaicin via an in-dwelling 
cannula. Using the Cre-lox system, Arenkiel et al. (Arenkiel et al., 2008) expressed 
 19 
TRPV1 throughout the brain using a nestin-Cre driver line. In acute slices, 
application of capsaicin triggered action potentials in TRPV1-expressing cells 
(identified by a bicistronic ECFP reporter). In live, anesthetized mice, the authors 
infused capsaicin directly into the dorsal cortex and recorded the resultant high-
frequency action potentials. The spiking activity was dose-dependent (EC50 500 nM) 
and lasted for several seconds. Finally, they infused 500 nM capsaicin into awake, 
freely-moving mice and elicited stereotypies during the fifth to fifteenth minutes after 
infusion. At that concentration, capsaicin had no damaging effects, but doses of 5 to 
10 µM were excitotoxic. 
Recently, another group compared TRPV1 with its family member TRPM8, a 
menthol-gated non-selective cation channel important for sensing temperature. 
Notably, Zemelman et al. had used TRPM8 in their initial description of remote 
control of neuronal activity (Zemelman et al., 2003). Crawford et al. (Crawford et al., 
2009) determined that TRPM8 generated similar depolarizing currents to TRPV1 but 
did not result in excitotoxicity. Additionally, TRPV1, but not TRPM8, expression 
altered baseline neurotransmission in the absence of agonist. Moreover, recent 
evidence had shown that TRPV1 is endogenously expressed in the central nervous 
system while TRPM8 is not, which raises the possibility of additional effects of 
capsaicin on neuronal firing independent of exogenous TRPV1 (Toth et al., 2005; 
Cristino et al., 2008; Gibson et al., 2008). Therefore, Crawford et al. reasoned that 
TRPM8 is probably a better tool than TRPV1 for activating neuronal activity. 
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1.2.2 Tools for Silencing 
More so than neuronal activation, neuronal silencing – and in particular, 
reversible silencing – has remained a challenge to neuroscientists. Knockout and 
lesion models, while in wide use, are both irreversible, and targeting particular cells 
is difficult or impossible with those approaches. Unsatisfied with the selectivity that 
the then-current generation of tools offered, Lechner et al. (Lechner et al., 2002) 
expressed in cultured mammalian neurons the Drosophila AlstR, which couples to 
Gi/o to modulate GIRK channel activity and silence neuronal activity (Birgul et al., 
1999). The AlstR ligand, allatostatin, is a short peptide that is a selective and highly 
potent agonist for the Drosophila receptor; additionally, the cognate ligands of 
related mammalian receptors (e.g., somatostatin and opioid receptors) are inactive 
at AlstR. Therefore, the AlstR-allatostatin system offers desirable two-way 
selectivity. Gosgnach et al. (Gosgnach et al., 2006) expressed AlstR in mice in V1 
motor neurons in an attempt to dissect the role of the central pattern generator in 
triggering locomotion. Activating AlstR-expressing neurons in acute spinal cord 
slices decreased neuronal excitability, while activating AlstR in an isolated, intact 
spinal cord lengthened the electrophysiological interval corresponding to the step-
cycle period – a finding that mimics the effects of developmental defects of V1 
neurons. In rats, ferrets, and monkeys expressing AlstR, local application of high-
nanomolar concentrations of allatostatin inhibited both spontaneous and evoked 
neuronal activity (Tan et al., 2006). Neuronal inhibition occurred within minutes of 
allatostatin application, and neurons usually recovered within minutes of washout 
with saline. Moreover, allatostatin repeatedly silenced neuronal activity without 
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desensitization. Additionally, expression and activation of AlstR in rat neurons that 
express glutamate and somatostatin in the preBötzinger Complex, a region of the 
ventrolateral medulla involved in respiratory drive, prevented respiratory movements 
and reduced breathing, suggesting that these somatostatin neurons are necessary 
for normal breathing rhythm (Tan et al., 2008). 
These effects of allatostatin were highly specific: even at concentrations 
several orders of magnitude above the effective dose, allatostatin had no effect on 
wild-type tissues. The AlstR-allatostatin system is thus selective, reversible, and 
potent. The disadvantages of this system are that allatostatin must be locally applied 
via invasive techniques; its ability to reach its target (through infusion and diffusion) 
might limit its activity; and the temporal control over its activity depends on the ease 
of washing in or washing out the ligand. As allatostatin is a small peptide, systemic 
administration in not feasible; it would likely undergo enzymatic degradation and 
would not cross the blood-brain barrier. 
Also in search of an inducible and reversible method of neuronal silencing, 
Karpova et al. (Karpova et al., 2005) developed Molecules for Inactivation of 
Synaptic Transmission (MISTs) that prevent neurotransmitter release and the 
subsequent spread of action potentials. These MISTs are modified synaptic proteins 
that disrupt the synaptic vesicle cycle when they form homo- or heterodimers in the 
presence of small-molecule ‘dimerizers.’ The authors fused synaptic proteins (i.e., 
VAMP2/synaptobrevin, synaptophysin) to FK506 binding protein (FKBP). In the 
presence of an FKBP ligand, the fusion protein dimerizes (chemical induction of 
dimerization) and sequesters the presynaptic proteins, thereby inhibiting normal 
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neurotransmitter release. In vitro, application of dimerizer compounds to neurons 
expressing MISTs elicited a rapid decrease (50 to 100%) in monosynaptic EPSPs; 
this inhibition was highly selective for neurons expressing MISTs. In vivo, Karpova et 
al. expressed MISTs in cerebellar Purkinje neurons and then injected dimerizer 
compounds into the lateral ventricles. They found that they could selectively disrupt 
performance in the rotarod task. The inhibition lasted up to 36 h after injection and 
was reversible. The half-life of the dimerizer compound in blood is approximately 5 
h, but the authors hypothesize that it remains longer when bound to FKBP. While 
MISTs are certainly an innovative approach to remote control of neuronal signaling, 
the temporal control is insufficient for many applications, and the blood-brain barrier 
permeability of the dimerizers is unknown. Whether MISTs affect cellular processes 
other than neurotransmitter release via ‘off-target’ actions is also unknown. 
 The approaches described herein have their advantages, but none of them 
permits non-invasive remote control or achieves millisecond-timescale resolution. 
Additionally, these systems do not enable bidirectional modulation. Therefore, two 
techniques have emerged in the quest for methods of experimental manipulation of 
neuronal signaling: microbial opsins and orthogonal GPCR-ligand pairs. The first 
technique provides exquisite temporal control while the second provides non-
invasive control. 
 
1.3 Optical Approaches 
 
 In 2003, researchers cloned channelrhodopsin-2 (ChR2), a cation channel 
structurally similar to vertebrate rhodopsin that opens to allow Na+ to flow into a cell 
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in response to blue light. Nagel et al. (Nagel et al., 2003) cloned ChR2 from the 
green alga Chlamydomonas reinhardtii and then demonstrated through functional 
expression, both in oocytes of Xenopus laevis and in mammalian cells, that ChR2 is 
a directly light-gated cation-selective ion channel that opens rapidly upon stimulation 
with light to allow cation flux. Neuroscientists readily appreciated the potential utility 
of ChR2 as a neurobiological tool: 1) photostimulation is a reliable and reproducible 
approach to induce neuronal spiking; 2) upon activation of ChR2, current flows 
within milliseconds; and 3) vertebrates already express the necessary cofactor, all-
trans retinal (ATR), that would enable the translation of this technology to in vivo 
applications (Li et al., 2005; Herlitze and Landmesser, 2007). Indeed, in vivo studies 
based on activation of ChR2 were quickly forthcoming (see Table 1.2). Researchers 
also recognized that ion pumps or channels that either depolarize or hyperpolarize 
neurons in response to wavelengths of light distinct from those that activate ChR2 
would have tremendous value as in vivo tools. Thus, several groups subsequently 
sought – and identified – rhodopsin-like proteins with those characteristics (Li et al., 
2005; Han and Boyden, 2007; Zhang et al., 2007b; Zhang et al., 2008) (Figure 1.2). 
The ‘optogenetic’ approach combines light-activated receptors, or ‘opsins,’ for 
temporal control with genetic approaches to spatial control and now constitutes an 
established technique for direct depolarization and hyperpolarization of neurons in 
vivo. 
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Figure 1.2.  Activation of optical tools by distinct wavelengths of light 
Spectrum depicts the distinct wavelengths and corresponding colors of light that 
maximally activate each of the various microbial opsins. Opsins labeled in black text 
depolarize neuronal membranes; those labeled in green hyperpolarize membranes; 
and those labeled in red couple to G protein. 
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1.3.1 Depolarizing opsins 
 Karl Deisseroth’s group published the first study that used ChR2 to alter 
neuronal firing. Boyden et al. (Boyden et al., 2005) used a lentiviral approach to 
express ChR2 in cultured rat hippocampal neurons. Importantly, the receptor 
trafficked to the cell membrane; expression was stable for several weeks; and 
expression did not alter baseline membrane potential or resistance. This last finding 
suggested that ChR2 does not have significant basal activity and is non-toxic to 
neurons. Illumination of the cultures with blue light (450 to 490 nm) induced large 
and rapid depolarizing currents, while illumination with longer wavelengths (490 to 
510 nm) induced much smaller currents. Only neurons expressing ChR2 responded 
to the light stimulus. Continuous illumination evoked a rapid and predictable initial 
spike, but thereafter no spiking pattern was evident. Pulsed light, however, evoked 
reliable spike trains. 
 Concurrently, Stefan Herlitze’s group used ChR2 and vertebrate rat rhodopsin 
4 (RO4) – a light-activated, Gi-coupled GPCR that therefore silences neuronal firing 
(see below) – to bi-directionally modulate the electrical activity of cultured 
hippocampal neurons and of intact embryonic chick spinal cords (Li et al., 2005). 
This study independently replicated the results of Deisseroth’s group, verifying that 
ChR2 rapidly and reliably depolarizes neurons and elicits action potentials. This 
study was also the first to demonstrate bi-directional control of neuronal firing with 
opsins. In particular, this study was important because it showed that light 
penetration through tissue does not interfere with opsin activation; light successfully 
activated opsins in intact chick embryos through a window in the eggshell.
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 Simultaneously, Nagel and colleagues also validated ChR2 as a tool for 
controlling cellular activity (Nagel et al., 2005). They expressed the channel in 
muscle cells of C. elegans, raised the animals on an ATR-containing diet, and 
demonstrated light-induced muscle cell contraction in the whole animal. The 
contractions caused the animals to shrink and to lay eggs, and muscles relaxed 
within 1 s of the light turning off. Importantly, photocurrents did not occur in animals 
raised without ATR. Next, Nagel et al. used ChR2 to depolarize mechanosensory 
neurons and elicited withdrawal reflexes in ATR-treated animals, affirming the 
function of this tool for remote control of neuronal activity in vivo. 
Despite its wide use, several problems with ChR2 have persisted: 1) high 
(and sometimes even low) levels of ChR2 expression can result in extraneous 
spiking in response to a single light pulse; 2) ChR2 cannot sufficiently drive firing 
rates into the gamma range; and 3) high spike rates elicit plateau potentials. 
Hypothesizing that a decrease in the deactivation time of ChR2 could resolve all 
three of these problems, Gunaydin et al. (Gunaydin et al., 2010) used structural data 
from bacteriorhodopsin to identify point mutations in ChR2 that might accelerate the 
off-kinetics of channel activity. In particular, a ChR2E123T mutant demonstrated faster 
peak recovery, increased steady state-to-peak current ratio, faster flash-to-peak 
current time, and offset kinetics that were nearly twice as fast (5.2 versus 9.8 ms) as 
those of wild-type ChR2. The mutant, which the authors refer to as ChETA for ChR2 
E123T Accelerated, was functional in vitro both in cultured hippocampal neurons 
and in acute brain slices from a mouse expressing ChETA in cortical interneurons. In 
the latter condition in response to 2-ms light pulses, ChETA evoked neuronal spiking 
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more reliably than wild-type ChR2; each light pulse resulted in a single action 
potential, even at frequencies as high as 200 Hz. 
Volvox carteri expresses a photosensitive cation-conducting 
channelrhodopsin (VChR1) that responds maximally to 589-nm light (Zhang et al., 
2008). This excitation spectrum is red-shifted from that of ChR2, most likely because 
of electrostatic potential differences of the ATR-Schiff base complex in the opsin 
active site (Kloppmann et al., 2005; Zhang et al., 2008). Importantly, Zhang et al. 
found that light wavelengths of 406 and 589 nm are selective for ChR2 and VChR1, 
respectively, meaning that one could selectively activate these receptors within a 
single neuronal population. Another difference between the two cation channels is 
that VChR1 deactivates with a decay constant of 133 ms, which is notably slower 
than the 12 ms that ChR2 requires; they both activate within several milliseconds. 
However, the two opsins share many other properties: they are both non-selective 
cation channels; expression of neither opsin appears to be toxic to cells or alters 
membrane integrity; and supplementation with ATR is unnecessary in mammalian 
neurons. 
 
1.3.2 Hyperpolarizing opsins 
The necessity of developing complementary tools to directly hyperpolarize 
neurons is self-evident. Han and Boyden (Han and Boyden, 2007) and Zhang et al. 
(Zhang et al., 2007b) initially described the use of halorhodopsin (NpHR), a light-
activated chloride channel from Natronomonas pharaonis that responds to yellow 
light (580 nm), to silence neuronal firing. Like ChR2, NpHR silences with extremely 
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fast kinetics. Additionally, after exposure to continuous light, NpHR remains active 
for several minutes, allowing sustained neuronal silencing. As the wavelengths of 
light that activate ChR2 and NpHR are distinct, one can express the two receptors in 
the same cells to bi-directionally modulate their activity. Han and Boyden 
demonstrated that alternating pulses of yellow and blue light drive hyperpolarizations 
and depolarizations, respectively, in cultured neurons expressing both ChR2 and 
NpHR. Zhang et al. expressed both ChR2 and NpHR in cholinergic motor neurons or 
muscle cells of C. elegans and demonstrated that NpHR activation could block 
ChR2-induced muscle contraction. 
One problem with ectopic NpHR expression is that high levels of surface 
expression are necessary to optimally silence neuronal firing; however, the channel 
accumulates in the ER (Gradinaru et al., 2008; Zhao et al., 2008). To overcome this 
obstacle, Gradinaru et al. (Gradinaru et al., 2008) identified an N-terminal signal 
peptide and a C-terminal ER export sequence that increase trafficking to the cell 
membrane and decrease channel retention in the ER. Moreover, these N- and C-
terminal modifications increase the peak photocurrent that this enhanced NpHR 
(eNpHR or eNpHR2.0) could generate. Recently, further modifications (i.e., addition 
of the trafficking signal from the Kir2.1 potassium channel) to eNpHR generated 
eNpHR3.0 (Gradinaru et al., 2010), which has improved cell-membrane expression, 
particular in the processes; coincident with the improved expression are a 20-fold 
increase in NpHR photocurrents and sensitivity to far-red (630 to 680 nm) light. 
Importantly, this last improvement permits more selective activation of ChR2 and 
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eNpHR3.0 in the same cells, albeit with moderately (40%) reduced peak 
photocurrents compared to expression of only one opsin. 
The NpHR pore is permeable to chloride ions, and light-activated chloride 
pumps inactivate for long periods of time (tens of minutes). However, light-activated 
outward proton pumps spontaneously reactivate within seconds. Therefore, Chow et 
al. (Chow et al., 2010) mined the plant, archaebacterial, bacterial, and fungal opsins 
for light-sensitive hyperpolarization and identified two outward proton pumps, 
archaerhodopsin-3 (Arch) from Halorubrum sodomense, and Mac from the fungus 
Leptosphaeria maculans (Waschuk et al., 2005), that enable neuronal silencing. In 
response to yellow light (peak photoactivation at ~550 nm), Arch pumps protons out 
of the cell within ten milliseconds with minimal effects on intracellular pH, and 
silencing of neuronal spiking occurs with 900 pA of current. Continuous light causes 
the current to decay, and the pump rapidly inactivates within 20 ms of the removal of 
light and then recovers – all within seconds. Critically, Arch-generated current did 
not saturate at high light intensities, as does NpHR-generated current, and Arch-
induced silencing was of greater magnitude than that of NpHR; Waschuk et al. 
speculate that Arch could silence ten-fold more brain tissue that NpHR. In vivo, Arch 
rapidly (with near-zero millisecond latency) reduces neuronal firing, with maximal 
silencing of 90%. The baseline firing rate recovers within a few hundred 
milliseconds. Like Arch, Mac also hyperpolarizes neurons, but does so in response 
to blue-green light, a feature that is rare among chloride pumps. Independent 
silencing of distinct neuronal populations is now possible with blue and red light. 
 31 
Indeed, 630-nm and 470-nm light selectively silence NpHR- and Mac-expressing 
neurons, respectively. 
 
1.3.3 G protein-coupled opsins 
Stefan Herlitze’s group first used light to inactivate GPCR pathways, 
expressing RO4 in cultured hippocampal neurons and in intact embryonic chick 
spinal cord neurons (Li et al., 2005). Li et al. determined that RO4 functions both 
presynaptically, to inhibit voltage-gated calcium channels and to modulate 
neurotransmitter release and paired-pulse facilitation, as well as postsynaptically, to 
modulate the activity of GIRK. Therefore, RO4 allows one to study G protein 
signaling and the effects of neuronal silencing on a millisecond time scale. Recently, 
the same group cloned the C-terminal tail of the Gi-coupled 5-HT1A serotonin 
receptor onto RO4 (Oh et al., 2010). The resultant chimeric protein, Rh-CT5HT1A, 
traffics and signals like the native 5-HT1A receptor and rescues 5-HT1A-mediated 
signaling in neurons or tissue from 5-HT1A knockout mice. These data demonstrate 
the ability of opsins to substitute for native mammalian receptors, which should 
provide new opportunities for the functional dissection of neural circuits. 
To modulate the same intracellular biochemical pathways as GPCRs, but with 
the time resolution of optical techniques, Deisseroth’s group created a family of 
opsin-GPCR fusion proteins that are light-activated and couple to G proteins (Airan 
et al., 2009). They exchanged the intracellular portions of rhodopsin, which couples 
to Gt, with those of the α1- or β2−ARs to direct coupling to Gq or Gs, respectively. 
Airan et al. validated the selectivity of optoXRs for the appropriate Gq or Gs-coupled 
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intracellular pathways. Whereas ligand-activated GPCRs can adopt a variety of 
active conformational states, thus leading to ligand functional selectivity (Urban et 
al., 2007), light-activated optoXRs most likely adopt a unique conformation in 
response to light (Airan et al., 2009). Hence, optoXRs offer less functional versatility 
but greater temporal resolution than designer GPCRs.  
 
1.3.4 Advances in light delivery, penetration, and manipulation 
Optogenetics can be a technically complicated approach for in vivo 
manipulation of neuronal activity, depending on the species, target tissue, and other 
experimental variables. For example, targeting deep brain areas (e.g., raphe nuclei) 
or diffuse neuronal populations (e.g., all parvalbumin-positive neurons throughout 
the forebrain) is difficult. Recently, technology for such photostimulation has greatly 
improved, incorporating flexible fiber-optics (Aravanis et al., 2007), two-photon 
imaging (Mohanty et al., 2008; Rickgauer and Tank, 2009; Andrasfalvy et al., 2010), 
and/or improved spatial resolution (Schoenenberger et al., 2008; Andrasfalvy et al., 
2010). While a detailed description of these advances is beyond the scope of this 
review, a few advances are highlighted here. 
One problem with the basic optogenetic approach is that single-cell 
activation, even in vitro, has not been possible on an ultrafast time scale (i.e., < 1 
ms), in part because ChR2 has a low channel conductance, requiring activation of 
many channels to sufficiently depolarize a neuron. With standard one-photon 
imaging, enough channels are not activated to depolarize neurons with single-cell 
spatial resolution. Two-photon imaging techniques have improved the spatial 
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resolution of optogenetic control of neuronal activity, but some of the time resolution 
is lost because the laser must scan a large area to activate enough channels to 
cause depolarization above threshold. Andrasfalvy et al. (Andrasfalvy et al., 2010) 
developed a technique, which they refer to as temporally focused laser pulses, that 
enables simultaneous excitation of many channels on single neurons or in individual 
neuronal compartments (e.g., dendrites, presynaptic terminals). Their approach uses 
multiple, brief (0.1-ms) light pulses, with extremely fast (within 0.2 ms) movement of 
the light focus within a 100-µm field. This technique is effective in vitro on acute 
brain slices. 
Another challenge in optogenetics is the simultaneous stimulation and 
recording of neural activity. To overcome this challenge, some groups have fixed 
electrodes to the optical fibers so that both stimulation and recording from the same 
location are possible (Gradinaru et al., 2007), while others have developed and 
employed ‘optrodes,’ dual-modality devices that simultaneously illuminate and 
record from neurons (Zhang et al., 2009a). Additionally, simultaneous stimulation of 
scattered cell populations is difficult. High-intensity light-emitting diode (LED) arrays, 
optical prosthetics, and grids can provide multiple points of illumination or 
illumination to deep structures (Zhang et al., 2007a; Bernstein et al., 2008; 
Grossman et al., 2010). Undoubtedly, technical advances will continue to improve 
the in vivo and translational applications of optogenetics. 
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1.3.5 In vivo applications of optogenetics 
Optogenetic strategies are now widely used for investigation of neuronal 
circuits in vivo and will soon become de rigueur tools for circuitry-based dissection of 
neuronal function. Various groups have published data on optogenetic applications 
in zebrafish, Drosophila, and C. elegans, and a few recent papers have described 
applications in non-human primates (see Table 1.2). The majority of the in vivo data, 
however, comes from rodents. Table 1.2 describes the principal findings of many of 
these in vivo studies, and I highlight below some of the most exciting reports. 
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Table 1.2. Applications of optogenetics in vivo 
 Opsin Expression Pattern Principal Findings Reference 
Spinal neurons 
in and around 
phrenic motor 
pool 
Photostimulation rescues 
diaphragmatic respiratory motor 
activity in mice with cervical spinal 
cord injuries and induces plastic and 
adaptive changes to enable motor 
activity in the absence of light  
(Alilain et al., 
2008) 
Layer 2/3 
pyramidal 
neurons in 
somatosensory 
cortex 
Mice learned to detect optical 
stimulation and to make decisions 
based on the presence or absence of 
the resultant cortical activity 
(Huber et al., 
2008) 
Pyramidal cells 
of lateral 
amygdala 
Optical stimulation of lateral amygdala 
is sufficient to induce fear learning; 
mice learned to freeze in response to 
a tone that was paired with 
photoactivation 
(Johansen et 
al., 2010) 
Dopaminergic 
neurons in 
ventral 
tegmental area  
Phasic stimulation was sufficient to 
drive behavioral conditioning and 
elicited dopamine transients 
(Tsai et al., 
2009) 
Cortical 
interneurons 
Developed PINP (photostimulation-
assisted identification of neuronal 
populations): can use ChR2 to “tag” 
neurons and monitor their activity 
(Lima et al., 
2009) 
Cortical and 
thalamic 
pyramidal 
neurons 
Neuronal activation induces local 
blood oxygenation level-dependent 
signals on fMRI; optogenetic fMRI 
demonstrates causal effects – can 
visualize and map downstream neural 
activity  
(Lee et al., 
2010) 
Astrocytes in 
brainstem 
chemoreceptor 
areas 
Activating astrocytes activated the 
chemoreceptor neurons in an ATP-
dependent manner and caused a 
respiratory response, thus 
demonstrating a role of glia in a 
physiological reflex 
(Gourine et 
al., 2010) 
M
ic
e 
ChR2 
Neuronal 
subsets 
throughout 
brain 
Mapped spatial distribution of neural 
circuits in cortex 
(Wang et al., 
2007a) 
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Hypocretin 
neurons 
Directly activating hypocretin neurons 
via ChR2 increased probability of 
awakening from slow-wave or REM 
sleep 
(Adamantidis 
et al., 2007) 
Prefrontal 
cortex 
Stimulation of ChR2 has 
antidepressant-like effects in mice 
previously exposed to chronic social 
defeat stress 
(Covington et 
al., 2010) 
ChR2 
Central 
amygdala 
Two simultaneous papers mapped the 
microcircuitry required for conditioned 
fear 
(Ciocchi et 
al., 2010; 
Haubensak et 
al., 2010) 
M
ic
e 
opto-
XRs 
Nucleus 
accumbens 
Opto-α1AR induced conditioned place 
preference, but activation of ChR2 or 
opto-β2AR did not  
(Airan et al., 
2009) 
 
Abnormal 
chemosensory 
jump-6 
neurons 
These neurons are required for startle 
response and mediate escape 
behavior; stimulation of cells with 
ChR2 elicited escape in response to 
light 
(Zimmermann 
et al., 2009) 
D
ro
so
ph
ila
 
ChR2 
Larval olfactory 
receptor 
neurons 
Stimulation caused illusion of attractive 
odor with associated crawling towards 
the stimulus 
(Bellmann et 
al., 2010) 
 
NpHR, 
eNpHR, 
ChR2 
Throughout 
brain 
Localized swim command circuitry to 
hindbrain region; activating eNpHR in 
this region caused larvae to stop 
moving and lose coordination, while 
activating ChR2 elicited swimming 
behavior 
(Arrenberg et 
al., 2009) 
ChR2 
Subset of 
Rohon-Beard 
and trigeminal 
somatosensory 
neurons 
Inducing a single action potential 
generates escape behavior; first 
demonstration of electrical activation 
of single cells in unrestrained 
zebrafish; determined that 
endogenous ATR is sufficient 
(Douglass et 
al., 2008) 
NpHR, 
ChR2 
Throughout 
brain 
Mapped eye moments that follow 
visual stimulus; ChR2 activation can 
restore saccades in a genetic mutant 
that does not normally exhibit them; 
determined that saccade circuit in 
zebrafish is similar to mammalian 
burst generator 
(Schoonheim 
et al., 2010) 
Ze
br
af
is
h 
ChR2 
Olfactory bulb, 
ventral 
telencephalon 
Adapted tet system and viral gene 
delivery to zebrafish; ChR2 activation 
induced forward and backward 
swimming 
(Zhu et al., 
2009) 
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One in vivo application of optogenetics has been to Parkinsonian research. 
Opsins provide a method of directly addressing some of the unproven hypotheses 
regarding the mechanisms of action of various therapies. For example, in classical 
basal ganglia circuitry, ‘direct’ and ‘indirect’ pathway stimulation facilitates and 
inhibits movement, respectively, and activating D1 receptors on direct medium spiny 
neurons (MSNs) should be therapeutic. Previously, directly activating direct pathway 
neurons without off-target effects has been difficult. Moreover, high-frequency deep 
brain stimulation (DBS) is a treatment for refractory Parkinson’s Disease (PD), but its 
therapeutic mechanism is unclear. To investigate this circuitry, Kravitz et al. (Kravitz 
et al., 2010) expressed ChR2 in D1 (direct) or D2 (indirect) dopamine receptor-
expressing MSNs and determined that activation of D1 neurons facilitates 
locomotion and decreases freezing, while activation of D2 neurons inhibits 
locomotion and increases freezing behavior. Moreover, they showed in 6-
hydroxydopamine (6-OHDA) -lesioned mice, an animal model of PD, that activation 
with light of the direct pathway completely rescues the PD phenotype. This paper 
was the first to directly demonstrate a causal role of D1-expressing neurons in 
ameliorating PD symptoms. Also using 6-OHDA-lesioned mice, Gradinaru et al. 
(Gradinaru et al., 2009) used optogenetics to dissect the various subcomponents of 
the basal ganglia circuitry to determine the location of action of the therapeutic 
effects of DBS. They found no positive changes in locomotor symptoms from either 
optical inhibition (via eNpHR) or high-frequency optical stimulation (via ChR2) of 
substantia nigral excitatory neurons nor from optical activation (via ChR2) of 
substantia nigral astrocytes and subsequent inhibition of substantia nigral neuron 
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firing. However, when they targeted ChR2 to afferent terminals in the substantia 
nigra, high-frequency stimulation improved PD symptoms for the duration of the 
stimulation. Importantly, as soon as the light pulses were discontinued, locomotion 
immediately returned to its pre-stimulation level, and low-frequency stimulation of the 
same afferent fibers worsened PD symptoms. These findings have significantly 
improved our understanding of therapeutic targets for PD and demonstrate nicely 
the translational potential of optogenetics. 
One of the most promising translational applications of opsins thus far is to 
the restoration of vision after retinal degeneration. A variety of groups have 
expressed opsins in the retina of several species (mice, rats, marmosets) in 
photoreceptors, retinal ganglion cells, and on- or off-bipolar cells (Lin et al., 2008; 
Ivanova and Pan, 2009; Tomita et al., 2009; Zhang et al., 2009b; Busskamp et al., 
2010; Ivanova et al., 2010a; Ivanova et al., 2010b; Thyagarajan et al., 2010; Tomita 
et al., 2010). Busskamp et al. (Busskamp et al., 2010) expressed an eNpHR-EYFP 
fusion protein in photoreceptors using the human rhodopsin, human red opsin, and 
mouse cone arrestin-3 promoters. They administered eNpHR-EYFP AAV to mice 
with either slow or fast forms of retinal degeneration. Transgene expression in cone 
cells lasted for more than eight months with no evidence of toxicity. Expression of 
eNpHR-EYFP and subsequent application of light resulted in large and sustained 
photocurrents that were faster than those in wild-type cones. In addition, the cones 
successfully transmitted current to downstream ganglion cells, and spatial 
processing features (e.g., lateral inhibition, directional selectivity for motion) 
remained intact. In light-dark box and optomotor reflex tests, eNpHR-expressing 
 39 
mice performed better than control mice, indicating that eNpHR-mediated 
photocurrent can modulate visually evoked behaviors and suggesting that higher-
order sensory processing remains intact. Finally, Busskamp et al. treated human ex 
vivo retinal explants with AAV or lentivirus, successfully expressed eNpHR in human 
photoreceptors, and induced photocurrents and photovoltages via NpHR. The 
authors propose optogenetics as a novel therapeutic approach to treating blind 
patients who retain cone cell bodies in the central region of the retina.  
Other groups have also attempted to rescue blindness in animal models of 
retinal degeneration. Tomita et al. (Tomita et al., 2010) expressed ChR2 in retinal 
ganglion cells of genetically blind adult rats and observed visually evoked potentials 
and optomotor responses, while Zhang et al. (Zhang et al., 2009b) expressed NpHR 
or NpHR and ChR2 in inner retinal cells in mice with retinal degeneration and 
restored off or on-off responses, respectively. 
In two simultaneously published reports, Sohal et al. and Cardin et al. 
employed optogenetic strategies to investigate the molecular underpinnings of 
gamma rhythm (Cardin et al., 2009; Sohal et al., 2009). Both studies used DIO AAV 
constructs to target opsins to the forebrain. Sohal et al. expressed eNpHR-EYFP in 
parvalbumin-expressing interneurons and ChR2-EYFP in CaMKIIα-expressing 
pyramidal neurons of the frontal cortex. Application of blue light elicited gamma 
oscillations that were phase-locked to the flashes of blue light, while yellow light 
inhibited, but did not eliminate, gamma rhythm; yellow light did not affect non-
gamma LFPs. Sohal et al. also showed in vitro in acute slices that direct activation of 
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interneurons with ChR2 resulted in parvalbumin-interneuron firing, gamma rhythm 
(even after non-rhythmic illumination), and inhibition of pyramidal neurons.  
Cardin et al. targeted ChR2-mCherry to parvalbumin-containing interneurons 
or CaMKIIα-containing pyramidal neurons in the barrel cortex of adult mice, a region 
that processes sensory input from the vibrissae (whiskers). In vivo, 1-ms light pulses 
to the barrel cortex of mice with interneuron ChR2 expression induced IPSPs in 
pyramidal cells and inhibited the normal pyramidal response to vibrissae deflection; 
the reversal potentials implicated GABAA-mediated chloride conductance at the 
interneuron-pyramidal neuron synapse. To probe gamma rhythms in particular, they 
stimulated at 20 to 80 Hz the barrel cortex in mice with interneuron ChR2 expression 
and observed an increase in the corresponding gamma band on the LFP. On the 
other hand, an 8-Hz stimulation to mice with pyramidal ChR2 expression increased 
the power of the theta band on the LFP. Importantly, light-induced gamma rhythm 
was inhibited by AMPA or NMDA blockade, suggesting that both the GABAergic 
interneurons and the glutamatergic pyramidal neurons are necessary to evoke 
gamma rhythms. 
The studies summarized here are just a few examples of the emerging body 
of literature regarding in vivo applications of optogenetics. The rapidly growing 
number of reports validates the optogenetic approach and demonstrates that the 
technical aspects of photostimulation in vivo, while challenging, are not 
insurmountable. 
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1.4 Designer G protein-coupled receptors 
 
 Another approach to remote control of neuronal signaling, and the subject of 
this thesis, is through designer GPCRs. This approach, like optogenetics, relies on a 
specific ligand-receptor pair. In this case, instead of photons, the ligand is a small 
drug-like molecule that selectively activates a non-native GPCR. Whereas opsins 
briefly alter membrane potential, designer GPCRs modulate diverse intracellular 
pathways and can effect long-lasting changes in cellular activity. 
 
1.4.1 G protein-coupled receptor overview 
 G protein-coupled receptors are one of the largest classes of signaling proteins 
in the human genome and are involved in diverse biological processes. Moreover, 
GPCRs are highly suitable for pharmacological modulation; indeed, they currently 
comprise the largest class of drug targets (Hopkins and Groom, 2002; Armbruster and 
Roth, 2005). Over 90% of non-sensory GPCRs are expressed in the brain (Vassilatis et 
al., 2003), and many of those receptors are implicated in neurological and psychiatric 
diseases. 
 
1.4.1.1 The G protein cycle 
 GPCRs are a superfamily of membrane-bound receptors with seven 
transmembrane α-helices. The receptors are sensors for diverse stimuli, ranging from 
light and odors to hormones and neurotransmitters (Kristiansen, 2004). The receptors 
couple to heterotrimeric guanine nucleotide binding proteins (G proteins), made up of α, 
β, and γ subunits. Upon ligand binding, GPCRs change their conformation to transduce 
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signals across the membrane to their G protein partners. Activated GPCRs function as 
guanine nucleotide exchange factors (GEFs) and promote the exchange of guanosine 
tri-phosphate (GTP) for guanosine di-phosphate (GDP) on the G protein, which triggers 
the dissociation of the α subunit from the βγ complex, each of which then activates a 
range of second-messenger signaling cascades and effectors (Gainetdinov et al., 2004; 
Kristiansen, 2004). This signaling ultimately results in changes in molecular, cellular, 
and physiological processes. GPCR signaling concludes with hydrolysis of the bound 
GTP to GDP, which occurs through the intrinsic GTPase activity of the G protein; this 
process is catalyzed by GTPase-activating proteins (GAPs) and results in reassociation 
of the inactive α subunit with the βγ dimer. 
 
1.4.1.2 Canonical G protein effectors 
 GPCR subtypes couple to specific classes of G proteins that vary in their α 
subunit, and each class of α subunits couples to particular second messengers (Figure 
1.3) (Kristiansen, 2004). The Gαq (Gq) subunit activates phospholipase C-β (PLC-β) 
resulting in hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) in the plasma 
membrane and subsequent release of inositol-1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG). Each of these molecules then initiates other signal transduction 
processes: IP3 binds to IP3 receptors (IP3R) on the ER to trigger release of intracellular 
calcium stores, while DAG activates protein kinase C (PKC). 
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Figure 1.3. Activation of second-messenger cascades by designer G protein-
coupled receptors 
The RASSLs and DREADDs activate Gq-, Gs-, and Gi-coupled GPCRs. Activation of 
Gq activates PLC-β to stimulate PIP2 hydrolysis into inositol-trisphosphate (IP3) and 
diacylglycerol (DAG), then DAG activates PKC, and IP3 activates the IP3 receptor 
(IP3R) to cause calcium release from the ER, which causes ERK1/2 activation. 
Activation of Gs activates adenylyl cyclase (AC) to promote cAMP formation and 
subsequent PKA activation, while activation of Gi inhibits AC activity, cAMP 
formation, and PKA activation. The Gβγ subunit of Gi-coupled GPCRs opens GIRK 
to allow hyperpolarizing potassium flux. Finally, G protein-independent signaling 
occurs through β-arrestin, which activates ERK1/2. 
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The subunits Gαs (Gs) and Gαi (Gi) activate and inhibit adenylyl cyclase, respectively, to 
alter cyclic adenosine mono-phosphate (cAMP) levels. The Gα12 family of G proteins 
activates Rho GEFs. Meanwhile, the Gβγ dimer also acts as a second messenger; in 
neurons, it activates G protein inwardly rectifying potassium channels (GIRK) to 
hyperpolarize the membrane and inhibit action potential firing. 
 
1.4.1.3 Desensitization and trafficking of G protein-coupled receptors 
 G protein-coupled receptors undergo desensitization, whereby responsiveness 
to an agonist decreases over time; internalization and sequestration, whereby receptors 
are removed from the cell surface; and down-regulation, whereby the total number of 
cellular receptors decreases. All of these processes modulate the magnitude and 
duration of GPCR signaling. 
 Desensitization is dependent on the activity of cellular kinases and occurs in 
both activity-independent (heterologous) and activity-dependent (homologous) manners 
(Ferguson, 2001; Gainetdinov et al., 2004). In heterologous desensitization, GPCR 
activation increases the activity of downstream kinases (e.g., PKA, PKC) that then 
indiscriminately phosphorylate intracellular residues on both active and inactive 
receptors to inhibit G protein coupling and initiate desensitization. In homologous 
desensitization, the family of GPCR kinases (GRKs) phosphorylates only agonist-bound 
receptors. This process promotes the recruitment of arrestins from the cytoplasm to the 
plasma membrane, where they interact with the intracellular portions of GPCRs to 
initiate receptor internalization. 
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 Arrestins were first identified in the retina, where visual arrestin or arrestin1 was 
identified and shown to inhibit the interaction of phosphorylated rhodopsin with its 
cognate G protein transducin (Kuhn et al., 1984; Pfister et al., 1985; Wilden et al., 
1986a; Wilden et al., 1986b). Professor Robert Lefkowitz’s group then described a 
protein that similarly enhanced inactivation of the β2-AR (Benovic et al., 1987), which 
they cloned and named β-arrestin1 or arrestin2 (β-arr) (Lohse et al., 1990). A third 
family member, β-arrestin2 or arrestin3 (β-arr2), shares 78% sequence homology with 
β-arr (Attramadal et al., 1992). Importantly, Attramadal et al. reported that β-arr and β-
arr2 are enriched in neural tissue and are ubiquitous at low levels. 
 Arrestins bind to GPCRs following phosphorylation of the receptors by GRKs.  
This binding blocks further G protein coupling and targets GPCRs for internalization via 
the endocytic pathway in a clathrin- and dynamin-dependent manner. Many of these 
internalized receptors then undergo dephosphorylation/resensitization and recycling 
back to the cell surface (Zhang et al., 1997; Ferguson, 2001). 
 
1.4.1.4 Non-canonical G protein signaling 
 In the last ten years, various groups have described arrestinergic or G protein-
independent signaling. It is now well accepted that arrestins are crucial effectors for 
GPCRs. First, their binding to GPCRs prevents further activity of the G protein-
dependent pathway, so they shift signaling to G protein-independent pathways (Luttrell 
and Gesty-Palmer, 2010). Second, arrestins act as scaffolds or adapters for a variety of 
cellular proteins, including the adapter protein AP2, which mediates sequestration of 
receptors into clathrin-coated pits. Additionally, arrestins recruit Src family tyrosine 
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kinases, components of the ERK/MAPK cascade, E3 ubiquitin ligase, cAMP 
phosphodiesterases (PDEs), NFκB, and a variety of other intracellular signaling 
molecules to the agonist-bound GPCR. This arrestinergic signaling has a slower, more 
delayed onset and a longer duration that canonical G protein signaling (Luttrell and 
Gesty-Palmer, 2010).  
 
1.4.1.5 Functional Selectivity 
 While the basic mechanisms of activation of G protein effectors are well 
characterized, the ability of a ligand, acting at a GPCR, to differentially activate these G 
protein-dependent and -independent effectors is incompletely defined. Such “functional 
selectivity” or “biased agonism,” through which a ligand can preferentially activate 
particular downstream signaling pathways, implies that specific GPCRs could effect 
diverse consequences, depending on the cell populations and sub-cellular 
compartments in which the GPCRs are active (Urban et al., 2007). A technique 
enabling the differentiation of these signaling consequences would improve the 
understanding of pathologies involving GPCRs and might enable more focused 
treatment strategies that target particular intracellular signaling pathways downstream of 
GPCRs, rather than the GPCRs themselves (Whalen et al., 2010). 
 
1.4.2 Designer receptors as pharmacological tools 
 G protein-coupled receptor pathways are involved in a multitude of CNS 
disorders, and remotely activating and/or inhibiting select GPCR pathways both 
illuminate disease processes and identify potential avenues of treatment. Unlike 
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microbial opsins, which are not activated in vivo by endogenous compounds or by 
ambient light, and thus are functionally silent at baseline, a variety of endogenous 
ligands modulate native GPCR signaling in vivo, and GPCRs often display 
constitutive activity [for review, see (Seifert and Wenzel-Seifert, 2002; Smit et al., 
2007)]. Moreover, drug-like exogenous ligands are neither selective enough nor do 
they provide adequate spatial regulation for probing specific pathways in vivo. 
Therefore, over the past two decades, researchers have worked to develop highly 
selective orthologous ligand-receptor pairs that would convey a high degree of 
spatiotemporal control over GPCR signaling networks in vivo. This work has been 
reviewed previously (Conklin et al., 2008; Pei et al., 2008; Nichols and Roth, 2009; 
Dong et al., 2010a). 
 Efforts to selectively activate GPCRs began with the work of Strader et al. to 
mutagenize the β2-adrenergic receptor (β2-AR) (Strader et al., 1991). The Strader 
group identified Asp113 as a critical residue for ligand binding to the β2-AR (Strader 
et al., 1987; Strader et al., 1988; Strader et al., 1989) and mutated Asp113 to serine 
to interrupt ionic interactions in the binding pocket. While isoproterenol and the 
endogenous agonists epinephrine and norepinephrine activated β2-ARD113S weakly 
and with low potency, catchol-esters and -ketones, which are inactive at the wild-
type β2-AR, were agonists at the mutant receptor. Unfortunately, although it was a 
full agonist, the most potent ligand at β2-ARD113S had an EC50 of 40 µM, which was 
still insufficient for in vivo applications. Presciently, the authors proposed rational 
design of drugs and genetically engineered receptors as a new therapeutic approach 
(Strader et al., 1991). 
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 Since this first effort at rational design of a GPCR, mutations to more than a 
dozen native GPCRs have yielded a large family of selectively activated designer 
receptors. Most of these receptors fall into two classes: the first-generation RASSLs, 
which were developed using rational design; and the second-generation DREADDs, 
which were evolved through directed molecular evolution in yeast. 
 
1.4.3 First-Generation Receptors Activated Solely by Synthetic Ligands 
 
1.4.3.1 Development and in vitro pharmacology 
 After Strader’s progress, the next advancements in the field of designer 
GPCRs came from Bruce Conklin’s group, which took the same rational design 
approach as Strader et al. (i.e., mutagenizing key residues for native ligand binding) 
and applied it to the human κ opioid receptor (hKOR). Importantly, peptide ligands 
bind to the extracellular loops while small drug-like molecules bind to 
transmembrane regions of peptide receptors. Therefore, Conklin and colleagues 
predicted it to be feasible to eliminate native ligand binding to hKOR without 
decreasing the affinity of small molecules for the receptor (Coward et al., 1998). 
Indeed, by exchanging the second extracellular loop of hKOR with that of the δ 
opioid receptor (DOR), Coward et al. successfully reduced the binding affinity of the 
endogenous peptide dynorphin A by 200-fold (from 0.06 nM to 14.6 nM), yet 
maintained the affinity of synthetic small molecule agonists such as spiradoline and 
bremazocine (Coward et al., 1998). This novel receptor, Ro1, faithfully couples to Gi 
to inhibit adenylyl cyclase, and the potency of the native and small molecule ligands 
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parallels their respective binding affinities. Additionally, Coward et al. generated a 
second RASSL (Ro2) with an E297Q mutation of Ro1. This mutation replaces a 
negatively charged residue implicated in ligand binding (glutamate) with a highly 
polar residue (tryptophan) at the top of the sixth transmembrane region of hKOR. 
The affinity of several endogenous opioids for Ro2 was further decreased as 
compared to Ro1 (e.g., the Ki of dynorphin A at Ro2 was 124.5 nM, a nearly 2000-
fold decrease in affinity compared to wild-type hKOR). Moreover, in response to 
spiradoline, Ro2 induced cellular proliferation in a pertussis toxin-sensitive manner. 
While dynorphin A elicited no detectable response in Ro2-expressing cells at 
concentrations up to 1 µM, spiradoline was equipotent at hKOR and at Ro2 (EC50 
4.4 and 5.5 nM, respectively). Importantly, the basal proliferation rate was not 
different in spiradoline-treated and -untreated Ro2-expressing cells, suggesting that 
Ro2 does not signal constitutively in this cellular context. Additional RASSLs derived 
from Ro1 and Ro2 that contain fluorescent tags or have altered internalization and/or 
desensitization properties now exist (Scearce-Levie et al., 2001; Scearce-Levie et 
al., 2005; Pei et al., 2008). 
 The Coward paper set the groundwork for the rational design of an entire 
class of engineered receptors. The authors had proposed biogenic amine – in 
particular serotonin – receptors as RASSL templates, and had further suggested the 
benefit of developing RASSLs that signal through each of the canonical G protein 
signaling pathways. Indeed, such RASSLs were soon developed (Table 1.3, Figure 
1.3). 
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 Kristiansen et al. (Kristiansen et al., 2000) reported that mutation to 
glutamate of the highly conserved Asp155 residue of the serotonin 2A receptor (5-
HT2A), a Gq-coupled receptor, greatly decreased the potency of serotonin (5-HT) but 
increased the potency of gramine, a 5-HT analog that is inactive at the native 5-HT2A 
receptor. Additionally, the 5-HT2AD155E receptor had reduced basal activity compared 
to the wild-type receptor. Bruysters et al. (Bruysters et al., 2005) also developed a 
Gq-coupled RASSL, which they engineered from the H1 histamine receptor. An 
F435A mutation reduced the affinity and potency (25- and 200-fold, respectively) of 
histamine yet increased the affinity and potency of the synthetic phenylhistamines 
(54- and 2600-fold, respectively). 
 Srinivasan et al. (Srinivasan et al., 2007; Srinivasan et al., 2003) developed 
the first RASSLs to signal through Gs. They introduced into the melanocortin-4 
(MC4) receptor naturally occurring mutations that abolish activity of the cognate 
ligand α-melanocyte-stimulating hormone (α-MSH). The resulting RASSLs, Rm1 and 
Rm2, are active in response to low (2 to 3) nanomolar concentrations of the 
synthetic ligand tetrahydroisoquinoline (THIQ) and differ primarily in their level of 
basal signaling. Importantly, THIQ is a more potent agonist at the wild-type MC4 
receptor than is α-MSH (EC50 0.8 nM and 30.3 nM, respectively), so it is not 
selective for Rm1 or Rm2. 
 Around the same time, Claeysen et al. (Claeysen et al., 2003) introduced into 
the Gs-coupled mouse 5-HT4 serotonin receptor (5-HT4) a D100A mutation that 
abolished the efficacy of 5-HT at the receptor without eliminating the activity of 
synthetic ligands. Interestingly, they noted that two of the synthetic ligands that were 
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antagonists at the wild-type receptor were agonists at the D100A receptor. In a 
subsequent paper, they introduced the same D100A mutation into the human 5-HT4B 
serotonin receptor (5-HT4B) to generate Rs1 (Chang et al., 2007). Like the mouse 
homolog, this receptor was insensitive to 5-HT, but a variety of synthetic ligands had 
full- or partial-agonist activity, and some ligands demonstrated functional selectivity 
(Urban et al., 2007) by directing coupling selectively to Gs or jointly to Gs and Gq. 
Further mutations to Rs1 or chimeras of Rs1 and the 5-HT2C or 5-HT1A serotonin 
receptors generated receptors that differed in their specificity of coupling to Gs, Gq, 
and Gi or that had varied levels of constitutive activity. Thus, using a single receptor 
template, Claeysen et al. generated a family of RASSLs that signal through the three 
primary G proteins. 
 In addition to these RASSLs, Pauwels and Colpaert generated α2A-
adrenergic receptors (α2A-AR) with S200A or S204A mutations. Epinephrine had 
reduced potency at both mutant receptors and a 70% decrease in efficacy at the 
S204A mutant, and synthetic imidazoline derivatives including UK-14304 had 
improved potency at both mutant receptors (Pauwels, 2003; Pauwels and Colpaert, 
2000). Nonetheless, the reduction in potency of epinephrine (45-fold and 251-fold for 
the S200A and S204A mutations, respectively) is insufficient for in vivo selectivity. 
 Thus, a variety of mutant receptors (coupling to the Gq, Gi, and Gs signaling 
pathways) and corresponding synthetic ligands convey some level of experimental 
control over cellular activity. Most of these ligand-receptor systems are only useful 
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for in vitro applications because of their insufficient selectivity, but researchers have 
developed transgenic mice expressing two of these receptors, Ro1 and Rs1. 
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Table 1.3 Point mutations in GPCRs generate RASSLs 
Template Mutation Ligand Notes Reference 
5-HT2A D155E Gramine 
Reduced basal activity; 
reduced potency of 5-HT 
(Kristiansen et 
al., 2000) 
H1-
histamine F435A 
Synthetic 
phenylhistamines 
Decreased affinity and 
potency of histamine 
(Bruysters et 
al., 2005) 
MC4 
(Rm1, 
Rm2) 
Naturally 
occurring 
mutations 
abolishing 
α-MSH 
activity 
Tetrahydroiso-
quinoline (THIQ) 
Rm1, Rm2 differ in basal 
signaling level; THIQ is 
more potent at WT MC4 
than α-MSH 
(Srinivasan et 
al., 2003; 
Srinivasan et 
al., 2007) 
5-HT4 
(Gs), 
5-HT4B 
(Rs1) 
D100A Various synthetic ligands 
5-HT efficacy eliminated; 
antagonists at WT are 
agonists; functionally 
selective ligands direct 
coupling to other G 
proteins 
(Claeysen et 
al., 2003) 
(Chang et al., 
2007) 
α2A-AR S200A, S204A 
Synthetic 
imidazoline 
derivatives, e.g., 
UK-14304 
Reduced potency and 
efficacy of epinephrine 
(Pauwels and 
Colpaert, 
2000; 
Pauwels, 
2003) 
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1.4.3.2 In vivo applications of first-generation designer receptors 
 The first application of RASSLs to an in vivo setting came from Conklin’s 
group. Redfern et al. (Redfern et al., 1999) developed transgenic mice that 
expressed Ro1 in the heart under control of the α-myosin heavy chain promoter (α-
MHC) in a tet-off manner. Eleven days after weaning adult mice from dox, 90% of 
atrial myocytes and 50% of ventricular myocytes expressed Ro1. As expected based 
on data from other Gi-coupled receptors present in cardiomyocytes (e.g., M2 
muscarinic, A1 adenosine), spiradoline induced a dose-dependent decrease in heart 
rate selectively in Ro1-expressing mice; at 5 mg/kg spiradoline i.p., heart rate 
decreased by an average of 55% in approximately 26 s. Thus, the onset kinetics of 
spiradoline’s peripheral effects are relatively fast. Heart rate gradually returned to 
near baseline over the course of two hours. Additionally, Redfern et al. showed that 
Ro1 desensitizes to spiradoline; repeated injections every four hours elicited 
progressively weaker responses. 
 Surprisingly, once mice had been off dox for three weeks, they began to die, 
and mortality was virtually 100% by 16 weeks off dox (Redfern et al., 2000). 
Physiological and histological studies revealed that Ro1 expression per se (in the 
absence of agonist) induced a lethal dilated cardiomyopathy. Ventricular conduction 
delays (indicated by a wide QRS complex on electrocardiogram), enlarged 
ventricular size and decreased ventricular myocardial thickness, myocyte disarray, 
collagen deposition, reduced myocardial force and rate of contraction/relaxation, 
anasarca, and labored breathing – all characteristic of cardiomyopathy and/or 
indicative of systolic dysfunction – were present only in mice off dox (Redfern et al., 
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2000; Baker et al., 2001). Importantly, a single injection of pertussis toxin restored 
sinus rhythm for more than three days, confirming that the arrhythmias were due to 
Gi-coupled signaling. Additionally, mRNA microarray studies revealed changes in 
ventricular expression of components of the Gi signaling pathway: GIRK gene 
expression decreased by 50% while expression of adenylyl cyclase 7, PKA, and 
PKA regulatory proteins all increased. Thus, the heart tissue appeared to be trying to 
compensate for excessive Gi signaling by altering gene expression. 
 These data are critical for evaluating RASSLs as an in vivo and 
neurobiological tool. On the one hand, the pertussis toxin sensitivity and the 
alterations in expression of genes associated with Gi signaling suggest that Ro1 
signals selectively through Gi in vivo, as does hKOR. The complete penetrance of 
dilated cardiomyopathy in transgenic mice off dox suggests, however, that Ro1 is 
signaling in the absence of spiradoline or another synthetic ligand. Whether that 
activity indicates constitutive activity or an insufficient reduction in the efficacy and/or 
potency of dynorphins is unclear. Recently, McCloskey et al. (McCloskey et al., 
2008) attempted to answer this question by administering the KOR antagonist nor-
binaltorphimine. The antagonist did not reverse the contractile dysfunction, thus that 
dysfunction does not stem from acute Ro1 signaling, but it is possible that the 
myocardial changes are irreversible and that administration of an antagonist after 
damage occurs cannot mitigate the accumulated effects of excess Gi signaling. 
 Other studies have revealed severe pathologies stemming from Ro1 
expression, thus the baseline phenotype is not specific to the cardiac system. Ro1 
expression in osteoblasts induces trabecular osteopenia (Peng et al., 2008) and in 
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astrocytes induces hydrocephalus (Sweger et al., 2007). For osteoblast expression, 
the mouse 2.3-α type 1 collagen promoter drives expression of tTA, thus double-
transgenic mice carrying both the tTA and Ro1 transgenes express Ro1 protein 
selectively in osteoblasts in a tet-off manner. Few Ro1-expressing mice survive to 
weaning, and those that do survive are severely runted, weighing less than 50% that 
of their sex-matched littermate controls. Double-transgenic embryos are normal and 
occur in Mendelian ratios. At birth, Ro1-expressing mice have reduced 
mineralization of bones and altered bone structure, and most die within two hours 
from respiratory failure. In particular, trabecular bone formation is decreased. 
Double-transgenic mice that are maintained on a dox-containing diet until P28 
develop reductions in trabecular bone volume. Clearly, overexpression of Ro1 is 
pathologic in multiple peripheral tissues. 
Pathology develops from Ro1 expression in the central nervous system as 
well. Sweger et al. (Sweger et al., 2007) expressed Ro1 in the tet-off system under 
control of the human GFAP promoter and on a KOR-/- background. Maintenance of 
mice on dox elicited no detectable phenotype and protein expression was 
undetectable by Western blot. In the absence of dox, Ro1 expression resulted in 
fatal hydrocephalus. All Ro1-expressing mice that were never exposed to dox 
developed macrocephalus by P15 and severe hydrocephalus by 12 weeks; half of 
transgenic mice died by 12 weeks. If mice were exposed to dox until weaning, they 
developed hydrocephalus once dox was withdrawn, indicating that the phenotype is 
not developmentally regulated. The hydrocephalus was characterized by grossly 
enlarged ventricles (particularly the lateral ventricles), reduced thickness of the 
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cerebral cortex, disruption and displacement of other brain structures, hemorrhage, 
altered white tract tissue, denudation of the ependymal lining of the lateral ventricles, 
and occlusion of the aqueduct of Sylvius. Expression of GFAP, which indicates 
reactive glia, and phosphorylated ERK, which is a downstream mediator of Gi 
signaling, both increased in Ro1-expressing animals. These Ro1-expressing mice 
represent a new in vivo model of hydrocephalus. The model is particularly useful 
because it occurs with 100% penetrance, and it does not require administration of 
any toxin or exogenous agent. Additionally, one can remotely control the age of 
onset of hydrocephalus by administering or witholding dox and thereby can 
determine the role of development on hydrocephalus and its manifestations. 
Thus far, Ro1 expression in transgenic mice has not induced a detectable 
baseline phenotype in only one cell type: taste receptors. Zhao et al. (Zhao et al., 
2003) used Ro1 to investigate the sensory underpinnings of taste. They first 
demonstrated that specific GPCRs in the T1R class of taste receptors detect distinct 
classes of tastants (sweet or umami). Importantly, different populations of taste cells 
express the sweet or umami receptors. To determine whether it is activation of the 
particular receptors for sweet/umami or whether it is the sweet/umami receptor-
expressing cells that encode taste, Zhao et al. expressed Ro1 selectively in sweet-
sensing cells under control of a tet-on system. Transgenic mice on dox, but not 
animals off dox or wild-type animals, were attracted to spiradoline. In a two-bottle 
preference assay, Ro1-expressing animals preferred a spiradoline-containing 
solution at concentrations as low as 10 nM; preference for the spiradoline solution 
increased in a concentration-dependent manner. That a non-taste receptor can elicit 
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the sensation of sweet taste suggests that specific pathways, and not specific 
receptors, encode taste. In support of that hypothesis, Ro1 expression in bitter taste 
cells of transgenic mice induced behavioral aversion to low nanomolar 
concentrations of spiradoline (Mueller et al., 2005). Accordingly, mice expressing a 
native “bitter” receptor in sweet taste cells exhibit a strong attraction to bitter 
compounds. The same receptor can convey sweet and bitter taste, depending on 
where it expresses. These studies demonstrate that taste cells, and not taste 
receptors, encode the individual taste modalities (sweet, salty, sour, bitter, umami). 
Although most in vivo work with RASSLs has used Ro1, a few studies have 
reported on Rs1 expression and function in vivo. While Ro1 expression in 
osteoblasts decreases bone mass, as we described above, Rs1 expression in 
osteoblasts increases bone mass (Hsiao et al., 2008; Hsiao et al., 2010a; Hsiao et 
al., 2010b). Here, we have a nice example of bi-directional modulation of the 
signaling and phenotype for the same cell type, albeit it not in the same animal. As 
one might expect, inhibiting and activating adenylyl cyclase, via Gi and Gs, 
respectively, have opposing effects on bone structure and growth. Interestingly, 
unlike Ro1 expression in cardiomyocytes and astrocytes, the timing of Rs1 
expression and signaling in osteoblasts is critical for the development of pathology; 
Rs1 induction after P28 does not alter trabecular bone mass, which suggests a role 
for pre-pubertal bone growth in osteosclerosis (Hsiao et al., 2008). Significantly, 
induction of Rs1 expression in mice at P28, followed by continuous or intermittent 
exposure to the Rs1 agonist RS67333 from P70 to P140, greatly increased bone 
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formation (Hsiao et al., 2010b), indicating that adult bone tissue is still sensitive to 
Gs-mediated signaling. 
As these in vivo data show, RASSLs provide new models of human 
pathology, including cardiomyopathy, hydrocephalus, osteoperosis, and 
osteosclerosis. These models are useful for investigating the signaling abnormalities 
that contribute to these disorders, but the lack of external control over the timing or 
magnitude of RASSL signaling limits their utility for probing the signaling pathways 
behind complex behaviors. 
 
1.4.4 Second-generation Designer Receptors: Designer Receptors Exclusively 
Activated by Designer Drugs 
 While the first generation of orthologous ligand-GPCR pairs represented a 
significant advancement in tools for manipulating neuronal signaling pathways, both 
the in vitro and in vivo data reveal shortcomings of RASSLs. First, while the 
receptors are activated solely by synthetic ligands, the synthetic ligands do not 
solely activate the designer receptors. For example, spiradoline has only 200-fold 
higher potency at Ro1 than at hKOR (Coward et al., 1998), and THIQ is more potent 
at MC4 than at Rm1 or Rm2 (Srinivasan et al., 2007). Therefore, to selectively 
activate only the RASSL and not the native receptor in vivo, one must either use a 
knockout background, which introduces a variety of confounds into the experimental 
design, or one must locally infuse the synthetic ligand to a tissue or region that 
expresses only the RASSL and not the wild-type receptor. This latter option 
eliminates one of the advantages of this system, namely, its non-invasiveness. 
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Second, in vivo use of RASSLs (Ro1 and Rs1) has resulted in fatal baseline (in the 
absence of agonist) pathologies in multiple tissues. Whether these pathologies result 
from constitutive activity of RASSLs or whether the local concentration of 
endogenous ligand is sufficient to activate RASSLs is unclear; however, the baseline 
pathologies stem from upregulated signaling of GPCR pathways. 
 Given these limitations of first-generation RASSLs, the Roth laboratory 
sought to develop a new generation of designer receptors that would meet all the 
criteria of first-generation RASSLs [i.e., no endogenous ligand would activate the 
receptors; a synthetic ligand with favorable pharmacokinetics would activate the 
receptors with affinity suitable for in vivo use (low nanomolar), and the receptors 
would couple to each of the canonical G proteins] with the following additional 
stipulations: 1) the receptor would have no or minimal baseline activity; and 2) the 
synthetic ligand would be inert, that is, active only at the designer receptor and not at 
any endogenous target. This section summarizes the development of receptors that 
meet these requirements. 
 
1.4.4.1 Orthologous ligand-receptor complexes with two-way selectivity 
 The first designer receptor that displayed two-way selectivity was actually a 
rationally mutated β2-AR. With a goal of developing a tool suitable for gene therapy, 
Small et al. (Small et al., 2001) developed what they termed a Therapeutic Receptor-
Effector Complex (TREC). They mutagenized the binding pocket and several 
regulatory residues of the β2-AR and fused the C-terminus of the receptor to a 
modified Gs subunit. A non-biogenic amine (L-158,870) that Strader et al. (Strader et 
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al., 1991) had originally identified as being inactive at the wild-type β2-AR fully 
activated their mutant β2-AR with low micromolar potency, and endogenous β2-AR 
agonists were inactive at the novel receptor. Thus, they had achieved the two-way 
selectivity necessary for a TREC and a DREADD. However, they did not screen L-
158,870 for activity at other endogenous targets and, while the TREC was an 
improvement upon the work from the Strader lab, the potency of L-158,870 for the 
designer receptor was still relatively low (EC50 7 μM) and not ideal for in vivo 
applications. 
 Neoceptors and neoligands represent additional tools with two-way 
selectivity (Jacobson et al., 2001; Jacobson et al., 2005; Gao et al., 2006; Jacobson 
et al., 2007). Neoceptors are modified adenosine receptors, and their cognate 
ligands are modified nucleotides. Jacobson et al. (Jacobson et al., 2001; Jacobson 
et al., 2007) employed rational design to generate an H272E mutation in the seventh 
transmembrane domain of the A3 adenosine receptor (A3A) that impaired affinity of 
native A3A ligands, including adenosine. Additionally, they added an amino group to 
the ribose moiety of adenosine to yield 3ʼ-amino-3ʼ-deoxyadenosine, a novel 
nucleotide with seven-fold higher potency for A3AH272E than for wild-type A3A. 
Additional adenosine derivatives yielded more selective neoligands (Gao et al., 
2006). A similar approach generated a neoceptor/neoligand pair for the A2 
adenosine receptor (A2A). The A2A neoligand has 161-fold higher potency at the 
neoceptor, A2AQ89D, than at the wild-type A2A (Jacobson et al., 2005). As with the 
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TREC, neoceptors/neoligands were an advancement in selective modulation of a 
mutant receptor but were still not well-suited for in vivo use. 
 
1.4.4.2 Directed Molecular Evolution generates a family of designer receptors 
Doctor Roth’s group took a novel approach to creating designer receptors that 
exhibit the desired properties, namely, directed molecular evolution (Armbruster et 
al., 2007; Dong et al., 2010b). The approach relied not on rational design – 
generating receptors with deliberate mutations at residues critical for ligand binding 
– but instead on random mutagenesis via error-prone PCR. Investigators have 
successfully applied this approach to generate proteins with specific enzymatic or 
catalytic activities, for instance (Yuan et al., 2005).  
A designer ligand was selected first: clozapine-N-oxide, which was known to 
be inert at endogenous targets (Weiner et al., 2004; Armbruster et al., 2007) and 
highly bioavailable and blood-brain barrier-permeable in both humans and mice 
(Bender et al., 1994; Chang et al., 1998). Given its structural similarity to clozapine, 
which is a weak partial agonist at muscarinic receptors (Davies et al., 2005), it was 
predicted that introducing only a few mutations to that receptor family could yield 
receptors that are sensitive to CNO (Armbruster et al., 2007). The early work on this 
project was completed by Dr. Blaine Armbruster, a former member of the Roth 
laboratory. Using the Gq-coupled M3 muscarinic receptor [modified for optimal 
expression in yeast (Erlenbach et al., 2001)], for which clozapine has moderate 
affinity and weak potency, as the template receptor, he used error-prone PCR to 
generate a library of several hundred thousand mutants, and transformed the library 
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into yeast. He utilized a strain of Saccharomyces cerevisiae in which heterologously 
expressed GPCRs couple to the pheromone signaling pathway, and activation of 
that pathway drives transcription and expression of essential nutrients, thus enabling 
growth on selective media (Pausch et al., 1998; Erlenbach et al., 2001; Dong et al., 
2010b). Doctor Armbruster developed three successive generations of mutant 
receptor libraries; screened them for growth in response to 10 µM clozapine, 1 µM 
CNO, and 5 nM CNO, respectively; and selected mutants that exhibited potent 
growth profiles in response to CNO but not in response to ACh or in the absence of 
ligand [for a detailed protocol, see (Armbruster et al., 2007; Dong et al., 2010b)]. 
As predicted, two mutations rendered M3 insensitive to its native ligand, ACh, 
and highly sensitive to the designer ligand, CNO. Importantly, these two mutations 
(Y149C and A239G; Figure 1.4A), which were necessary and sufficient to generate 
a DREADD, were at highly conserved residues. Mutating the analogous residues of 
other muscarinic family members generated a family of DREADDs that couple to Gi 
and Gq G proteins, as do the native muscarinic receptors. In smooth muscle cells, 
the Gq-coupled human M3 DREADD (hM3Dq) potently and selectively stimulates 
PIP2 hydrolysis (Figure 1.4B), calcium release, and ERK1/2 activation in response to 
CNO, while the Gi-coupled human M4 DREADD (hM4Di; derived from the M4 
muscarinic receptor) stimulates calcium release (in a pertussis toxin-sensitive 
manner) and ERK1/2 activation, inhibits forskolin-induced cAMP formation, and, in 
cultured neurons, activates GIRK, thereby causing hyperpolarization and inhibition of 
basal action potential firing (Armbruster et al., 2007). As Figure 1.4B shows, these 
cellular responses occur only following treatment with CNO; they are notably absent 
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following treatment with ACh or carbachol. Additionally, the receptors exhibit no 
baseline activity. 
As none of the native muscarinic receptors couple to Gs, Jurgen Wess’ group 
generated a chimera of the rat M3 receptor in which they introduced the Y149C and 
A239G mutations and exchanged the intracellular loops for those of the Gs-coupled 
turkey β1-adrenergic receptor (β1-AR) (Figure 1.4A). Clozapine-N-oxide maintains its 
potency and efficacy at the chimeric receptor, and the receptor couples selectively to 
Gs to stimulate adenylyl cyclase, thus yielding a Gs-coupled DREADD (rM3/β1Ds) 
(Guettier et al., 2009). 
The Roth laboratory and others have now validated DREADDs that couple to 
the canonical Gq, Gi, and Gs signaling pathways. In vitro, these receptors have 
served as tools for investigating allosterism (Nawaratne et al., 2008) and GPCR 
dimerization (Alvarez-Curto et al., 2010). This thesis describes the in vivo validation 
of hM3Dq function; a discussion of the in vivo activity of hM4Di and rM3/β1Ds is 
presented in the final chapter. 
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Figure 1.4. DREADDs are mutant muscarinic receptors 
 A. DREADDs are formed by point mutations in the third and fifth transmembrane 
regions of muscarinic receptors (stars; Y149C and A239G in hM3). Additionally, the 
Gs-coupled DREADD contains the second and third intracellular loops of the β1-AR 
in place of those of the M3 muscarinic receptor (gray loops). B. In human pulmonary 
artery smooth muscle cells, the hM3Dq receptor (hM3D) is selectively activated by 
CNO but not by ACh, resulting in PIP2 hydrolysis. Conversely, the wild-type M3 
muscarinic receptor (hM3) is potently activated by ACh but not by CNO. Adapted 
from (Armbruster et al., 2007). 
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 CHAPTER 2: MATERIALS AND METHODS 
 
*This chapter is adapted from Alexander et al., 2009. The protocols for the 
electrophysiology studies are described by Dr. Georgia Alexander. 
 
 All animal experiments were performed in accordance with the National 
Institutes of Health’s guidelines for the care and use of animals and with approved 
animal protocols from the Institutional Animal Care and Use Committees of the 
University of North Carolina at Chapel Hill and Duke University. 
 
2.1 hM3Dq expression and signaling in neuronal cultures 
 
2.1.1 Viral Construct 
 A lentiviral construct was developed by Dr. Ying Pei. Briefly, an IRES 
sequence from the pIRES-neo vector (Clontech, Palo Alto, CA) was cloned into an 
mCherry vector (Shu et al., 2006) using the Xi-clone High-Speed Cloning Kit (Gene 
Therapy Systems, Inc., San Diego, CA) to generate pIRES-mCherry. The coding 
region for hM3Dq was subsequently subcloned into pIRES-mCherry upstream of the 
IRES sequence to generate p-hM3Dq-IRES-mCherry. 
 To generate a lentiviral construct, the coding region for hM3Dq-IRES-
mCherry was subcloned into the lentiviral expression vector FUGW [(Lois et al., 
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2002), a gift from Dr. Guoping Feng (Duke University)]. Fugene6 (Roche Applied 
Science, Indianapolis, IN) was used to co-transfect seven 15 cm2 dishes of 
HEK293T cells with the FUGW plasmid and two viral packaging constructs (Δ8.9 
HIV-1 and VSVG) in a ratio of 3.3:2.5:1. Lentivirus-containing media was collected 
48 hours post-transfection. Virus was concentrated by centrifugation and Amicon 
ultra-15 centrifugal filter devices (Millipore, St. Louis, MO), aliquoted, and frozen at -
80°C until use. 
 
2.1.2 Primary neuronal cultures 
 For primary mouse hippocampal cultures, the hippocampus of a P1 mouse 
brain was dissected, digested for 20 minutes at 37°C in 0.1% papain in neurobasal 
media supplemented with 0.2% BSA, washed with complete neurobasal media 
(neurobasal media supplemented with 1x B27, 10 mg/ml L-glutamine, and 10 mg/ml 
glutamate), and mechanically dissociated with a Pasteur pipette. The sample was 
centrifuged at 200 x g for 5 minutes at room temperature and pellets were 
resuspended in pre-equilibrated (37°C, 95% O2/5% CO2) complete neurobasal 
medium. Cells were seeded on 96-well plates pre-coated with poly-L-lysine solution 
(0.1 mg/ml low molecular weight poly-L-lysine, 0.625% boric acid, 0.955% borax) at 
an approximate density of 40,000 cells/well and maintained in 95% O2/5% CO2 at 
37°C with periodic additions of complete neurobasal media. 
 
2.1.3 Calcium Flux Assay 
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 After 5-7 days in vitro (DIV), mouse primary hippocampal cultures were 
infected with concentrated hM3Dq-IRES-mCherry lentivirus in a 1x polybrene 
solution (2 µl/well). Several wells per plate were not treated with virus to provide 
uninfected control cultures. Forty-eight hours post-infection, complete media was 
replaced with Calcium Plus dye (Molecular Devices, Sunnyvale, CA) reconstituted in 
FLIPR buffer (HBSS, 2.5 mM probenecid, 20 mM HEPES, pH 7.4; 15 ml buffer/bottle 
of lyophilized dye yielded a 20x dye stock) and incubated for one hour. Cells were 
imaged with a BD Pathway 855 high content imaging microscope (BD Biosciences, 
Rockville, MD) equipped with automated fluid handling and environmental control, 
and cells were maintained at 37°C. Prior to drug addition, infected neurons were 
identified by detection of mCherry fluorescence. The calcium signal was measured 
for 10 seconds to obtain baseline fluorescence, after which CNO was added at a 
final concentration of 1 µM. Imaging continued for approximately 90 seconds after 
addition of drug. Whole-cell fluorescence of each cell over the course of the assay 
was determined using ImageJ software (http://rsbweb.nih.gov/ij/; National Institutes 
of Health, Bethesda, MD) and was normalized to initial baseline fluorescence. Cells 
were classified as responding if they exhibited at least a 0.3-fold change in whole-
cell fluorescence. Data from responding cells from three independent experiments 
were pooled and analyzed with Prism 4.0. 
 
2.2 Development of hM3Dq mice and characterization of hM3Dq receptor 
expression 
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2.2.1 Generation of TRE-HA-hM3Dq mice 
The cloning of the DNA plasmid for transgenesis was performed by Dr. Blaine 
Armbruster. The plasmid pTre-Tight, containing the tetracycline response element 
(TRE) upstream of a multiple cloning site, was purchased from Clontech 
Laboratories (Mountainview, CA). To generate pHA-Tre-Tight, a Kozak sequence 
and a hemagglutinin (HA) epitope tag with an initiating methionine residue 
(MYPYDVPDYA) were inserted into the BamHI site of pTre-Tight. The plasmid 
pcDNA3.1(+) containing human muscarinic 3 (hM3) receptor (University of Missouri-
Rolla cDNA Resource Center; Rolla, MO) was obtained, and the receptor was 
cloned into pcDNA3.1(+)-EcoRI, a modified vector, generated by Dr. Armbruster, 
with an additional EcoRI site downstream of the XbaI site. To generate hM3Dq from 
the wild-type hM3 receptor, the mutations Y149C3.33 and A239G5.46 were 
sequentially introduced into the insert using the Quikchange Site-Directed 
Mutagenesis kit (Stratagene; La Jolla, CA). Additionally, a mutation was generated 
in the XhoI site (TCGCGA to TCCCGA) to eliminate that enzyme’s recognition 
sequence. The hM3Dq insert was then digested with BamHI and XbaI and 
subcloned into the respective sites of pHA-Tre-Tight, generating pHA-Tre-Tight-
hM3Dq. Sequence identity of the receptor was confirmed by automated sequencing 
(Cleveland Genomics; Cleveland, OH). The plasmid pHA-Tre-Tight-hM3Dq was 
subsequently digested with PvuI and XhoI to generate Tre-HA-hM3Dq DNA. 
Pronuclear injection of B6SJL hybrid mouse oocytes using this 2.36 kb digestion 
product was performed by the Case Transgenic and Targeting Facility (Case 
Western Reserve University; Cleveland, OH). 
 72 
 
2.2.2 Genotyping and breeding of hM3Dq mice 
Founder mice were identified by PCR of genomic DNA extracted from tail 
clips. The following oligonucleotide primers were used: 5’-
CAAATGTTGCTTGTCTGGTG and 5’-GTCAGTCGAGTGCACAGTTT, to amplify a 
200 bp endogenous mouse genomic DNA control fragment; and 5’-
ACCGTCAGATCGCCTGGAGA and 5’-TCATCGGTGGTACCGTCTGGAG, to 
amplify a 259 bp TRE-HA-hM3Dq fragment. The PCR conditions were as follows: 
94˚C for 3 min; 12 cycles of 94˚C for 20 sec, 64-58˚C (step-down over the 12 cycles) 
for 30 sec, 72˚C for 35 sec; 28 cycles of 94˚C for 20 sec, 58˚C for 30 sec, 72˚C for 
35 sec; and 72˚C for 4 min. 
 Upon identification, founder TRE-HA-hM3Dq mice were crossed with mice 
carrying the tTA transgene driven by the calcium-calmodulin dependent kinase II 
alpha (CaMKIIα) promoter on a B6/CBA background (The Jackson Laboratory; Bar 
Harbor, Maine). These CaMKIIα-tTA Tet-off mice have been described previously 
(Mayford et al., 1996). Double-transgenic mice carrying both the TRE-HA-hM3Dq 
and CaMKIIα-tTA transgenes (hM3Dq mice) were identified as described above, 
with the addition of the primers 5’-CGCTGTGGGGCATTTTACTTTAG and 5’-
CATGTCCAGATCGAAATCGTC to amplify a 450 bp fragment of the tTA coding 
region. Gene expression in double transgenic mice was maintained by raising mice 
on a diet free of doxycycline. 
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2.2.3 Immunoprecipitation and Western detection of hM3Dq transgene 
 To verify that mice carrying both the TRE-HA-hM3Dq and CaMKIIα-tTA 
transgenes were expressing hM3Dq protein, immunoprecipitation of HA-containing 
protein followed by detection of protein by Western blot were performed. Briefly, 
mice were anesthetized with 20 µl/g Avertin (12.5 µg/ml tribromoethanol and 0.8% 
tert-amylalcohol); the brains were removed; and the cerebellum was discarded. The 
brain was homogenized in HEPES-sucrose buffer (320 mM sucrose, 2 mM EDTA, 
10 mM HEPES, pH 7.4, supplemented with 1x Complete EDTA-free protease 
inhibitors (Roche; Indianapolis, IN)) followed by centrifugation at 1,000 x g for 15 min 
at 4˚C. The nuclear pellet was discarded. Supernatants were centrifuged at 40,000 x 
g for 2:40 hrs at 4˚C, and membranes were resuspended in 700 ul of 4˚C RIPA-
EDTA lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% SDS, 0.5% 
deoxycholate, 1% NP-40, 1x complete protease inhibitors [Roche], 1 mM DTT) and 
allowed to lyse at 4˚C for 30 min with agitation. Non-solubilized material was 
removed by centrifugation at ~14,000 x g for 30 min at 4˚C.  Protein content in 
supernatant was normalized, and 10 mg protein was added to 15 µl of settled anti-
HA affinity matrix (clone 3F10, Roche). An equal volume of PBS with 1x complete 
protease inhibitors was added, and immunoprecipitation was allowed to proceed 
overnight at 4˚C with mild agitation. Resin was pelleted at 500 x g for 1 min, 
supernatant was removed, and resin was washed twice with 1 ml of cold PBS-IP 
buffer wash (1xPBS, 0.2% deoxycholate, 0.2% NP-40). Forty microliters of 2x SDS 
dye was added to resin and heated at ~70˚C for 6 min to release 
immunoprecipitated protein from resin. Proteins were then separated by SDS-PAGE, 
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transferred to nitrocellulose, and probed with 0.2 ng/ml of mouse anti-HA antibody 
(12CA5, Roche) followed by horse anti-mouse secondary antibodies (1:1000; Vector 
Labs; Burlingame, CA). The blot was incubated with chemiluminescent substrate 
(Thermo Scientific; Rockford, IL) and imaged on a Kodak Imager. 
  
2.2.4 Immunohistochemistry 
Adult mice were anesthetized with Avertin as described above and 
transcardially perfused with PBS followed by 4% paraformaldehyde in PBS (PFA), 
pH 7.4. The brains were collected, post-fixed overnight at 4°C in 4% PFA, and 
incubated overnight at 4°C in a 30% sucrose (w/v) solution in PBS.  Brains were 
then frozen at -80°C, and 30 µm frozen coronal tissue sections were cut and 
mounted on SuperFrost Plus Slides (Fisher Scientific, Houston, TX) for 
immunohistochemistry. 
 Slides were blocked for 1 hour at room temperature in 3% bovine serum 
albumin in PBS containing 0.3% Triton X-100 (PBS-Tx). Rabbit polyclonal anti-HA 
(1:250, Zymed, Carlsbad, California) and mouse monoclonal anti-parvalbumin 
antibodies (1:1000, Sigma-Aldrich, St. Louis, MO) were diluted in blocking buffer and 
applied to slides overnight at 4°C. Slides were washed with PBS-Tx, after which 
AlexaFluor 488 and 594 goat anti-rabbit antisera (1:250 for each, Invitrogen, 
Eugene, OR) were diluted in blocking buffer and applied to slides for 1 hour at room 
temperature. Slides were then washed in PBS-Tx and mounted with fluorescent 
mounting media. Fluorescent images were collected on a Nikon 80i Research 
Upright Microscope (Nikon, Tokyo, Japan) equipped with Surveyor Software with 
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TurboScan (Objective Imaging, Kansasville, WI). Tiled images were collected with a 
Qimaging Retiga-EXi camera (Qimaging, Surrey, BC, Canada). 
 
2.2.5 Radioligand Binding Assays 
 Homogenates were prepared as follows: the cortex and hippocampus were 
rapidly dissected out of adult mouse brains and immediately frozen on dry ice. 
Brains were thawed in standard binding buffer (0.1 mM EDTA, 10 mM MgCl2, 50 mM 
Tris, pH 7.4) and homogenized using a Tissue Tearor™ (BioSpec Products 
Bartlesville, OK). The homogenate was centrifuged at 25,000 x g for 10 minutes at 
4°C. The pellet was resuspended in standard binding buffer and centrifuged at 
18,000 x g for 5 minutes at 4°C, and the pellet was then frozen and stored at -80°C. 
 At the time of the assay, pellets were resuspended in 3 ml standard binding 
buffer, and protein concentration was determined using a Bradford protein assay. 
Binding assays were as previously described (Armbruster et al., 2007) with 
modifications. In brief, following normalization for protein content, samples were 
added to drug wells containing 1.5 nM [3H]QNB, ACh at concentrations ranging from 
10-2 to 10-8 M (prepared in standard binding buffer from 1-mM DMSO stocks), and 
buffer and incubated for 1 hour at room temperature. Atropine (1 µM) was used to 
determine non-specific binding; total binding was determined in the absence of cold 
ligand. All conditions were measured in duplicate. Reactions were harvested by 
vacuum filtration through Whatman glass fiber filters (GF/B) (Laboratory Products 
Sales, Rochester, NY), and filters were washed three times with ice-cold harvesting 
buffer (50 mM Tris, pH 7.4; pH 6.9 at room temperature). Radioactivity was 
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determined by liquid scintillation counting using a Tri-Carb 2800TR (Perkin Elmer, 
Norwalk, CT). The Bmax and Ki values were determined simultaneously by LIGAND 
(Munson and Rodbard, 1980) using a weighted non-linear regression algorithm, and 
the fitted parameters were entered into Prism4.0 to generate competition curves. 
 
2.2.6 Nissl Staining 
 Following induction of anesthesia, adult mice (3 hM3Dq, 3 controls) were 
euthanized by cervical dislocation, and their brains were removed and immediately 
frozen. A cryostat was used to make 30 µm coronal sections that were mounted on 
SuperFrost Plus Slides (Fisher Scientific, Houston, Tx). For Nissl staining, slides 
were incubated in the following solutions: 95% ethanol for 15 minutes, 70% ethanol 
for 1 minute, 50% ethanol for 1 minute, water for 2 minutes, water for 1 minute, 0.1% 
(w/v) cresyl violet acetate in water for 30 minutes, water for 1 minute, 50% ethanol 
for 1 minute, 95% ethanol for 2 minutes, and 100% ethanol for 1 minute. Slides were 
dried and mounted with Permount. (Fisher Scientific, Houston, Tx). Montage images 
were acquired on the BD Pathway 855 High Content Microscope using a 4x 
objective. The width of five hippocampal regions (CA1, CA2, CA3, dorsal dentate 
gyrus, and ventral dentate gyrus) was determined using ImageJ software. Values 
from both hemispheres of three representative sections from each animal were 
pooled. 
 
2.3 Behavioral Assays 
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2.3.1 Baseline Behavioral Testing 
 Eleven littermate pairs (6 male pairs, 5 female pairs) of hM3Dq double-
transgenic mice and TRE-hM3Dq single-transgenic mice (lacking the CaMKIIα-tTA 
transgene) underwent an extensive regimen of behavioral testing; this testing was 
performed by the Mouse Behavioral Phenotyping Core at the University of North 
Carolina at Chapel Hill. Mice were approximately three months old when testing 
began. Tests were given in the following order, with one or two procedures per 
week: elevated plus maze, neurobehavioral screen, open field activity, accelerating 
rotarod, prepulse inhibition of acoustic startle responses, buried food test for 
olfactory ability, and Morris water maze (visual cue test, hidden platform acquisition, 
and reversal learning). All measures were taken by an observer blind to mouse 
genotype. Data were analyzed using one-way or repeated measures analyses of 
variance (ANOVA). Fisher’s protected least significant difference (PLSD) tests were 
used to compare group means when a significant F value was determined. Data are 
presented as mean ± SEM, with p<0.05 considered significant. 
 
2.3.1.1 Elevated plus maze test for anxiety-like behavior 
Mice were given one five-minute trial on the plus maze, which had two walled 
arms (the closed arms, 20 cm in height) and two open arms. The maze was elevated 
50 cm from the floor, and the arms were 30 cm long. Animals were placed on the 
center section (8 cm x 8 cm), and allowed to freely explore the maze. Measures 
were taken of time on, and number of entries into, the open and closed arms. 
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2.3.1.2 Neurobehavioral screen for reflex, sensory, and motor impairment 
The neurobehavioral screen consisted of several measures to assay overall 
appearance and behavior of the mice. Measures included general observations on 
coat condition, body posture, and normality of gait. Reflexive reactions to a gentle 
touch from a cotton-tipped swab to the whiskers and the approach of the swab to the 
eyes were assessed. Each subject was placed in a small, empty, plastic cage, and 
ability to remain upright when the cage was moved from side-to-side or up-and-down 
was noted. Locomotor coordination was assayed by allowing the mouse to walk 
across an elevated dowel (wrapped in nylon rope to facilitate grasping) and to climb 
a similar pole. Each subject was also placed on a wire grid and allowed to hang for 
one minute. Reaction to 20 seconds of tail suspension was recorded. 
 
2.3.1.3 Accelerating Rotarod 
Subjects were evaluated for motor coordination and balance on an 
accelerating rotarod (Ugo Basile, Stoelting Co., Wood Dale, IL). For the first test 
session, animals were given 3 trials, with 45 seconds between each trial. Two 
additional trials were given 48 hours later. The rpm (revolutions per minute) was set 
at an initial value of 3, with a progressive increase to a maximum of 30 rpm across 5 
minutes (the maximum trial length). Measures were taken for latency to fall from the 
top of the rotating barrel. 
 
2.3.1.4 Open Field Activity 
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Exploration in a novel environment was assessed by a one-hour trial in an 
open field (40 cm x 40 cm x 30 cm) crossed by a grid of photobeams (VersaMax 
system, AccuScan Instruments, Columbus, OH). Counts were taken of the number 
of photobeams broken during the trial in five-minute intervals, with separate 
measures for ambulation (total distance traveled), fine movements (repeated 
breaking of the same set of photobeams within 1 s), and vertical activity (rearing 
movements). Time spent in the center region of the activity chamber was used as a 
measure of anxiety-like behavior in a novel environment. 
 
2.3.1.5 Acoustic startle and pre-pulse inhibition of acoustic startle 
The acoustic startle test was used to assess auditory function and sensorimotor 
gating. The test is based on the measurement of the reflexive whole-body flinch, or 
startle response, that follows exposure to a sudden noise. Assessments were made 
of startle magnitude and of pre-pulse inhibition, which occurs when a weak 
prestimulus leads to a reduced startle in response to a subsequent louder noise. For 
this study, animals were tested with a San Diego Instruments SR-Lab system (San 
Diego Instruments, San Diego, CA). Briefly, mice were placed in a small Plexiglas 
cylinder within a larger, sound-attenuating chamber. The cylinder was seated upon a 
piezoelectric transducer, which allowed vibrations to be quantified and displayed on 
a computer. The chamber included a houselight, fan and a loudspeaker for the 
acoustic stimuli. Background sound levels (70 dB) and calibration of the acoustic 
stimuli were confirmed with a digital sound level meter (San Diego Instruments). 
Each mouse was given one session, consisting of 42 trials, that began with a 5 min 
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habituation period.  There were 7 different types of trials:  the no-stimulus trials, trials 
with the acoustic startle stimulus (40 msec; 120 dB) alone, and trials in which a 
prepulse stimulus (20 msec; either 74, 78, 82, 86, or 90 dB) occurred 100 ms before 
the onset of the startle stimulus.  Measures were taken of the startle amplitude for 
each trial across a 65-msec sampling window, and an overall analysis was 
performed for each subject's data for levels of prepulse inhibition at each prepulse 
sound level (calculated as 100 - [(response amplitude for prepulse stimulus and 
startle stimulus together / response amplitude for startle stimulus alone) x 100].  
 
2.3.1.6 Test for olfactory function 
Several days before the olfactory test, an unfamiliar food (Froot Loops, 
Kellogg Co., Battle Creek, MI) was placed overnight in the home cages of the 
subject mice. Observations of consumption were taken to ensure that the novel food 
was palatable to the mice. Sixteen to twenty hours before the test, all food was 
removed from the home cage. On the day of the test, each mouse was placed in a 
large, clean tub cage (46 cm L x 23.5 cm W x 20 cm H), containing paper chip 
bedding (3 cm deep), and allowed to explore for five minutes. The animal was 
removed from the cage, and one Froot Loop was buried in the cage bedding. The 
animal was then returned to the cage and given fifteen minutes to locate the buried 
food. Measures were taken of latency to find the food reward. 
 
2.3.1.7 Morris water maze test 
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The Morris water maze task was used to assess visual ability and spatial 
learning in the mice. The water maze consisted of a large circular pool (diameter = 
122 cm) partially filled with water (45 cm deep, 24-26oC) located in a room with 
numerous visual cues. Mice were tested for their ability to find an escape platform 
(diameter = 12 cm) in three different procedures: ability to find a cued visible 
platform, acquisition in the hidden (submerged) platform test, and reversal learning 
with the hidden platform moved to the opposite quadrant. In addition, at the end of 
the hidden platform acquisition and reversal learning phases, mice were given 1-min 
probe trials with the platform removed. In these probe trials, spatial learning could be 
demonstrated by higher levels of swimming in the quadrant where the platform had 
been located in the training trials, versus swimming in the other quadrants of the 
pool. 
In the visual cue test, each animal was given 4 trials per day, across 3 days, 
to swim to an escape platform cued by a patterned cylinder extending above the 
surface of the water. For each trial, the mouse was placed in the pool at one of four 
possible locations (randomly ordered) and then given 60 sec to find the cued 
platform. If the mouse found the platform, the trial ended, and the animal was 
allowed to remain 10 sec on the platform before the next trial began. If the platform 
was not found, the mouse was placed on the platform for 10 sec, and then given the 
next trial. Measures were taken of latency to find the platform and swimming speed 
via an automated tracking system (Noldus Ethovision).  
The following week, mice were trained on the hidden platform test. Using the 
same procedure as described above, each animal was given 4 trials per day, across 
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9 days, to learn the location of the submerged platform. The criterion for learning 
was an average latency of 15 sec or less to locate the platform across a block of 4 
consecutive trials per day. At the end of day 9 of testing, mice were given a 1-min 
probe trial in the pool with the platform removed. Selective quadrant search was 
evaluated by measuring percent of time spent in each quadrant of the pool. In the 
week following the acquisition phase, mice were tested for reversal learning, using 
the same procedure. In this phase, the hidden platform was located in a different 
quadrant in the pool, diagonal to its previous location. On the day that the group met 
the 15-sec criterion for learning, mice were given a 1-min probe trial with the 
platform removed from the pool. 
 
2.3.2 Behavioral Responses to CNO 
 
2.3.2.1 Stereotypy and locomotion 
 Stereotypic movements and overall locomotion were assessed by sessions in 
an open field chamber (40 cm x 40 cm x 30 cm) crossed by a grid of photobeams 
(VersaMax system, AccuScan Instruments). For each trial, mice were placed in 
activity chambers for 20-30 minutes, depending on the expirement, prior to initiation 
of the session to control for novelty-induced locomotion. At the end of the 
acclimation interval, mice were injected with either vehicle (saline) or CNO (Biomol 
International) in vehicle, i.p., and the trial was initiated. Counts were taken of the 
number of photobeams broken during the trial in five-minute intervals, with separate 
measures for ambulation (total distance traveled) and fine movements (repeated 
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breaking of the same set of photobeams, reflecting stereotypic behaviors such as 
grooming). To allow time for CNO distribution and recovery of the animal from 
handling-induced locomotor changes, data from the first 15 minutes following CNO 
administration were excluded from analyses in which data from multiple 5-minute 
intervals were pooled. 
 
2.3.2.2 Seizure activity 
 Behavioral seizure classification was performed by Dr. Georgia Alexander 
and was based on a modified description of the Racine seizure scale (Racine, 1972; 
Borges et al., 2003). Seizure classes included 1, facial clonus; 2, head nodding; 3, 
unilateral forelimb clonus; 4, rearing and bilateral forelimb clonus; 5, rearing and 
falling (loss of postural control); 6, running or bouncing; and 7, death. 
 
2.3.2.3 Modulation of CNO- and PCP-induced locomotion 
 Locomotion was measured as described above in Section 2.3.2.1. All drugs 
were administered i.p. in a 0.9% saline vehicle. Mice were injected with saline or 
M100907 (0.5 mg/kg body weight), LY379268 (5 mg/kg body weight; Tocris 
Bioscience, Ellisville, MO), or haloperidol (0.2 mg/kg body weight) at the beginning 
of the 20-min acclimation session.  At the end of that period, control mice received 
PCP (6 mg/kg body weight; Sigma-Aldrich, St. Louis, MO) while hM3Dq mice 
received CNO (0.2 mg/kg body weight). Data were analyzed by one-way ANOVA 
followed by Bonferroni’s multiple comparison post-tests. 
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2.4 Electrophysiology 
 
 All electrophysiology experiments were performed at Duke University by Dr. 
Georgia Alexander. 
 
2.4.1 In vitro electrophysiology 
Mice (P18-P32) were anesthetized and decapitated, and the brain was 
quickly removed and placed in ice-cold buffer containing (in mM): sucrose 110, NaCl 
60, KCl 3, NaH2PO4 1.25, NaHCO3 28, CaCl2 0.5, MgCl2 7.0, and dextrose 5, 
saturated with 95% O2/5% CO2, pH 7.4. After blocking the anterior and posterior 
ends of the brain, coronal slices (400 µm in thickness) were cut with a vibratome and 
incubated in oxygenated artificial cerebrospinal fluid (ACSF) containing (in mM): 
NaCl 124, KCl 1.75, KH2PO4 1.25, NaHCO3 26, CaCl2 2.4, MgCl2 1.3, and Dextrose 
10 for at least 1 hour at room temperature before recording.  
For recordings, slices were transferred to a recording chamber at room 
temperature. Hippocampal slices were continuously perfused with oxygenated ACSF 
at a flow rate of 1.5-2 ml/min. CNO or carbachol (Sigma) was infused into the ACSF 
with a calibrated syringe pump at an infusion rate that produced a known drug 
concentration in the bath based on the ACSF flow rate. Data were collected using an 
Axopatch 1D amplifier and pClamp 10 software (Axon Instruments). CA1 pyramidal 
cells were acquired by targeting the pyramidal cell layer of CA1 and advancing 
pipettes “blind” through the tissue until forming a gigaseal. The membrane was then 
ruptured to allow whole-cell access.  
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Once accessed, CA1 pyramidal cell identity was confirmed by characteristic 
spike firing patterns of CA1 pyramidal cells (Schwartzkroin, 1977). All experiments 
were carried out in current clamp mode. To monitor changes in membrane potential 
in response to drugs, cells were held at resting membrane potential while ACSF 
containing tetrodotoxin (TTX, 1 mM; Sigma) bathed the slice to block action 
potentials and to permit the study of CA1 pyramidal cell membrane responses in the 
absence of any synaptic involvement. TTX ACSF was perfused for the duration of 
the experiment in which 3 sec long sweeps with a 300 msec hyperpolarizing step 
were taken every 10 sec. Baseline recordings were taken for 5-7 min, followed by 
infusion of either CNO or carbachol for 5 min. Response to drugs was monitored for 
at least 30 minutes or longer if recovery from drugs was not reached after 30 min. 
For investigation of PLC dependence of CNO effects on CA1 pyramidal cells, the 
active or inactive PLC inhibitor, U71322 or U73343 (Biomol International), 
respectively, were continuously perfused in the bath along with TTX, and CNO was 
bath applied. To examine effects of CNO on spike firing of CA1 pyramidal cells, TTX 
was omitted from the ACSF and cells were held at resting membrane potential. 
 
2.4.2 In Vivo Electrophysiology 
 
2.4.2.1 Animals and Surgical Procedures 
 Ten double transgenic (hM3Dq), 8 single transgenic, and 5 wild-type mice 
were used for the in vivo electrophysiological studies. Of these animals, 4 hM3Dq, 6 
single transgenic (4 expressing tTA alone, 2 expressing TRE alone) and 5 wild-type 
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mice were used to generate CNO dose-response curves. A separate group, 
including 1 single transgenic and 3 hM3Dq animals, was used for doxycycline 
studies. Finally, a group of 1 single transgenic and 3 hM3Dq animals was used for 
evaluation of hM3Dq desensitization and 24-hour monitoring of LFP recovery from 
CNO. 
 Animals were anesthetized with 5% isoflurane followed by intramuscular 
injection of xylazine (5 mg/kg) and ketamine (75 mg/kg). Supplemental doses were 
administered when necessary. A ground screw was secured in the cranium as well 
as 3 anchor screws. Two craniotomies (~1.25 mm2 each) were then drilled over the 
hippocampi and microarrays were lowered into the brain through the craniotomies. 
Microarray design included [32S]-isonel-coated tungsten microwire electrodes (35 
mm in diameter) arranged in two 4x4 grids (intrawire spacing 250 mm), one grid 
targeting each hippocampus, with each wire cut to 5 mm length. The stereotaxic 
coordinates used to target hippocampi with each electrode grid were 1.5 - 2.25 mm 
posterior to Bregma, 1.55 – 2.3 mm lateral, ~1.9 mm ventral. Wires were lowered 
using physiological guidance toward hippocampus, and electrodes were secured at 
this depth with dental acrylic.  
 
2.4.2.2 Electrophysiological Procedures 
 Microwire electrodes were connected to a printed circuit board (PCB), which 
was connected to a pre-amplifier by a miniature connector. Neural activity was 
recorded from the 32 implanted microwires and processed using a Multineuron 
Acquisition Processor (Plexon Inc., Dallas, TX). Local field potentials (LFPs) were 
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preamplified (500x), filtered (0.3– 400 Hz), and digitized at 1000 Hz using a Digital 
Acquisition card (National Instruments, Austin, TX) and a Multi-Neuron Acquisition 
Processor (Plexon, Dallas, TX). Simultaneous single unit recordings were made 
from the same wires that were used to collect LFP data (Nicolelis et al., 1997). 
Waveforms were categorized as single units online by means of a voltage threshold 
and principal component analysis. Waveforms were subsequently sorted offline 
using Offline Sorter (Plexon Inc.) to confirm the quality of the recorded spikes and 
separated into individual single units. Behaviors were recorded with a CCD video 
camera and a videocassette recorder. Video and neural recordings were 
synchronized with a millisecond precision timer (model VTG-55; For-A, Tokyo, 
Japan).  
For each experiment, baseline recordings were taken for at least 15 minutes 
followed by treatment with vehicle (saline) or drug. Following a post-operative 
recovery of one week, recordings were taken before and following treatment with 
saline. Responses to increasing doses of CNO (0.03-5 mg/kg) were subsequently 
examined following treatment at three-day intervals. Recordings were taken for at 
least 2 hours during each session except when CNO evoked status epilepticus (SE; 
persistent class 4-6 seizures). When SE was evoked, recordings were taken for 3 
hours from the start of SE unless the animal died during those 3 hours. If the animal 
survived the entire 3 hours, diazepam (10 mg/kg, ip) was administered to suppress 
seizures.  
For doxycycline control experiments, animals were treated with a diet 
including doxycycline (200 mg/kg) for 4 weeks. During the third week, electrodes 
 88 
were surgically implanted so that the one-week post-operative recovery period 
coincided with the 4th week of doxycycline treatment. Responses to saline were 
examined and responses to CNO (5 mg/kg) were examined the following day. 
Thereafter, animals were returned to a normal diet, and 4 weeks later responses to 
saline and CNO (5 mg/kg) were examined a second time. 
  
2.4.2.3 Electrophysiology Data Analysis 
All electrophysiological data analyses were performed using Neuroexplorer 
software (Nex Technologies, TX) and Matlab (MathWorks, Inc., Natick, MA). For 
power spectral analyses of LFPs, power spectrograms were first generated to 
visualize LFP frequency changes following drug administration. Subsequent power 
spectral density analyses examined frequency bands of interest. Peak power in 
gamma range (30-80 Hz) was measured for a 1000 sec epoch before drug 
administration and for a 1000 sec epoch between 3000 and 4000 sec following drug 
administration. The latter time was chosen based on pilot experiments that revealed 
spectral alterations from baseline peaked between 3000 and 4000 sec after CNO 
administration, and this time was therefore used for all animals and all treatments. A 
repeated-measures ANOVA was used to compare the effect of drug dose on power 
spectral changes in animals of different genotypes and before and after doxycycline 
treatment. 
CHAPTER 3: REMOTE CONTROL OF NEURONAL ACTIVITY IN TRANSGENIC 
MICE EXPRESSING EVOLVED G PROTEIN-COUPLED RECEPTORS 
 
*This chapter is adapted from Alexander et al., 2009. The electrophysiology studies 
were performed and described by Dr. Georgia Alexander, and the discussion was a 
collaborative effort between Dr. Alexander and myself. 
 
3.1 Introduction and rationale 
 
 Methods to examine the behavioral consequences of activation of neuronal 
ensembles are powerful tools for understanding brain function, as exemplified by 
Wilder Penfield’s pioneering studies of focal electrical stimulation of human cortex 
(Penfield and Jasper, 1954). The development of genetic and optical tools to 
visualize and activate neuronal activity with exquisite temporal resolution using 
microbial opsins (e.g. channelrhodopsin-2, halorhodopsin, Volvox carteri 
channelrhodopsin, optoXRs) has provided an expanding toolbox for decoding the 
neuronal correlates of brain function (Boyden et al., 2005; Li et al., 2005; Zhang et 
al., 2007b; Zhang et al., 2008; Airan et al., 2009; Berndt et al., 2009). However, as I 
described in Chapter 1, the equipment, technological expertise, and invasiveness 
required for light-mediated activation, together with the relative inaccessibility to light 
of scattered neuronal populations, limits the potential applicability of these methods. 
Ideally, noninvasive remote control of neuronal activity in the mammalian brain 
would provide a valuable tool for elucidating how the activity of discrete populations 
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of neurons and local circuits underlies behavior in health and disease.  
Accordingly, the Roth laboratory sought to develop a chemical-genetic 
approach to control neuronal activity noninvasively in the mammalian brain by 
regulating signaling through a G protein-coupled receptor (GPCR). Others have 
worked toward similar goals (see Chapter 1), and this work represents an effort to 
advance this field. These approaches represent important advances for the 
pharmacological manipulation of neuronal activity and are valuable for many 
applications. However, continued improvements are needed to facilitate regulation of 
activity of discrete populations of CNS neurons selectively and non-invasively in 
vivo. An ideal system for neuronal regulation would meet the following criteria: 1) the 
exogenous ligand would be pharmacologically inert; 2) the exogenous ligand could 
be administered in the periphery and cross the blood-brain barrier to access receptor 
in deep brain structures and/or widely-distributed neuronal populations; 3) receptor 
expression alone would not induce pathology; 4) neuronal activity could be both 
increased and decreased; and 5) both spatial and temporal resolution would be 
sufficient to facilitate study of brain function in health and disease. 
With this ideal in mind, DREADDs were developed by directed molecular 
evolution, as described in Chapter 1 (Armbruster et al., 2007; Dong et al., 2010b). 
This chapter describes, as a proof-of-concept, a method by which the activity of 
identified populations of CNS neurons is regulated noninvasively in vivo. These 
studies used mice that express hM3Dq specifically in principal neurons within the 
forebrain, particularly in the hippocampus and cortex, by driving expression in 
double-transgenic mice in a reversible fashion with the CAMKIIα tet transactivator 
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[tTA; (Mayford et al., 1996)]. Then, local field potential (LFP) and single unit activity 
within hippocampus were recorded and showed a correlation between changes in 
neuronal activity and behaviors induced by the peripheral administration of CNO in 
mutant mice. The data demonstrate CNO-mediated neuronal activation within 
hippocampus, as measured by dose-dependent changes in the LFP and increases 
in the firing rate of interneurons (likely driven by principal neuron firing). Moreover, 
excessive activation of this pathway by high-dose CNO resulted in limbic seizures 
and status epilepticus. The selective activation of GPCRs in defined neuronal 
populations afforded by this chemical-genetic approach provides an improved tool 
for the study of mammalian brain function in health and disease. 
  
3.2 Results 
 
3.2.1 Validation of hM3Dq signaling in neurons 
 Previously, Armbruster et al. (Armbruster et al., 2007) showed in vitro that 
hM3Dq signals exclusively via the canonical Gq pathway in non-neuronal cell types. 
To assess whether hM3Dq couples to Gq in mixed neuronal-glial cultures, I 
visualized calcium flux with a calcium-sensitive dye in primary cultures of mouse 
postnatal day 1 (P1) hippocampal cells infected with hM3Dq-transducing lentivirus. 
CNO stimulated calcium transients only in those neurons expressing hM3Dq 
(identified by an IRES-driven mCherry reporter) and was without effect in uninfected 
neurons (Figure 3.1). 
 
 92 
3.2.2 Generation of hM3Dq-expressing mice 
Having thus demonstrated that hM3Dq conferred the ability to stimulate 
neuronal Gq-signaing in vitro, we sought to determine whether expression of hM3Dq 
could alter neuronal function in vivo. First, transgenic mice expressing tetracycline-
sensitive HA-tagged hM3Dq were generated using the Tet-off system (i.e. transgene 
expression is repressed upon administration of tetracycline or its analog, 
doxycycline). This system allows for inducible, spatiotemporally-regulated transgene 
expression. Pronuclear injection of B6SJL hybrid mouse oocytes with Tet Response 
Element (TRE)-hM3Dq DNA (Figure 3.2A) resulted in the birth of 35 mouse pups, of 
which ten carried the transgene. To determine whether these mice could yield brain 
region-specific expression of hM3Dq protein, TRE-hM3Dq founders were crossed 
with CaMKIIα-tTA mice in which tTA expression is targeted to principal neurons 
mainly in cortex, hippocampus, and striatum (Mayford et al., 1996) (Figure 3.2A). 
Brains were removed from F1 adults and HA-hM3Dq protein was 
immunoprecipitated from membrane fractions of whole brain (minus cerebellum) 
homogenates. Initial immunoblot analysis of the immunoprecipitates revealed 
expression of HA-hM3Dq in double-transgenic (both TRE-hM3Dq and tTA 
transgenes) F1 progeny from two of the founder mice (data not shown). Subsequent 
studies of mutant F1 progeny from both sets of founder mice did not reveal any 
differences in receptor expression or activity; therefore, I chose only one of the 
founder lines (Line 1) for all subsequent studies. Hereafter, I refer to the mice from 
this line, which express HA-hM3Dq driven by the CaMKIIα promoter, as hM3Dq 
mice. 
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Figure 3.1. hM3Dq signals through canonical Gq protein pathways in neurons 
A) A Lentiviral construct containing the hM3Dq sequences, an IRES, and an 
mCherry sequence allow for expression of DREADDs in neurons via viral infection. 
B) Hippocampal neurons infected with FUGW-hM3Dq-IRES-mCherry, but not 
uninfected neurons, respond to CNO administration with increases in intracellular 
calcium. C) Infected neurons (top row), but not uninfected neurons (bottom row), 
express mCherry and mobilize calcium following CNO application. Calcium was 
visualized with a calcium-sensitive fluorescent dye and images were pseudocolored 
using ImageJ such that warmer colors represent greater calcium mobilization. 
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Having determined that the CaMKIIα-tTA transgene effectively drives hM3Dq 
expression in the brain, I next sought to repress hM3Dq expression by doxycycline 
administration. Immunoprecipitation and immunoblot analyses similar to those 
described above revealed undetectable hM3Dq expression in both hM3Dq F1 
progeny fed doxycycline-containing chow (200 mg/kg) for one month and single-
transgenic (TRE-hM3Dq transgene only) mice fed normal chow (Figure 3.2C). These 
findings demonstrated, first, that doxycycline successfully repressed tTA-driven 
hM3Dq expression in vivo and, second, that hM3Dq expression could be temporally 
regulated. 
 
3.2.3 Characterization of hM3Dq expression 
 To examine the spatial distribution of transgene expression, I prepared 
coronal brain sections for immunofluorescence and probed them with an anti-HA 
antibody. Immunofluorescence was most intense in the cortex and hippocampus 
(Figure 3.3A-C), as expected for CaMKIIα-tTA-driven transgene expression (Mayford 
et al., 1996). Within the hippocampus, immunofluorescence was most intense in 
CA1 strata radiatum and oriens (Figure 3.3A), a pattern consistent with expression in 
the apical and basal dendrites of CA1 pyramids. Confocal immunofluorescent 
microscopic analysis of single CA1 pyramidal cells confirmed immunoreactivity in the 
soma and apical and basal dendrites (Figure 3.3B).  
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Figure 3.2. Generation of transgenic mice with inducible expression of HA-
hM3Dq 
A) Pronuclear injection of murine oocytes with the 2.36 kb XhoI restriction digest 
fragment containing HA-hM3Dq downstream of the Ptight TRE promoter produced a 
tet-responsive mouse line. When crossed with a CaMKIIα-tTA tet-driver line, tTA 
protein, produced when the CaMKIIα promoter is active, binds the TRE promoter to 
activate transcription of HA-hM3Dq; tTA binding to TRE is inhibited by doxycycline. 
B) Ethidium bromide-stained agarose gel of DNA amplified from tail clips of a single-
transgenic (TRE-hM3Dq) mouse (Lane 1), water (Lane 2), and a double-transgenic 
mouse (Lane 3) reveals presence of CaMKIIα-tTA transgene (450 bp), TRE-hM3Dq 
transgene (250 bp), and murine genomic DNA control band (200 bp). C) 
Immunoprecipitation followed by immunoblot does not detect any transgene in 
single-transgenic mice (TRE-hM3Dq transgene only, Lane 1) or double transgenic 
(hM3Dq) mice maintained on 200 mg/kg doxycycline (Lane 3), in contrast to hM3Dq 
mice maintained on normal chow in which HA protein is detectable (Lane 2). β-actin 
was detected as a loading control. Mouse brains (with cerebellum removed) were 
homogenized and the membrane-containing fraction was isolated through differential 
centrifugation. HA-affinity matrix immunoprecipitated HA-tagged proteins, which 
were then separated by SDS-PAGE and detected by Western blot with anti-HA 
antibody. 
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Figure 3.3. Receptor expression and localization in transgenic mouse brains 
A-E) Immunohistochemistry for HA-tagged protein in coronal sections from hM3Dq 
mouse brain; HA immunoreactivity localizes to the CA1 region of the hippocampus 
(A) where staining is specifically observed in the apical and basal processes of 
pyramidal neurons (B). In the cortex (C), immunoreactivity is detected in apical 
dendrites. HA immunoreactivity is present in mutant mice fed normal chow (D) but 
not in mice maintained on 200 mg/kg doxycycline (E). F) hM3Dq expression is not 
found in parvalbumin-positive interneurons; immunohistochemistry for HA-tagged 
protein (green, left panels) and parvalbumin (red, center panels) in coronal sections 
from hM3Dq mouse brain reveals that HA immunoreactivity is excluded from 
parvalbumin positive cells. 
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Apical dendrite immunoreactivity was also detected in cortex (Figure 3.3C). 
Importantly, inclusion of doxycycline in the diet resulted in no detectable 
immunoreactivity in either cerebral cortex or CA1 (compare Figure 3.3D and E). 
Additionally, a Nissl stain revealed no overt structural differences between WT and 
hM3Dq mice (Figure 3.4). 
 To obtain independent evidence of hM3Dq expression in the hM3Dq mice, I 
measured the Bmax of [3H] quinuclidinyl benzilate (QNB) binding in cortical and 
hippocampal membranes from wild-type and hM3Dq mice. Radioligand competition 
binding isotherms were first modeled based on prior affinity estimates obtained with 
cloned wild-type and hM3Dq receptors expressed in vitro [KD=0.05 nM at hM3; 
KD=1.6 nM at HA-hM3Dq; (Armbruster et al., 2007)]. Computerized simulations were 
conducted with Prism4.0 using different concentrations of [3H]QNB and various 
ratios of native to transgenic receptor expression in order to determine the optimal 
concentration of [3H]QNB, a non-selective muscarinic antagonist, for detection of 
both endogenous muscarinic receptors and hM3Dq receptors. Having determined 
the optimal assay conditions, competition curves were then obtained using 
unlabeled acetylcholine [which binds hM3Dq albeit with lower affinity compared to 
wild type mAChRs; (Alexander et al., 2009)] and [3H]QNB. Data were fit 
simultaneously by LIGAND (Munson and Rodbard, 1980) using weighted non-linear 
regression analysis and a two-site model, which best described all data sets (by F-
test). In hM3Dq tissue, a distinct site emerged for which ACh had low affinity (1.0 
mM in cortex, 1.7 mM in hippocampus) (Figure 3.5, Table 3.1). The affinity of ACh 
for this site was similar to that of ACh for cloned hM3Dq, but not wild-type 
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muscarinic, , receptors (Armbruster et al., 2007). The inclusion of doxycycline in the 
diet of hM3Dq mice eliminated this low-affinity site (Table 3.1). These data led to the 
conclusions that (1) this low-affinity ACh site accounted for the difference in Bmax 
between hM3Dq and wild-type or doxycycline-treated tissue, and (2) the difference 
in Bmax was due to hM3Dq transgene expression. Indeed, computerized non-linear 
least-squares regression analysis taking into account the difference in affinity of 
[3H]QNB for the hM3Dq and native mAChRs revealed an increase of four- and 
seven-fold in the Bmax of [3H]QNB binding to membranes isolated from cortex and 
hippocampus, respectively, of hM3Dq compared to WT mice (Figure 3.5, Table 3.1). 
These data indicate that hM3Dq was expressed in both cortex and hippocampus at 
levels greater than endogenous muscarinic receptors. 
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Figure 3.4. hM3Dq mice exhibit no gross changes in hippocampal 
cytoarchitecture 
Fresh frozen coronal sections from hM3Dq and control mice were stained with cresyl 
violet, and the width of cell body layers in the hippocampus was measured. No 
differences were detected between hM3Dq and control mice (N=3 mice/group). 
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Figure 3.5 Quantification of hM3Dq expression by radioligand binding 
A) [3H]QNB binding to cortical (left panel) and hippocampal (right panel) mouse brain 
membranes was determined by radioligand competition-binding assays. Competition 
curves depict data from one representative animal of each group. Data were fit 
simultaneously by non-linear regression. B) Mice expressing hM3Dq protein have a 
higher Bmax of [3H]QNB binding than wild-type mice or hM3Dq mice on doxycycline. 
*p < 0.05 by F test. N=3 mice/group. 
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Table 3.1. Ki of ACh and Bmax of [3H]QNB binding in wild-type and transgenic 
mouse tissue membranes 
Brain 
Region Group KiH (M) 
BmaxH 
(mol/mg) KiL (M) 
BmaxL 
(mol/mg) 
WT 8.7 x 10-9 9.9 x 10-13 1.4 x 10-6 8.8 x 10-13 
hM3Dq 3.9 x 10-6 4.8 x 10-12 1.0 x 10-3 3.6 x 10-12 Cortex 
hM3Dq + Dox 1.1 x 10-10 1.0 x 10-12 1.0 x 10-6 1.5 x 10-12 
WT 4.3 x 10-8 6.1 x 10-13 1.8 x 10-6 8.9 x 10-13 
hM3Dq 2.3 x 10-5 6.1 x 10-12 1.7 x 10-3 4.0 x 10-12 Hippocampus 
hM3Dq + Dox 2.3 x 10-8 9.9 x 10-13 1.4 x 10-6 1.8 x 10-12 
 
*N=3 mice/group; KD values for [3H]QNB binding to DREADD and native muscarinic 
receptors in human Pulmonary Artery Smooth Muscle Cells (hPASMCs) have been 
published previously ([D= 0.05 nM at hM3, KD= 1.6 nM at HA-hM3Dq; (Armbruster et 
al., 2007)]. 
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3.2.4 Behavioral analyses of hM3Dq mice in the absence of CNO  
A major goal of the evolution of the second generation of RASSLs was to minimize 
constitutive activity of hM3Dq and also to eliminate the activation of hM3Dq by 
endogenous ACh, thus limiting hM3Dq signaling in vivo in the absence of CNO. 
When expressed in yeast, cultured mammalian cells, and mouse pancreatic β-cells, 
no detectable constitutive activity of hM3Dq in the absence of CNO was found 
(Armbruster et al., 2007; Guettier et al., 2009). To test whether hM3Dq expression in 
vivo modified behavior in the absence of its exogenous activating ligand (CNO), 
mouse appearance and behavior were examined through a battery of 
neurobehavioral tests on single-transgenic (TRE-hM3Dq transgene only) and 
hM3Dq mice (Figures 3.6 to 3.9; n = 11 littermate pairs). No qualitative differences 
were evident between control and hM3Dq mice. Specifically, the two groups were 
similar in observations regarding size, overall morphology, coat condition, body 
posture and gait, reflex response to gentle touch with a cotton swab on the whiskers 
or eyes, balance in an empty, shifting plastic cage, ability to climb a pole or walk 
across an elevated dowel, grip-strength in a wire-hang test, and responses during 20 
seconds of tail-suspension.  
A variety of quantitative assessments of behavior were also performed. Motor 
coordination was quantified using an accelerating rotarod, the results of which 
revealed no significant differences between hM3Dq and control mice (Figure 3.6). 
Likewise, no significant differences were detected in the elevated plus maze, 
acoustic startle response, pre-pulse inhibition of startle responses (PPI), latency to 
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locate a food reward buried in bedding, the Morris water maze visual cue test, or 
acquisition and reversal learning in the Morris water maze (Figures 3.7 to 3.9). 
In contrast to these measures that revealed no differences between the two 
genotypes, activity in an open field did reveal subtle but unremarkable differences 
(Figure 3.10). The hM3Dq mice demonstrated a tendency toward reduced locomotor 
activity as measured by total distance traveled in a locomotor chamber 
[F(1,20)=6.15, p<0.05] (Figure 3.10A). They further demonstrated fewer fine, 
stereotypic movements [F(1,20)=6.63, p=0.0181] (Figure 3.10B). However, no 
differences in rearing movements or in time spent in the center of the open field 
were detected (data not shown). Apart from the mild reduction of spontaneous 
locomotor activity, the hM3Dq mice were similar to controls on an extensive battery 
of tests of diverse behaviors, implying that overexpression of a Gq-coupled receptor 
has minimal untoward effects. 
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Figure 3.6. Latency to fall from an accelerating rotarod 
Data shown are means (+ SEM) for each group. Trials 4 and 5 were given 48 hours 
after the first three trials. 
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Figure 3.7. Performance on the elevated plus maze 
Measures were taken for (A) time spent in the open and closed arms, and (B) 
number of entries onto the arms. 
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Figure 3.8. Sensory Tasks 
A) Acoustic startle test for auditory ability. Trials included no stimulus (No S) trials 
and acoustic startle stimulus (AS; 120 dB) alone trials. B) Pre-pulse inhibition for 
sensorimotor gating. C) Latency to find buried food (left panel) and percent of each 
group finding buried food (right panel) in olfactory function test. Data shown are 
means (+ SEM) for each group. 
 
 114 
 
 
 
 115 
Figure 3.9 Morris Water Maze task 
A) Visual cue test in the Morris water maze across three days of testing. Data shown 
are mean (± SEM) of four trials per day; p<0.05. B) Swimming speed in the Morris 
water maze. Data shown are mean (± SEM) of four trials per day. Data for two mice 
from the hM3Dq group which were unable to perform the visual cue task were not 
included. C) Acquisition of the hidden platform task. D) Reversal learning in the 
Morris water maze. Data shown are mean (± SEM) of four trials per day. In C-D, 
data were also excluded from two mice from the control group and one mouse from 
the hM3Dq group that had poor performance during acquisition. 
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Figure 3.10 Activity in an open field 
A) Total distance traveled in a novel environment. B) Non-ambulatory repetitive 
photobream breaks (stereotypic fine movements) in a novel environment. Data 
shown are means (±SEM) for each group for a one-hour test session. *p<0.05 
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3.2.5 In Vitro CA1 Pyramidal Cell Response to CNO 
 After characterizing the behavior of hM3Dq mice in the absence of exogenous 
ligand, we sought to determine the effects of hM3Dq receptor activation by CNO. We 
first asked whether neurons from hM3Dq animals would respond to CNO. To 
address this question, we isolated acute hippocampal slices from hM3Dq and 
littermate control animals and performed whole-cell recordings from CA1 pyramidal 
neurons in the absence and presence of bath applied CNO. To isolate membrane 
potential responses from synaptic responses, we performed these recordings in the 
presence of tetrodotoxin (TTX). We found that bath application of CNO (500 nM) to 
hippocampal slices isolated from hM3Dq mice depolarized CA1 pyramidal cells by 
8.0 ± 1.8 mV compared with baseline membrane potentials (p<0.01; n=7 neurons 
from 5 animals; Figure. 3.11Ai, iii). In contrast to these findings in hM3Dq mice, we 
found no significant change in membrane potential of CA1 pyramidal neurons of 
hippocampal slices isolated from control (either single transgenic or wild-type) mice 
(p>0.05, n=7 neurons from 5 animals; Figure 3.11Aii-iii). We additionally asked 
whether bath application of CNO to hippocampal slices isolated from hM3Dq mice 
would increase the firing rate of CA1 pyramidal neurons. To that end, we performed 
whole-cell recordings from CA1 pyramidal cells in the absence of TTX. We found 
that bath application of CNO (500 nM) in the absence of TTX increased the firing 
rate of CA1 pyramidal cells (n=8 neurons from 4 animals; Figure 3.11C).  
Because Gq signaling can affect membrane conductances through 
phospholipase C (PLC)-dependent mechanisms, we tested the dependence of the 
CNO-evoked depolarization on PLC. We performed whole-cell recordings from CA1 
 120 
pyramidal cells in acute slices isolated from hM3Dq animals in the presence of TTX 
and the PLC inhibitor, U73122 (10 µM), and then bath applied CNO (500 nM). We 
found that in the presence of U73122, CNO had no significant effect on the 
membrane potential of CA1 pyramidal cells (p>0.05, n=6 neurons from 4 animals; 
Figure 3.11Bi, iii). By contrast, in the presence of U73343 (10 µM), the inactive 
analog of U73122, CNO produced a significant depolarization of CA1 pyramidal 
neurons by 5.0 ± 0.72 mV (p<0.01, n=4 neurons from 4 animals; Figure 3.11Bii-iii). 
These findings indicate that CNO-induced activation of hM3Dq depolarizes and 
increases the firing rate of CA1 pyramidal neurons through a PLC-dependent 
mechanism.  
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Figure 3.11 CNO effects on CA1 pyramidal neurons recorded in vitro 
Acute hippocampal slices were isolated from hM3Dq and control animals, and CA1 
pyramidal cells were recorded from in the whole-cell configuration. Cells were held 
at resting membrane potential in the presence (A-B) or absence (C) of TTX, and 
CNO was bath applied. A, Bath application of CNO (500 nM) depolarized CA1 
pyramidal cells from hM3Dq animals (i), but CNO did not affect resting membrane 
potential of CA1 pyramidal cells from control animals. However, bath application of 
carbachol (5 µM) did depolarize CA1 pyramidal cells from control animals (ii). Aiii, 
Population data from hM3Dq and control animals showing the mean resting 
membrane potential of CA1 pyramidal cells before and in the presence of CNO [500 
nM for hM3Dq (n=7 cells from 5 animals) and 1 µM for control animals (n=7 cells 
from 5 animals)]. B, In the presence of an active PLC inhibitor (U73122, 10µM) the 
CNO-induced depolarization of hM3Dq CA1 pyramidal neurons was blocked (i), but 
in the presence of an inactive analog (U73343, 10µM) CNO was capable of 
depolarizing hM3Dq CA1 pyramidal neurons (ii). Biii, Population data showing 
change in resting membrane potential of hM3Dq CA1 pyramidal neurons induced by 
CNO (500nM) in the presence of U73122 (n=6 cells from 4 animals) or U73343 (n=4 
cells from 4 animals). C, Bath application of CNO (500 nM) to hippocampal slices 
isolated from hM3Dq animals in the absence of TTX resulted in increased firing 
frequency and recurrent bursting. 
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3.2.6 Behavioral Response of hM3Dq mice to CNO 
 Treatment of hM3Dq but not WT mice with CNO induced striking behavioral 
effects. Using a cohort of adult mice distinct from that in which baseline behavioral 
characterization was performed, I measured ambulation and episodes of repetitive 
beam breaks (generally representing fine movements or stereotypic behaviors) 
following peripheral administration of vehicle (saline) and low dose (0.1 and 0.3 
mg/kg) CNO (hM3Dq, n=10; control, n = 14). Among hM3Dq mice, significant 
behavioral effects were noted. When CNO was administered, activity (both total 
ambulation and repetitive beam breaks) increased in a dose-dependent fashion 
among hM3Dq mice and exceeded control levels. The administration of 0.1 mg/kg 
CNO resulted in a significant increase in repetitive beam breaks (p<0.01) and a 
trend toward a significant increase in total locomotion in hM3Dq mice relative to 
controls. Administration of 0.3 mg/kg CNO produced a statistically significant 
increase in both total locomotion and repeated beam breaks in hM3Dq mice relative 
to controls (p<0.01; Figure 3.12Ai, Bi). Furthermore, the increases in locomotion and 
repetitive beam breaks following CNO administration occurred in a time-dependent 
manner such that locomotor activity gradually increased with time relative to controls 
(Figure 3.12Aii, Bii), and the increase in locomotor activity persisted >9 hours (Figure 
3.15A). These data provide behavioral evidence of neuronal activation by CNO in 
hM3Dq mice and demonstrate the long duration of CNO activity in hM3Dq animals. 
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Figure 3.12. Behavioral consequences of CNO administration 
A-B, Effect of CNO administration on locomotor behavior in control and hM3Dq mice 
(n=10 hM3Dq and 14 control mice). CNO increased total locomotor activity (A) and 
repetitive beam breaks (B) in a dose-dependent (Ai, Bi) and time-dependent (Aii, Bii) 
manner in hM3Dq mice relative to control animals. For Aii and Bii, CNO was 
administered at time 0 following a 20-minute habituation period in the locomotor 
chamber. C, Behavioral seizure classes evoked by CNO administration (n=7 hM3Dq 
animals). All data presented here were measured during the 3 hours following CNO 
administration when SE did not occur and during the 3 hours following SE onset 
when SE did occur. Ci, Maximum behavioral seizure class elicited by various doses 
of CNO. No seizures were elicited by doses less than 0.5 mg/kg CNO. Cii, Percent 
of animals in which SE occurred at various doses of CNO. SE did not result from 
doses less than 1 mg/kg. Ciii, Latency from CNO administration to first occurrence of 
each behavioral seizure class for animals administered 5 mg/kg CNO. * represents 
p<0.05; ** represents p<0.01. 
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 To assess the behavioral responses of hM3Dq mice to higher doses of CNO, 
we observed control and hM3Dq mice treated in parallel with saline or increasing 
doses of CNO. We found that treatment of hM3Dq mice with 0.5 mg/kg CNO reliably 
evoked limbic seizures of behavioral Class 1 (Figure 3.12Ci); no behavioral evidence 
of seizure activity was detected after administration of lower doses (0.03, 0.1, or 0.3 
mg/kg CNO). Treatment with doses of CNO higher than 0.5 mg/kg evoked 
continuous seizure activity of classes three through seven, namely status epilepticus 
(SE) and death. Administration of CNO at doses of 1 or 5 mg/kg evoked SE in 2 of 4 
animals and 5 of 7 animals (Figure 3.12Cii). Among the 5 animals in which SE was 
elicited by 5 mg/kg CNO, an orderly progression of behavioral seizure intensity was 
observed over time following CNO treatment (Figure 3.12Ciii). The latency to onset 
of the first Class 1 seizure was 15.4 ± 3.7 minutes. SE was lethal in 4 of the 7 
animals during the 3 hr following SE onset. Whereas CNO reliably evoked seizures 
in hM3Dq animals, CNO evoked no behavioral seizures in control animals at any 
dose tested (0.03 – 5 mg/kg; n=4 carrying the tTA transgene alone; n=2 carrying the 
TRE-hM3Dq transgene alone; n=5 wild-type animals).  
 
3.2.7 In Vivo Recordings from Hippocampus 
We next sought to examine the electrophysiological correlates of the 
behavioral effects of CNO in the hM3Dq mice. Because the behavioral features of 
the seizures were typical for seizures arising from hippocampus and because 
hM3Dq is expressed in hippocampal neurons, we focused on the hippocampus. 
Towards this end, we implanted control and hM3Dq mice with multi-electrode arrays 
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to monitor both local field potentials (LFPs) and spike activity of multiple individual 
neurons in the hippocampus. These in vivo recordings were performed during the 
same sessions as the behavioral seizure observations described above. 
 CNO increased neuronal activity in a dose- and time-dependent fashion as 
measured by both LFP and single unit firing rate (Figures 3.13 and 3.14). With 
respect to the dose-dependent change in neuronal activity, we found that treatment 
of hM3Dq mice with saline (Figure 3.14C) or 0.03 mg/kg (Figure 3.13Ai) CNO 
produced no significant change in the LFP or in single unit firing, consistent with the 
lack of behavioral affects of these doses. However, doses of 0.1 mg/kg to 1 mg/kg 
elicited successively greater increases in power of the gamma frequency band of the 
LFP (Figure 3.13B). At the sub-convulsive doses of 0.1 mg/kg and 0.3 mg/kg, 
increased power in the gamma frequency band was seen in the LFP, with 0.3 mg/kg 
eliciting a greater magnitude of gamma power increase (Figure 3.13Aii-iii,B). In 
addition, during the period of increased gamma power we found an increase in the 
firing rate of hippocampal interneurons (Figures 3.13 and 3.14). Treatment of hM3Dq 
mice with convulsant doses of CNO (0.5, 1 and 5 mg/kg) induced striking alterations 
in neuronal activity evident in both LFP and single unit activity (Figure 3.13Aiv-vi). 
Notably, spectral analyses of LFP activity revealed an increase in gamma power 
preceding the onset of seizures (Figure 3.13Avi, 3.13D). Analyses of single neuron 
firing frequency revealed an increase in interneuron firing frequency that coincided 
with the increased gamma power in the LFP. This pattern of single neuron firing 
persisted until the onset of seizures, at which point interneuron firing dramatically 
decreased (Figures 3.13 and 3.14). By contrast, treatment of hM3Dq mice with 
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saline induced no significant change in LFPs or the firing frequency of interneurons 
(Figure 3.14C). Likewise, treatment of control mice with either CNO or saline 
induced no significant change in LFP spectral parameters or firing rate of 
interneurons (Figure 3.14A,B). 
We also assessed the time-dependent changes in neuronal activity following 
CNO administration. The effect of CNO on the LFP, as measured by changes in 
gamma power, was first seen between 5 and 10 minutes after CNO administration 
and peaked between 45 and 50 minutes for all doses tested (Figure 3.13C). To 
determine the duration of CNO effects on neuronal activity, we administered CNO 
(0.3 mg/kg or 0.5 mg/kg) and recorded LFP for 24 hours (n=3 mice for 0.3 mg/kg; 
n=2 mice for 0.5 mg/kg). At both doses tested, the CNO-induced increase in gamma 
power persisted for approximately 9 hr (Figure 3.15B), paralleling the pattern we 
observed in locomotor activity (Figure 3.15A). These data suggest that the offset 
kinetics are not dependent on CNO dose. Moreover, 24 hours after the first 0.3 
mg/kg dose, we readministered CNO (0.3 mg/kg) to the same mice and found no 
significant difference in peak gamma power response or duration of this response 
between day 1 and day 2, indicating that sensitivity to CNO, at least with 24 hours 
between administrations, was unaltered by such long-lasting effects (Figure 3.15Bii). 
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Figure 3.13. CNO dose-dependently increase neuronal activity and gamma 
power in hM3Dq mice 
A, CNO administration to hM3Dq mice evoked dose-dependent increases in 
hippocampal neuronal activity (i-vi), as seen by increased power in the gamma 
frequency band of the LFP and associated increased firing rate of presumed 
interneurons. Spectrograms show the power of all frequencies up to 100 Hz over the 
course of the recording session, with warmer colors representing greater power. 
Plots below spectrograms represent single unit firing rate of presumed interneurons, 
and each row corresponds to a single neuron. Here, warmer colors represent 
greater firing frequency. Classification of neurons as interneurons was based on 
firing frequency and pattern of firing. Arrows indicate the time at which CNO was 
administered s.c. at the dose indicated above each spectrogram. In A vi-vi, 
arrowheads indicate occurrence of isolated electrographic seizures, and SE 
represents onset of uninterrupted electrographic seizure activity. B, Peak power in 
the gamma frequency range measured from the LFP before and after administration 
of various doses of CNO displayed as percent of baseline gamma power (n=4 
hM3Dq and 11 control animals). C, Timecourse of peak LFP gamma power change 
from baseline following administration of various doses of CNO. CNO was given at 0 
minutes. ** represents p<0.01. 
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Figure 3.14. Local field potential and single unit recordings from hippocampus 
of control and hM3Dq animals administered either saline or 1 mg/kg CNO 
subcutaneously 
For each of A-D, i represent local field potential recordings. Spectrograms show the 
power of all frequencies up to 100 Hz over the course of the recording session, with 
warmer colors representing greater power. Letters on each spectrogram correspond 
to the example LFP epochs shown above each spectrogram. Arrows represent the 
time at which either saline or CNO was administered. ii in each of A-D show the 
firing frequency of individual putative interneurons recorded in hippocampus. Here, 
warmer colors represent greater firing frequency. Classification of neurons as 
interneurons was based on firing frequency and pattern of firing. As shown in the 
inset autocorrelogram between A and D, interneurons tended to fire tonically, as 
previously described (Henze et al., 2002). In Di, CNO (5 m/kg) elicited increased 
power in the gamma frequency range (b) before the onset of seizures (c). 
Arrowheads in D indicate occurrence of isolated electrographic seizures, and SE 
represents onset of uninterrupted electrographic seizure activity. 
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3.2.8 Efficiency of Tet-Off System in hM3Dq Mice 
As described above, doxycycline virtually eliminated hM3Dq protein expression as 
assessed by radioligand binding assays, Western blot analysis and 
immunofluorescence microscopy. To assess whether doxycycline also eliminates 
the behavioral and electrophysiological responses to CNO, hM3Dq mice were 
treated with doxycycline for 4 weeks and behavioral and electrophysiological 
responses to CNO were assessed. CNO (0.3 and 5 mg/kg) induced no locomotor 
response with respect to either total distance traveled (Figure 3.16Ai) or repetitive 
beam breaks (Figure 3.16Aii) in hM3Dq mice treated with doxycycline (n=5 mice). 
Moreover, behavioral seizures and alterations in LFP, as measured by spectral 
analysis, were notably absent from hM3Dq mice administered CNO (5 mg/kg) during 
doxycycline treatment (Figure 3.16Bi; n=3 mice). To assess the reversibility of 
doxycycline suppression of transgene expression on the electrophysiological 
response, administration of doxycycline was terminated and four weeks later the 
same mice were treated again with CNO (5 mg/kg) (Figure 3.16Bii). In this case, 
CNO induced increased power in the gamma frequency band as detected by LFP 
recordings as well as behavioral seizures culminating in SE and death, thereby 
demonstrating both the reversibility of doxycycline suppression of transgene 
expression and the specificity of CNO’s effects for the hM3Dq receptor.
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Figure 3.15. Behavioral and in vivo electrophysiological timecourse of CNO 
effects in hM3Dq animals 
A, Timecourse of CNO effects on locomotor activity, as measured by total distance 
traveled (i) and repeated beam breaks (ii), showing the latency to recovery of 
elevated locomotor activity following administration of 0.3 mg/kg CNO, which was 
administered at time 0 (n=4 littermate pairs). B, Timecourse of CNO effects on 
gamma power measured from the hippocampal LFP showing the latency to recovery 
of gamma power to baseline levels. Bi, Representative spectrogram of LFP from 
hM3Dq animal administered 0.3 mg/kg CNO at time 1.5 hr. ii, Population data 
demonstrating timecourse of acutely administered CNO on gamma power and 
gamma power response to two injections of CNO administered 24 hours apart from 
one another. The timecourse of onset and offset of CNO effects, as measured by 
changes in gamma power, was measured during an acute administration of either 
0.3 mg/kg (closed black squares; n=3 hM3Dq animals) or 0.5 mg/kg (open red circle; 
n=2 hM3Dq animals) CNO to determine dose-dependence of onset and offset 
kinetics. Twenty four hours following the acute administration of 0.3 mg/kg CNO 
(Day 1; closed black squares), a second injection of 0.3 mg/kg CNO was 
administered to the same animals and gamma power response was monitored (Day 
2; open black circles) for the purpose of assessing desensitization of the hM3Dq 
receptor. 
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Figure 3.16. Doxycycline treatment of hM3Dq animals prevents CNO induced 
behavioral and electrophysiological changes 
A, CNO administration to hM3Dq animals not exposed to doxycycline produced 
increased locomotor activity as measured by total distance traveled (i) and repetitive 
beam breaks (ii). However, four weeks of doxycycline exposure inhibited CNO-
induced changes in locomotor activity (n=5 hM3Dq mice). Bi, Four weeks of 
doxycycline exposure inhibited CNO (5 mg/kg) induced changes in the LFP. No 
increase in gamma power was elicited and no seizures resulted from CNO 
administration. Bii, Following 4 weeks of doxycycline exposure, animals were taken 
off doxycycline for 4 weeks and challenged with CNO (5 mg/kg) again. At this time, 
CNO elicited increased power in the gamma frequency range (b) and subsequent 
SE (c). 
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3.3 Discussion 
 
This chapter describes a novel chemical-genetic approach for the 
experimental manipulation of CNS neuronal activity. We paired a tetracycline-
repressible tissue-specific genetic system, which provided transgenic mice with 
inducible, reversible, and spatially controlled transgene expression, with a specific 
and selective pharmacologic system (e.g. second-generation DREADD-type 
RASSLs) to achieve remote spatial control over neuronal activity in vivo. In coupling 
these two systems, we demonstrated controlled activation of Gq-coupled pathways, 
resulting in striking behavioral and electrophysiological changes. Many systems are 
now available for controlling neuronal activity, each with its particular advantages 
and disadvantages. The technique we describe here provides an additional tool with 
some important advantages over existing approaches. 
 
3.3.1 Utility of the DREADD system for in vivo applications 
Several features of second-generation RASSLs tailor them for in vivo use, as 
exemplified by the hM3Dq mouse in this study. First, neuronal activation in hM3Dq 
animals is highly selective; CNO has no detectable off-target actions. Using multiple 
readouts including animal activity, in vitro slice recordings, and in vivo multi-
electrode array recordings, we detected no effect of CNO in wild-type, single-
transgenic, or doxycycline-treated double-transgenic animals. In this respect, our 
approach is an improvement upon its RASSL predecessors, as the small molecule 
agonists of first-generation RASSLs are pharmacologically active and necessitate a 
knockout background (Scearce-Levie et al., 2001). Together with a tissue- or even 
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cell-specific genetic or viral system, these second-generation RASSLs thus allow 
one to target specific cell types or networks without interference from undesired 
ligand actions. 
Second, our approach enables non-invasive modulation of neuronal activity. 
CNO, like other RASSL ligands, can be injected peripherally (or provided through 
drinking water; unpublished observations) and crosses the blood-brain barrier to 
activate receptors in discrete and even widely distributed cell populations. In 
contrast, other systems for neuronal manipulation [e.g. microbial opsins and 
optoXRs, AlstR, the ligand-gated ion channel TRPV1 (Arenkiel et al., 2008)] require 
direct application of light/ligand to brain tissue in order to alter neuronal activity and 
thus have spatial limitations with regard to cells that can be activated at a given 
time. Although the invasive procedures mandated by those systems are not a 
hindrance for all applications, remote control of neuronal activity could be beneficial 
in some instances, in particular for readouts such as animal behavioral tasks, which 
are exquisitely sensitive to handling stress, or for the activation of diffusely 
distributed populations of cells. Moreover, because neurons can be activated non-
invasively in hM3Dq animals, this technology is more readily accessible than optical 
approaches or the AlstR and TRPV1 systems. Once mice with the desired pattern of 
receptor expression have been generated, the receptor can easily be activated by 
peripheral injection; stereotaxic apparatus, light sources, fiberoptics, and the 
technological expertise they require are thus unneccesary. 
Third, hM3Dq activation is dose-dependent, allowing one to titrate the level of 
receptor activity by varying the dose of CNO. In the absence of CNO, we were able 
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to detect only a single difference in hM3Dq mice compared to controls, despite 
extensive observations and behavioral testing. Whether the mutant receptor lacks 
constitutive activity, whether the concentration of acetylcholine in the synaptic cleft is 
insufficient to activate hM3Dq given its reduced potency at the mutant receptor, or 
whether the lack of phenotype represents homeostatic neuronal equilibration is 
unclear.  However, in vitro evidence (Armbruster et al., 2007), together with the fact 
that mice expressing hM3Dq in pancreatic β-cells exhibit no detectable phenotype in 
the absence of CNO (Guettier et al., 2009) suggests that neuronally expressed 
hM3Dq exhibits little constitutive activity and is insensitive to endogenous 
acetycholine.  
In response to CNO administration, we describe both behavioral changes 
following low doses of CNO (0.1 and 0.3 mg/kg) and mild to severe seizures and 
status epilepticus resulting from higher doses of CNO (0.5, 1.0, 5.0 mg/kg). 
Moreover, dose-dependent LFP alterations are present at all doses from 0.1 to 5.0 
mg/kg. In this case, the high levels of hM3Dq overexpression might increase the 
dynamic range of the system. In the absence of CNO, the system is apparently 
silent. At low doses of CNO, occupancy of a small proportion of hM3Dq results in 
subtle phenotypes; by contrast, occupancy of higher proportions of hM3Dq with 
higher doses of CNO yields more profound effects. This characteristic of the second-
generation RASSLs increases their applicability to experimental manipulations as it 
provides the user considerable control over the extent of receptor activation. By 
contrast, when expressed in certain tissues, the first generation of RASSLs 
occasionally signals at high levels in the unstimulated state and results in significant 
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pathologies (see Chapter 1), thereby preventing one from precisely titrating the level 
of receptor activity by exogenous ligand application. 
Together, these aspects of the approach described here – its selectivity, non-
invasiveness, and dynamic range, as well as the spatiotemporal control over 
receptor expression that mouse genetics affords – render this technique attractive 
for in vivo manipulations of neuronal signaling. Additionally, although we report here 
only the ability of the Gq-coupled DREADD to activate neuronal firing via PLC-
dependent pathways, Gi- and Gs-coupled DREADDs permit the manipulation of 
other GPCR signaling cascades to effect alternative endpoints [(Guettier et al., 2009; 
Ferguson et al., 2010); see Chapter 5]. Thus, the DREADD system is well suited for 
investigating diverse experimental questions. While drawbacks persist, this system 
is nonetheless an improved and valuable tool for analysis of how the activity of 
discrete populations of neurons and local circuits underlies behavior. 
 
3.3.2 Molecular and cellular etiology of the hM3Dq mouse phenotype 
For this proof-of-concept study of hM3Dq function in vivo, we employed the 
CaMKIIα-tTA Tet-Off system to drive expression of a Gq-coupled GPCR in forebrain 
principal neurons. In addition to validating our technique for selective neuronal 
activation, this system allowed us to investigate Gq signaling cascades – both the 
molecular mediators of signal transduction and the pathology stemming from its 
over-activation – in this neuronal subpopulation. 
Using the in vitro slice preparation, we demonstrated that CNO directly 
depolarizes pyramidal cells from hM3Dq mice and does so in an apparently PLC-
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dependent manner; the active PLC inhibitor U73122, but not its inactive analog 
U73343, blocked the depolarizing effect of CNO. The observed PLC dependence of 
CNO’s effects on hM3Dq neurons is expected based on previous characterization of 
the specificity with which hM3Dq couples to Gq (Armbruster et al., 2007). The 
magnitude and kinetics of the CNO-induced depolarization and its PLC dependence 
suggests that one mechanism by which CNO may depolarize neurons is through 
inhibition of M-current, a slowly inactivating, outwardly rectifying potassium current 
important for depression of neuronal excitability (Brown and Yu, 2000). M-current is 
carried by PIP2-gated KCNQ channels (Biervert et al., 1998; Wang et al., 1998; 
Zhang et al., 2003). Importantly, humans with benign familial neonatal convulsions, 
an autosomal dominant form of neonatal epilepsy, carry an insertion in their KCNQ2 
gene that yields a non-functional protein (Biervert et al., 1998). Activation of PLCβ by 
numerous Gq-coupled GPCRs causes PIP2 hydrolysis, which reduces PIP2 content, 
closes KCNQ channels, and inhibits M-current, resulting in neuronal depolarization 
and a propensity for neurons to fire bursts rather than tonic spikes (Zhang et al., 
2003). While the closing of KCNQ channels is an appealing hypothesis for the 
molecular mechanism of hM3Dq action, further in vitro studies employing specific 
KCNQ channel blockers will be necessary to demonstrate its validity. 
Given our hypothesis that neuronal depolarization occurs at least in part 
through inhibition of M-current in hM3Dq-expressing neurons, it is unknown to what 
extent hM3Dq signaling might differ in other cell types or brain regions that do not 
express KCNQ channels [e.g. cerebellum; (Wang et al., 1998)]. Examining the 
diverse consequences of activating the same molecular signaling pathway in 
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different cell types is an attractive application of the DREADD system and provides 
just one example of the many uses for this technology. 
Our in vivo electrophysiology studies provide insights into the mechanism of 
CNO’s actions at the cellular and systems level in hM3Dq mice. We found that CNO 
evoked dose-dependent increases in gamma power as detected by spectral 
analyses of LFP recordings from hippocampus, selectively in hM3Dq mice. This 
increased gamma power was associated with an increase in hippocampal 
interneuron firing rate. We propose that hM3Dq activation modifies local 
hippocampal circuit activity by activating principal cells, which synaptically activate 
interneuron firing, thereby producing gamma oscillations. This hypothesis is based 
on three lines of evidence. First, the pattern of hM3Dq expression, coupled with the 
in vitro data described above, suggests that CNO’s direct effects are restricted to 
principal excitatory neurons. hM3Dq expression is driven by the principal neuron-
specific CaMKIIα promoter (Hanson and Schulman, 1992), and HA 
immunoreactivity, representing hM3Dq expression, is absent from the parvalbumin-
positive interneuron cell bodies (Figure 3.3) shown to contribute to the gamma 
rhythm (Bartos et al., 2007; Cardin et al., 2009). Second, our findings of persistently 
increased gamma power are consistent with previously described pharmacological 
models of gamma induction. For example, bath application of the muscarinic agonist 
carbachol to hippocampal slices in vitro is sufficient to induce gamma frequency field 
potentials that persist long after the drug has washed from the bath (Fisahn et al., 
1998). Third, the proposed mechanism by which the gamma rhythm is induced in the 
carbachol model of gamma oscillations includes excitation of pyramidal cells, leading 
 144 
to persistent synchronous firing of a circuit of interneurons connected by gap 
junctions. As described above, our in vitro whole-cell recordings from CA1 pyramidal 
cells revealed that CNO directly depolarizes pyramidal cells, and our in vivo 
hippocampal recordings revealed that CNO produces increased interneuron firing 
rate. Thus we conclude that the increased gamma rhythm and behavioral 
consequences of CNO administration to hM3Dq mice are the result of hM3Dq 
directly activating excitatory pyramidal neurons that subsequently induce 
synchronous interneuron firing. We further conclude that the CNO-evoked seizures 
are triggered by activation of excitatory pyramidal neurons, but the precise cellular 
events mediating the transition from increased gamma rhythm into seizure activity 
remain to be elucidated. 
 
3.3.3 Potential limitations of DREADD technology 
While the second generation RASSLs (DREADDs) described here overcome 
some of the previous problems plaguing experimental manipulation of neuronal 
signaling, we acknowledge potential limitations of this system. 
The primary disadvantage of the DREADD system in general, and these 
hM3Dq mice in particular, is the relatively coarse temporal resolution of neuronal 
manipulation. We have thoroughly characterized the kinetics of activation of hM3Dq 
and the ensuing electrophysiological response and shown activation to begin 
between 5 and 10 minutes after injection, with peak electrophysiological responses 
occurring 45 to 50 minutes after injection. We determined that both the behavioral 
and electrophysiological effects of CNO in hM3Dq mice are persistent, with 
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responses not returning to baseline for many hours. Both the onset and offset 
kinetics were unrelated to the dose of CNO. While the kinetics of onset of the CNO 
response are likely similar to that of other systemically administered drugs, including 
other RASSL ligands, they are certainly slower than that of locally infused ligands 
such as allatostatin (for AlstR) or capsaicin (for TRPV1) which occur on the order of 
minutes, or the microbial opsins, whose activation occurs on the order of 
milliseconds. The latency to onset of CNO’s effects is likely due to the 
pharmacokinetic properties of CNO. In contrast, the duration of CNO’s effects could 
be specific to the neuronal population in which hMDq is expressed and the signaling 
events the receptor mediates; hM3Dq expression in other tissues might not elicit 
such persistent effects. Thus, while CNO allows for noninvasive control of activity in 
select populations of CNS neurons in a freely moving adult mouse, the temporal 
resolution of that control is coarse, particularly in comparison to microbial opsins. 
The kinetics of inactivation of hM3Dq signaling in vivo might prove to be a 
greater limitation of this technology than those of activation. As shown by both 
locomotor and electrophysiological activity, the response to sub-seizure doses of 
CNO is long-lasting, with responses returning to baseline approximately 9 hours of 
injection. Clearly, for applications requiring defined termination points, these hM3Dq 
mice are not well suited. While the enduring responses may represent continual 
hM3Dq activation by CNO, three facts lead us to favor the idea that they are due to 
regenerative downstream events within hM3Dq expressing neurons and/or to 
activation of other neuronal populations. First, carbachol-induced gamma rhythm in 
hippocampal slices persists following removal of carbachol from the bath (Fisahn et 
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al., 1998), demonstrating that fleeting activation of muscarinic receptors can induce 
persistent responses. Second, CNO is removed from plasma within 2 hours of 
injection, without back-metabolism to clozapine (Guettier et al., 2009), arguing 
against persistent CNO-mediated activation of hM3Dq. Third, the time course of 
CNO-evoked physiological effects in transgenic mice expressing hM3Dq in 
pancreatic β-cells correlates with the plasma concentration of CNO, with effects 
diminishing within 2 hours (Guettier et al., 2009). It will be important for future users 
of DREADD technology to fully characterize the timing of offset of effects in each cell 
population. Additionally, such long-lasting augmentation of neuronal activity could 
have effects on receptor sensitivity and trafficking or on synaptic plasticity. Indeed, 
this hM3Dq mouse provides an attractive system for the study of synaptic changes 
stemming from long-term activation of hippocampal neuronal networks. 
A final note of consideration regarding first- and second-generation RASSL, 
optoXR, and AlstR approaches is that the mechanisms of neuronal modulation are 
indirect and dependent on intracellular effectors. Here, in hM3Dq mice, neuronal 
activation is secondary to coupling to PLCβ, and the molecular mechanism by which 
PLCβ increases neuronal activity is incompletely understood at this time. In contrast 
to systems that couple directly to an ion channel with no intermediaries (e.g. 
channelrhodopsin and TRPV1), it remains possible that if a given population of 
neurons lacks the required molecular mediators downstream of PLCβ, these 
neurons may not respond to CNO, or may do so by a different mechanism than that 
which we have hypothesized is occurring here. 
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To conclude, in this chapter I describe the validation and utility of the 
chemical-genetic DREADD approach, wherein a peripherally administered, 
pharmacologically inert drug-like small molecule (CNO) selectively modulates 
neuronal activity through an evolved Gq-coupled GPCR. In Chapter 1, I described 
the use in vitro of hM4Di, the silencing Gi-coupled DREADD, and of rM3/β1Ds, a Gs-
coupled DREADD. In Chapter 5, I describe their use in vivo. Collectively, these 
reagents provide useful tools for activating and silencing neurons and for modulating 
distinct GPCR-coupled signaling pathways in vivo. 
CHAPTER 4: DISSECTING THE NEUROCIRCUITRY OF CNO-INDUCED 
LOCOMOTION IN MICE 
 
4.1 Introduction and rationale 
 
 In Chapter 3, a stimulatory effect of CNO on the locomotor activity of hM3Dq 
mice was found, although the mechanism of that stimulatory effect was not 
evaluated. This chapter investigates that mechanism and the neural pathways 
involved in locomotion in mice in the context of rodent models of psychosis. 
 
4.1.1 The NMDA receptor antagonist model of psychosis 
 Many drugs that stimulate locomotion in rodents are considered 
psychotomimetic, and drug-induced locomotion is a commonly used animal model of 
psychosis (Geyer and Ellenbroek, 2003). Therefore, mapping the neural circuitry 
involved in drug-induced locomotion could be important for understanding the 
circuitry involved in psychosis. 
Since the 1960’s, antagonism of glutamate NMDA receptors by the 
“dissociative anesthetics” phencyclidine (PCP) and ketamine has served as a 
pharmacological model of psychosis (Domino et al., 1965; Javitt, 1987; Javitt and 
Zukin, 1991; Newcomer et al., 1999; Olney et al., 1999; Javitt, 2004). In rodents and 
humans, these drugs are psychotomimetic, inducing positive, negative, and 
cognitive symptoms reminiscent of schizophrenia. This property of NMDA receptor 
antagonists underlies the “NMDA receptor hypofunction” or “glutamate” hypothesis 
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of schizophrenia that attributes psychotic symptoms to a hypoglutamatergic state 
(Olney et al., 1999; Svensson, 2000). Antagonists of the NMDA receptor stimulate 
glutamate efflux and increase the firing rate of dopaminergic neurons in the ventral 
tegmental area (VTA). The resultant dopamine release is believed to be responsible 
for the behavioral effects of PCP and other psychotomimetic compounds (Svensson, 
2000). It should be noted that alternative hypotheses implicate glutamatergic 
hyperactivity (Javitt, 2004); hyper- and hypoglutamatergia could conceivably occur 
simultaneously in distinct brain regions. 
As I described in Chapter 3, in hM3Dq mice CNO induces ambulatory activity 
and stereotypies reminiscent of those that psychotomimetic compounds induce. 
Given that hM3Dq mice express the hM3Dq receptor on cortical pyramidal neurons 
and that CNO increases the firing rate of these neurons (see Chapter 3), it is 
possible that the locomotor effects of CNO in hM3Dq mice occur via activation of the 
corticostriatal pathway. This pathway consists of cortical pyramidal (i.e., 
glutamatergic) neurons that project to the VTA (Sesack and Pickel, 1992). Release 
of glutamate by these neurons activates the dopaminergic VTA neurons that project 
via the mesocortical and mesolimbic pathways to the prefrontal cortex (PFC) and 
nucleus accumbens (NAcc), respectively (Alex and Pehek, 2007). 
To test this hypothesis and to identify the pathways and receptors that 
modulate the effects of CNO, I evaluated the effect of several centrally-acting drugs 
on CNO-induced locomotion in hM3Dq mice. As a control, I evaluated the effect of 
the same drug dosages on PCP-induced locomotion in littermate control (wild-type 
or single-transgenic) mice. 
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4.1.2 The D2 receptor and psychosis 
First, to determine whether CNO-induced locomotion is sensitive to 
modulation of dopamine D2 receptors, I determined the effect of the typical 
antipsychotic and D2 antagonist haloperidol. The first-generation, or typical, 
antipsychotics exhibit high D2 affinity (Seeman et al., 1976), and, moreover, 
antipsychotic efficacy is highly correlated with D2 affinity and with D2 striatal 
occupancy (Creese et al., 1976; Peroutka and Synder, 1980; Nordstrom et al., 
1993). Indeed, these data underlie the “dopamine hypothesis” of schizophrenia 
(Snyder et al., 1974; Snyder, 1976), which posits that psychosis arises from 
hyperdopaminergia. If CNO causes behavioral activation by stimulating dopamine 
release, then haloperidol, which blocks post-synaptic dopamine receptors, should 
inhibit that behavioral activation. 
 
4.1.3 Metabotropic glutamate receptors and psychosis 
Next, to determine whether the effects of CNO are dependent on glutamate 
release, as would be expected with activation of the corticostriatal pathway, I 
determined the effects of the mGluR2/3 agonist LY379268 on CNO-induced 
locomotion. 
 In addition to the three types of glutamate ionotropic receptors (NMDA, 
AMPA, kainate), three classes of metabotropic glutamate receptors (mGluRs) are 
also present in the central nervous system (CNS), and drugs targeting these 
receptors are in preclinical development (Moghaddam, 2004). While Group I 
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mGluRs (mGluR1, mGluR5) increase presynaptic glutamate release and potentiate 
NMDA receptor-mediated neurotransmission, group II mGluRs (mGluR2, mGluR3) 
are presynaptic autoreceptors that inhibit glutamate release, and agonists of this 
receptor class are under investigation for antipsychotic efficacy (Javitt, 2004). The 
mGluR2/3 agonists LY354740 and LY379268 normalize both the increases in 
synaptic glutamate levels and the behavioral changes that occur following  treatment 
with NMDA antagonists (Moghaddam and Adams, 1998; Schoepp and Marek, 2002; 
Lorrain et al., 2003; Javitt, 2004; Homayoun et al., 2005). One hypothesis regarding 
this effect is that Group II mGluR agonists normalize excess glutamate release 
induced by NMDA antagonism, which would otherwise over-activate non-NMDA 
glutamate receptors and trigger cognitive impairment (Moghaddam, 2004). 
Therefore, if CNO-induced locomotion occurs downstream of an increase in 
glutamate efflux, pretreatment with LY379268 should inhibit locomotor activity in 
CNO-treated hM3Dq mice. 
 
4.1.4 The 5-HT2A receptor and psychosis 
 The 5-HT2A receptor was first implicated in psychosis when the second-
generation, or atypical, antipsychotics were developed. Exemplified by clozapine, 
the parent compound of CNO, these drugs had superior efficacy to the typical 
antipsychotics (Claghorn et al., 1987; Kane et al., 1988) yet resulted in less D2 
occupany in vivo than the typicals (Farde et al., 1989). A screen of drug affinity for 
the 5-HT2, D1, and D2 receptors revealed that atypical drugs display ten-fold 
selectivity for the 5-HT2A receptor over the D2 receptor, while typical drugs are more 
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selective for the D2 receptor (Meltzer et al., 1989). From this discovery, the 
“dopamine-serotonin hypothesis” (Meltzer, 1989) of schizophrenia emerged, which 
stipulated that schizophrenia might involve a disruption of the normal balance 
between serotonergic and dopaminergic signaling that is restored by clozapine and 
other antipsychotic drugs. 
The highest expression of 5-HT2A receptors is on the apical dendrites of 
cortical pyramidal neurons (Willins et al., 1997; Jakab and Goldman-Rakic, 1998), 
some of which have corticostriatal projections; receptors are also found on 
pallidostriatal neurons and striatal and cortical interneurons (Willins et al., 1997; 
Jakab and Goldman-Rakic, 1998; Bubser et al., 2001) and on some dopaminergic 
neurons in the VTA (Nocjar et al., 2002). Therefore, the 5-HT2A receptor is well 
positioned to modulate dopaminergic signaling. 
 Not surprisingly, the emergence of the dopamine-serotonin hypothesis led to 
a search for 5-HT2A selective antagonists. Unfortunately, such compounds have not 
been efficacious. In particular, the 5-HT2A selective antagonist M100907 lacked 
efficacy in clinical trials (de Paulis, 2001). However, M100907 has been shown to 
block dopamine release in the NAcc after treatment with the non-competitive NMDA 
receptor antagonist MK-801 (dizocilpine) (Schmidt and Fadayel, 1996) and in the 
PFC after treatment with the 5-HT2A agonist 2,5-dimethoxy-4-iodoamphetamine 
(DOI) (Pehek et al., 2001) and to decrease glutamate levels in the VTA after 
treatment with DOI (Pehek et al., 2006). Additionally, M100907 can block 3,4-
methylenedioxymethamphetamine (MDMA; ectasy)-stimulated striatal dopamine 
release (Schmidt et al., 1994). These data indicate that the 5-HT2A receptor can 
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modulate evoked dopamine release (Alex and Pehek, 2007). Accordingly, I 
investigated whether M100907 would have similar effects in hM3Dq mice and would 
normalize CNO-induced locomotion. 
 
4.2 Results 
 
 These studies compared the stimulatory effects of CNO in hM3Dq mice 
(double-transgenic) with those of PCP in littermate control mice (wild-type or single-
transgenic) and determined the ability of drugs that target D2, mGluR2/3, or 5-HT2A 
receptors to modulate the resultant locomotion. 
 In previous studies, mice that had received repeated administrations of the 
sub-seizure dose of 0.3 mg/kg CNO began to exhibit behavioral seizures on 
subsequent injections. Therefore, to decrease the likelihood of seizure induction, a 
dose of 0.2 mg/kg CNO was used for these studies. This dose significantly 
increased locomotor activity but did not induce behavioral seizures. For studies in 
control mice, a stimulatory dose of 6 mg/kg PCP was used. 
 
4.2.1 Effects of D2 antagonism on CNO- and PCP-induced locomotion 
 To determine the sensitivity of CNO-induced locomotion to antagonism of 
dopaminergic neurotransmission, hM3Dq mice were pretreated for 20 minutes with 
0.2 mg/kg haloperidol to block D2 receptors. Then, 0.2 mg/kg CNO was 
administered, and the activity of the mice was recorded for 2 h. As predicted, 
haloperidol significantly (p < 0.05) decreased the locomotor-stimulating effects of 
CNO (Figure 4.1A,C). Importantly, this dose of haloperidol was sufficient to 
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normalize locomotion in PCP-treated control mice (Figure 4.1B,C; p < 0.001). In a 
subset of control mice (N=9), 0.1 mg/kg haloperidol non-significantly inhibited the 
effect of PCP (data not shown). 
 
4.2.2 Effects of mGluR2/3 agonism on CNO- and PCP-induced locomotion 
 Next, to determine whether the effects of CNO on locomotion were dependent 
on glutamate release, mice were pretreated with LY379268. This compound 
activates presynaptic mGluR2/3 receptors to inhibit glutamate release from the 
terminals of pyramidal neurons. In a pilot study (N=7), 5.0 but not 2.5 mg/kg 
LY379268 was sufficient to normalize activity in mice treated with 0.3 mg/kg CNO 
(data not shown). Therefore, this study used a dose of 5.0 mg/kg LY379268. In both 
hM3Dq mice treated with 0.2 mg/kg CNO and control mice treated with PCP, 
pretreatment for 20 minutes with 5.0 mg/kg LY379268 successfully normalized 
locomotion (Figure 4.2; p < 0.001 for both genotypes). 
 
4.2.3 Effects of 5-HT2A antagonism on CNO- and PCP-induced locomotion 
 Finally, to determine whether the CNO-induced locomotion is dependent on 
subcortical serotonin release, the effect of pretreatment with the 5-HT2A-selective 
antagonist M100907 was evaluated. Pretreament for 20 minutes with 0.5 mg/kg 
M100907 had no effect on CNO-induced locomotion in hM3Dq mice (Figure 4.3A,C) 
but completely normalized PCP-induced locomotion in control mice (Figure 4.3B,C; 
p < 0.05). 
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Figure 4.1 Effects of haloperidol on CNO- and PCP-induced hyperlocomotion 
A, B) Ambulatory activity of mice was measured in 5-min bins over 140 minutes. 
Mice were pretreated with saline or haloperidol (0.2 mg/kg) and placed in activity 
chambers at time 0, and at 20 min (vertical dashed line), mice were injected with 
CNO (hM3Dq mice, 0.2 mg/kg, A) or PCP (CTL mice, 6 mg/kg, B). C) Total distance 
traveled in 120 minutes following various drug treatments. * indicates p < 0.05; N = 8 
hM3Dq animals and 17 CTL animals. 
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Figure 4.2 Effects of LY379268 on CNO- and PCP-induced hyperlocomotion 
A, B) Ambulatory activity of mice was measured in 5-min bins over 140 minutes. 
Mice were pretreated with saline or LY379268 (5 mg/kg) and placed in activity 
chambers at time 0, and at 20 min (vertical dashed line), mice were injected with 
CNO (hM3Dq mice, 0.2 mg/kg, A) or PCP (CTL mice, 6 mg/kg, B). C) Total distance 
traveled in 120 minutes following various drug treatments. * indicates p < 0.05; N = 8 
hM3Dq animals and 17 CTL animals. 
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Figure 4.3 Effects of M100907 on CNO- and PCP-induced hyperlocomotion 
A, B) Ambulatory activity of mice was measured in 5-min bins over 140 minutes. 
Mice were pretreated with saline or M100907 (0.5 mg/kg) and placed in activity 
chambers at time 0, and at 20 min (vertical dashed line), mice were injected with 
CNO (hM3Dq mice, 0.2 mg/kg, A) or PCP (CTL mice, 6 mg/kg, B). C) Total distance 
traveled in 120 minutes following various drug treatments. * indicates p < 0.05; N = 8 
hM3Dq animals and 17 CTL animals. 
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4.3 Discussion 
 
 These studies showed that, while PCP-induced locomotion in mice is 
sensitive to D2 and 5-HT2A antagonism and to mGluR2/3 agonism, at the same drug 
doses CNO-induced locomotion in hM3Dq mice is only sensitive to D2 and mGluR2/3 
and not to 5-HT2A modulation. 
 The findings with LY379268 and haloperidol were expected, given the 
hypothesis that the hM3Dq receptor is highly expressed on apical dendrites of 
pyramidal neurons, many of which project to the VTA. These data suggest that in 
hM3Dq mice, CNO works, at least in part, by stimulating glutamate release from 
these pyramidal neurons. The probable glutamate efflux would subsequently 
stimulate the dopaminergic neurons of the VTA that project to the cortex and NAcc. 
Haloperidol blocks D2 receptors in these projection areas to prevent the behavioral 
effects that would otherwise stem from enhanced dopamine release. Thus, these 
data are consistent with the hypothesis that CNO-induced behavioral activation 
occurs through the corticostriatal pathway. 
 The finding that M100907 has no effect on CNO-induced locomotion at a 
dose that normalizes PCP-induced locomotion suggests that CNO and PCP have 
different downstream modes of action. It is known that PCP stimulates glutamate 
efflux, and the ability of LY379268 to antagonize CNO’s effects suggests that CNO 
also stimulates glutamate efflux. However, these glutamatergic effects are 
differentially sensitive to inhibition of pyramidal neuron firing through antagonism of 
the 5-HT2A receptor. 
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 Interestingly, Schmidt and Fadayel (Schmidt and Fadayel, 1996) found that 
M100907 inhibits the dopamine release evoked by MK-801 in the NAcc but not in 
the PFC, and Takahata and Moghaddam (Takahata and Moghaddam, 2003) 
demonstrated a functional disconnect between PCP-induced behavioral changes 
and PFC, VTA, and NAcc dopamine levels. Specifically, Takahata and Moghaddam 
found that the inhibition of AMPA receptors in the PFC blocks PCP-induced 
locomotion, stereotypy, and PFC dopamine release. However, blockade of AMPA 
receptors in the NAcc blocks the behavioral effects of PCP but not the increase in 
accumbal dopamine, and blockade of AMPA receptors in the VTA blocked the 
behavioral effects of PCP and the increase in dopamine levels in the PFC but not in 
the NAcc. Together, these data demonstrate that 1) the effects of PCP in the PFC 
and the NAcc are distinct and differentially dependent on glutamatergic 
neurotransmission and 2) PFC dopamine levels might correlate better with 
behavioral activation than NAcc dopamine levels. 
 These findings are consistent with PCP having both cortical and subcortical 
actions and acting through multiple pathways or mechanisms that are differentially 
sensitive to modulation by M100907. Indeed, a recent paper from the Roth 
laboratory demonstrated a requirement for subcortical presynaptic serotonergic input 
in the normalization of PCP’s psychotomimetic effects by clozapine and olanzapine 
(Yadav et al., 2010).  Moreover, abolishing that subcortical input diminished the 
antipsychotic efficacy of M100907 on PCP-induced disruption of prepulse inhibition, 
a model for the sensory-motor gating deficits that accompany psychosis. Given the 
well-characterized role of 5-HT2A antagonism in the therapeutic action of atypical 
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antipsychotics, it seems that 5-HT2A-mediated antipsychotic efficacy is dependent on 
subcortical serotonergic input. Given that CNO cannot directly modulate that 
subcortical serotonergic input, the effects of CNO are thus insensitive to modulation 
by M100907. 
 Whether the hM3Dq mice represent a novel cortically-based model of 
psychosis is unclear. While CNO has apparent “psychotomimetic” effects on activity 
in these mice, psychosis is generally associated with a hypoglutamatergic state that 
is mimicked by the NMDA receptor antagonist models, including PCP. However, as I 
mentioned in the section 4.1.1, psychosis has also been linked to a 
hyperglutamatergic state. In particular, the activity of excitatory neurons is closely 
regulated by inhibitory GABAergic neurons that express NMDA receptors and are 
acutely sensitive to PCP (Homayoun and Moghaddam, 2007). It has been 
suggested that schizophrenia stems in part from deficits in cortical inhibition (Benes 
and Berretta, 2001; Daskalakis et al., 2007). For example, the brains of psychotic 
patients have been shown to have fewer interneurons, to express lower levels of 
presynaptic interneuron markers (e.g., GAD67, GAT, parvalbumin) in the frontal 
cortex, and to express higher levels of GABA receptors on pyramidal neurons in the 
PFC and hippocampus (Coyle, 2004; Daskalakis et al., 2007). These post-mortem 
findings suggest that these patients had deficits in GABAergic neurotransmission 
Moreover, as I described in Chapter 3, CNO induces gamma rhythm in the 
hippocampus of hM3Dq mice, and Dr. Alexander has subsequently showed that 
cortical gamma rhythms also occur following CNO administration (unpublished 
observations). This gamma rhythm stems from activity of GABAergic interneurons. 
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Schizophrenic patients have lower activity in the gamma range than normal patients, 
and the magnitude of that deficit correlates with symptom severity (Spencer et al., 
2003; Uhlhaas and Singer, 2010). These data, along with the post-mortem findings 
regarding the GABAergic system, suggest that inducing gamma rhythm should have 
antipsychotic effects. Therefore, the findings of prolonged enhanced gamma rhythm 
and behavioral activation in hM3Dq mice after CNO administration are incongruent. 
To further evaluate the hM3Dq mice as a tool for investigating the 
neurocircuitry of psychosis and locomotion, additional studies correlating CNO 
administration with dopamine release would be beneficial. Experiments are 
underway now to measure CNO-induced dopamine release by cyclic voltammetry, 
and hopefully these studies, along with further behavioral investigation, with better 
define the exact mechanism of CNO-induced hyperlocomotion. 
 
CHAPTER 5: CONCLUSIONS, CLINICAL APPLICATIONS, AND FUTURE 
DIRECTIONS 
 
*Portions of this chapter are adapted from Rogan and Roth, 2011. 
 
This thesis has provided in vivo validation of a novel approach to 
experimentally manipulating neuronal signaling. In Chapter 1, I discussed the value 
of tools enabling such experimental manipulation with high spatiotemporal 
resolution. I described the most widely used chemical and genetic approaches to 
achieving spatiotemporal control (i.e., Tet-on/off systems, viral gene transduction, 
caged ligands) and how existing technology incorporates those approaches. The 
other techniques rely on light, small molecules, peptides, toxins, and other 
compounds to alter neuronal activity at the levels of neurotransmitter release, 
membrane potential and electrical excitability, post-synaptic receptors, and second 
messenger pathways. Then, I discussed the development – through directed 
molecular evolution in yeast – of the DREADD system. This system has many 
advantages and disadvantages with respect to other techniques for remote control of 
neuronal activity, some of which were evaluated in Chapters 1 and 3; others are 
described below. In Chapter 3, I demonstrated that the hM3Dq receptor expresses 
and functions in transgenic mouse brains, and its activation effects dose-dependent 
behavioral and electrophysiological changes. Finally, in Chapter 4, I compared the 
behavioral (i.e., locomotor) activation that CNO induces in these mice to the PCP 
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model of psychosis and used the drugs haloperidol, M100907, and LY379268 to 
dissect the circuitry involved in the psychotomimetic actions of CNO and PCP. In 
particular, the studies in Chapter 4 demonstrate the utility of DREADD technology for 
biomedical research. In this chapter, I will describe some of the remaining 
uncertainties regarding hM3Dq function; I will broaden my focus and present recent 
data validating hM4Di and rM3/β1Ds in vivo; I will further discuss DREADD 
technology in the context of other tools for experimental manipulation of neuronal 
signaling; and I will elaborate on the basic science, translational, and clinical 
applications of such tools. 
 
5.1 Unanswered questions regarding hM3Dq function 
 
 While this thesis has described and validated many aspects of CNO-mediated 
behavioral, electrophysiological, and biochemical effects, some characteristics of 
CNO-hM3Dq signaling are still uncharacterized, namely, the specificity and diversity 
of coupling in vivo; G protein-independent signaling; and receptor desensitization, 
internalization, and down-regulation. 
 
5.1.1 Coupling of hM3Dq to diverse G protein-dependent signaling cascades 
The extent to which CNO’s effects in vivo depend on particular G protein 
intracellular signaling components is unclear. Armbruster et al. (Armbruster et al., 
2007) demonstrated that hM3Dq selectively activates canonical Gq signaling 
pathways (e.g., Ca2+ release, PIP2 hydrolysis, ERK1/2 activation, but not cAMP 
synthesis) in hPASMCs, and in Chapter 3, I present data consistent with Gq-
mediated release of intracellular Ca2+ in cultured neurons and activation of PLC in 
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transgenic mouse brain slices. However, the data in vivo do not exclude interactions 
between hM3Dq and other Gα subunits (e.g., Gα12/13), and there is no data, either in 
vivo or in vitro, on the ability of hM3Dq to modulate the activity of PLC isozymes 
other than β, to stimulate signaling through Gβγ, or to activate other G protein 
effectors. For example, Gαq can activate the Rho family of small G proteins thru 
interactions with RhoGEFs, including leukemia-activated Rho GEF (LARG) (Booden 
et al., 2002; Vogt et al., 2003) and p63RhoGEF (Lutz et al., 2005; Lutz et al., 2007; 
Rojas et al., 2007; Shankaranarayanan et al., 2010), but whether CNO triggers this 
interaction has not been investigated. If hM3Dq were to activate Rho or other small 
G proteins, CNO could alter membrane dynamics, cytoskeletal structure, and cell 
migration. It would be intriguing to investigate these possibilities in the setting of 
neurodevelopment and neuronal migration. 
 
5.1.2 Receptor desensitization, internalization, and downregulation 
 As described in Chapter 1 (section 1.4.1), signaling through GPCRs is 
regulated at several levels. The pathways for desensitization, internalization, 
resensitization, and/or downregulation of the wild-type M3 receptor are well 
described. The WT receptor is phosphorylated by GRKs, particularly GRK2, and 
undergoes arrestin-, dynamin-, and clathrin-dependent endocytosis (Vogler et al., 
1999; van Koppen, 2001; van Koppen and Kaiser, 2003; Popova and Rasenick, 
2004; Luo et al., 2008). The extent to which hM3Dq mimics the WT receptor is 
unknown. Presumably, as the two mutations in hM3Dq are in the binding pocket and 
not in the intracellular portions of the receptor, they should not alter the ability of 
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GRKs or other kinases to phosphorylate and regulate the receptor, nor should they 
affect interactions between the receptor and arrestins or other scaffolding molecules. 
Yet, if the mutations enable hM3Dq to assume a novel conformation in the presence 
of ligand (i.e., CNO), physical interactions with other proteins could be affected, 
resulting in altered regulation of hM3Dq expression and trafficking. The possibility 
should be investigated to fully define the similarities and differences between the WT 
and mutant M3 receptors. 
 
5.1.3 G protein-independent signaling 
Another aspect of hM3Dq function that remains undefined is its ability to 
signal via G protein-independent mechanisms (i.e., β-arrestin) (Luttrell and Gesty-
Palmer, 2010). For example, CNO increases levels of pERK1/2 in hM3Dq-
expressing cells (Armbruster et al., 2007), but whether ERK1/2 activation is 
mediated entirely by Gαq-dependent signaling, or whether arrestinergic signaling 
also contributes to that activation, is unclear. A discussion of the implications of 
DREADD signaling through G protein-independent mechanisms is presented below 
in section 5.6.1. 
 
5.2 Validation of Gi- and Gs-coupled DREADDs in vivo 
 
 Chapter 3 presented validation of hM3Dq in vivo, and, in the last few years, 
the first reports have been published describing the successful use of hM4Di and 
rM3/β1Ds in vivo to provide remote control of neuronal signaling through Gi and Gs 
proteins. Ferguson et al. (Ferguson et al., 2010) demonstrated the ability of hM4Di to 
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inhibit neuronal activity in vivo. The function of rM3/β1Ds in vivo was validated by 
Guettier et al. (Guettier et al., 2009) in the pancreas, and a fellow graduate student 
in the Roth laboratory, Martilias Farrell, has validated rM3/β1Ds function in the brain 
in vivo (unpublished data). This progress in the DREADD field greatly expands the 
clinical and translational applications of the technology. 
 
5.2.1. In vivo validation of hM4Di 
 Recently, Dr. John Neumaier’s group validated hM4Di function in vivo. 
Ferguson et al. (Ferguson et al., 2010) performed several proof-of-concept studies. 
First, in acute slices from rats infected with virus transducing hM4Di, application of 
CNO decreased striatal neuron excitability. Specifically, CNO mediated potassium 
conductance to hyperpolarize striatal neurons and decrease input resistance. 
Importantly, no change in input resistance occurred in the absence of CNO; no basal 
effect of hM4Di expression was evident. Second, administration of CNO to rats 
expressing hM4Di in the ventral tegmental area blocked the dopamine release that 
normally follows a food reward. Third, Ferguson et al. demonstrated inhibition with 
CNO of amphetamine-induced c-fos expression. Together, these studies validate the 
function of virally transduced hM4Di for neuronal silencing in vivo. 
Next, Ferguson et al. applied DREADD technology to the investigation of the 
neurobiological activity that contributes to addiction. Using viral constructs with 
promoters specific for the direct and indirect striatal pathways, they expressed 
hM4Di in rat brains and determined the effects of CNO on behavioral sensitization to 
amphetamine. They determined that hM4Di-mediated silencing of direct and indirect 
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pathway neurons inhibited and facilitated behavioral sensitization, respectively. 
These data demonstrate the utility of DREADDs for delineating the cellular 
populations that mediate particular aspects of addiction and reward. 
 
5.2.2 In vivo validation of rM3/β1Ds 
Guettier et al. (Guettier et al., 2009) generated transgenic mice expressing 
either hM3Dq or rM3/β1Ds selectively in pancreatic β-cells. While β-cell-hM3Dq mice 
had no basal differences in blood glucose or insulin levels, β-cell-rM3/β1Ds mice had 
mildly reduced basal blood glucose levels, suggesting some degree of constitutive 
signaling by the latter receptor. Upon CNO administration to the two groups of mice, 
dose-dependent hypoglycemic effects (increased insulin release and reduced blood 
glucose) were observed, with peak responses occurring approximately 2 h after 
injection. Chronic treatment with CNO increased β-cell number and size in β-cell-
hM3Dq mice, whereas β-cell-rM3/β1Ds mice had increased basal β-cell mass. 
Finally, Guettier et al. isolated islets from the two mouse lines and maintained them 
in culture in the presence of CNO and glucose and showed CNO-dependent 
changes in expression of genes involved in metabolic pathways. These data 
demonstrate that, while rM3/β1Ds might have some constitutive activity when 
expressed in the pancreas, it can still be selectively activated with CNO and can 
induce physiological changes. 
Currently, no published data on rM3/β1Ds expression in the brain exists, 
although the Roth laboratory has verified the system in vivo, showing that 
expression and activation of rM3/β1Ds in the indirect striatal pathway is sufficient to 
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block sensitization to cocaine (Farrell and Roth, unpublished data). In combination 
with the approach that Ferguson et al. used, it is now possible to bidirectionally 
modulate particular cell populations implicated in reward, sensitization, and addiction 
and to deconstruct the underlying neurocircuitry. 
 
5.3 Advantages and disadvantages of diverse techniques for remote control of 
neuronal signaling 
 
 Although I have already discussed some of the advantages and 
disadvantages of the various techniques for experimental manipulation of neuronal 
signaling, here I will broaden the discussion to include all the DREADDs (as 
opposed to just hM3Dq) and will compare the techniques to each other. 
 
5.3.1 Designer G protein-coupled receptors 
The RASSLs and DREADDs, unlike most of the other techniques for remote 
control of neuronal activity, directly target G protein signaling pathways and are likely 
to have extraordinarily diverse effects. These effects range from altering membrane 
excitability (e.g., Gi activation of GIRK, Gq activation of PIP2-gated KCNQ channels) 
to inducing gene expression (e.g., Gq induction of c-fos expression). On the one 
hand, such a broad spectrum of effects sometimes obscures the precise 
mechanisms underlying altered neuronal activity. On the other hand, most of the 
intracellular signaling pathways are well defined, and the induction of such varied 
effects increases the versatility of these tools. 
Direct, non-invasive remote control of GPCR activity is particularly important 
for translational applications. The majority of FDA-approved drugs act through 
 172 
GPCRs, and most prescribed drugs are available as oral formulations. As many of 
these techniques for controlling neuronal signaling have as a long-term goal clinical 
use in humans, in general designer GPCRs are perhaps the most feasible as 
therapeutics (except for certain treatments such as DBS). 
With regard to additional DREADD ligands, one disadvantage of second-
generation designer GPCRs is that, thus far, CNO is their only agonist. Therefore, 
one cannot express multiple DREADDs (e.g., hM3Dq and hM4Di) in the same cell or 
animal to bi-directionally modulate the same pathways, as is possible with 
optogenetics. On the other hand, first-generation designer receptors are based on 
multiple native receptors, so different ligands activate the receptors, thus the same 
mouse could express, for example, Rs1 and Ro1 in the same cell populations. 
Hopefully, other DREADDs that respond to novel ligands will soon be available to 
allow such bi-directional modulation within the same animal. 
Another problematic aspect of DREADDs is that, while in mice CNO is an 
ideal ligand – it is orally bioavailable, blood-brain barrier-permeable, and does not 
undergo back-metabolism to clozapine, which activates more than 50 neuronal 
targets – back-metabolism in humans is significant and would prevent the transfer of 
DREADD technology to humans. Therefore, a non-metabolized CNO derivative or a 
novel DREADD ligand is required before DREADDs can move into higher-order 
animals for pre-clinical testing. Alternatively, CNO analogs with altered 
pharmacokinetics (i.e., biodistribution) might permit the translation of DREADD 
technology to human therapeutics. 
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Finally, and probably the biggest drawback of designer GPCRs, particularly in 
comparison with opsins, is the time resolution they afford. Designer GPCRs activate 
over the course of tens of minutes. Many of the ligands are orally bioavailable and 
can penetrate the blood-brain barrier, thus their use enables non-invasive remote 
control of neuronal signaling. Some users have directly infused the ligands into the 
brain, thereby reducing the time required to activate the receptors and further 
increasing the spatial resolution of the technology, but the time resolution still does 
not approach that of the opsins. One method of improving the time resolution of 
CNO, for example, would be to develop a photo-activateable CNO derivative (PA-
CNO). The Roth laboratory has recently developed such a compound, and we are 
currently testing it in vitro. Ideally, one will soon be able to treat a live animal with 
PA-CNO, allow enough time for absorption and distribution, and then use focal light 
to activate CNO in particular brain regions. This approach would increase both the 
time and spatial resolution of designer GPCR technology. However, PA-CNO would 
no longer provide a non-invasive or non-technical method of controlling neuronal 
signaling because an invasive approach would be necessary to introduce the light 
stimulus necessary to activate the PA-CNO. 
On the one hand, GPCRs will never permit the time resolution of opsins. On 
the other hand, they might not need to. Signaling through GPCRs is notably slower 
than that through ion channels but is no less important for normal cellular function. 
While ion channels serve to rapidly transmit encoded information, GPCRs serve to 
amplify and diversify that transmission. Therefore, these two tools truly are 
complementary and equally valuable. Moreover, as previously mentioned, most 
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approved drugs act through GPCRs, so, clearly, altering cellular function over a 
longer period can be therapeutic. 
 
5.3.2 Opsins 
The numerous advantages of optogenetics are evident from the plethora of in 
vivo studies already reported in multiple species (see Table 1.2). Optogenetics, 
more than any other technology described in this thesis, enables ultrafast, 
millisecond timescale dissection of neural circuitry. Only optical approaches can 
replicate the kind of endogenous oscillatory activity seen in neurons. While this 
ability is paramount for high frequency DBS to alleviate PD symptoms (Gradinaru et 
al., 2009), whether such a high degree of temporal control is necessary for other 
applications is unclear. Certainly, some endogenous substances (e.g., hormones) 
travel a significant distance from their site of synthesis and release to their site of 
action where they alter transcription. Extreme temporal precision with regard to such 
pathways is likely unnecessary. 
Another advantage of the optical approaches is that they act via a simple 
mechanism: opening of a channel or pump to allow ion flow. In contrast to GPCRs, 
which directly activate Gα, Gβγ, and β-arrestin, each with their own downstream 
effectors, altering ion flow and therefore membrane potential is the only direct action 
of opsins. This well-defined mechanism of action simplifies data interpretation and 
analysis. Some intracellular signaling pathways are accessible through vertebrate 
rhodopsin, melanopsin (Lin et al., 2008), and the optoXRs, but these approaches are 
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unlikely to enable investigations into biased agonism or other forms of functional 
selectivity. 
Finally, the optogenetic approach is the most specific. In mammals, the only 
light-sensitive endogenous receptors are in the retina, so photostimulation generally 
induces only opsin-mediated effects. Moreover, while light scatters as it penetrates 
tissue, there are not the pharmacokinetic concerns (e.g., bioavailability, tissue 
distribution, metabolism, etc.) with light as a ligand that there are with CNO and 
other metabolized compounds. Additionally, some of the newer technical 
developments enable illumination of individual neuronal compartments (e.g., 
dendrites), providing an incredible degree of spatial resolution. With 
DREADDs/RASSLs, such spatial resolution is only possible through photo-caging of 
ligands or through targeting of receptor expression to those subcompartments. 
Photostimulation presents a few challenges, particularly in conjunction with 
recording of electrical activity. First, light that is too strong or is applied for too long 
can cause tissue damage, abnormal neuronal activity, and excitotoxicity (Cardin et 
al., 2010). One can minimize these effects by using lower light intensity or shorter 
pulses instead of continuous illumination, but between the light scatter and 
minimizing the light intensity, it might be difficult to sufficiently target deep brain 
structures without using a stereotaxic approach to photostimulation. Additionally, 
while high levels of opsin expression are sometimes necessary to generate sufficient 
current, trafficking signals and other modifications have improved surface expression 
and even maximal current flow. Finally, electrical artifacts are common sequelae of 
the light source illuminating metal recording electrodes. In a recent protocol paper, 
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Cardin et al. (Cardin et al., 2010) describe several approaches to minimizing such 
artifacts, including using opaque glass electrodes, minimizing exposed metal, and 
using thin wire stereotrodes adjusted so that minimal light directly reaches them. 
 
5.4 Biomedical and clinical applications of technology for remote control of 
neuronal signaling 
 
 The tools for remote control of neuronal signaling that this thesis describes 
and validates have infinite applications. In particular, I have focused on hM3Dq and 
shown its usefulness for scientific investigation [e.g., into the cellular and molecular 
basis of epilepsy (see Chapter 3) or the neural pathways responsible for drug-
induced psychosis (see Chapter 4)]. In this section, I will discuss some of the 
broader applications of DREADDs in general. Designer receptors and opsins have 
many potential clinical or therapeutic applications. Some of the applications of 
opsins were discussed in Chapter 1 (section 1.3.5). Promising applications of 
DREADDs are evident through two recent studies. 
 
5.4.1 Using Designer Receptors to treat diabetes and obesity 
In the work by Guettier et al., rM3/β1Ds and hM3Dq were expressed in 
pancreatic β-islet cells, where activation of the receptors stimulated insulin release 
and lowered blood glucose following CNO administration, as described above. But 
the authors went a step further: they placed β-cell-rM3/β1Ds or β-cell-hM3Dq mice 
on high fat (35%) diets. Over 12 weeks, mice gained weight, experienced three- to 
five-fold increases in plasma insulin, and developed insulin resistance and glucose 
intolerance – all abnormalities that develop in obese humans with metabolic 
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syndrome. Notably, when these mice received CNO along with glucose in a glucose 
tolerance test, glucose tolerance improved in accord with augmented insulin release 
(18-fold in β-cell-hM3Dq mice following 1 mg/kg CNO). This result is remarkable, as 
it demonstrates in a model of human disease that acute activation of DREADDs can 
have immediate therapeutic effects. As diabetes – a condition in which the pancreas’ 
ability to produce insulin is compromised and blood glucose reaches dangerously 
high levels – is a prevalent and severe human disease, one can envision a scenario 
in which diabetic patients receive gene therapy to express a DREADD receptor in 
their dysfunctional pancreatic cells, and then they take a daily pill to activate that 
receptor and stimulate insulin production and release, thereby improving insulin 
sensitivity and glucose tolerance. This particular study of DREADDs demonstrates 
perfectly their clinical potential. 
 
5.5. Using DREADDs to control feeding behavior 
 
A recent report of hM4Di and hM3Dq function came from Dr. Lowell’s group 
(Krashes et al., 2011). Krashes et al. used cre-inducible AAV constructs (see Figure 
1.1) encoding hM3Dq- or hM4Di-mCherry fusion proteins. They infused virus into the 
arcuate nucleus of the hypothalamus of mice expressing Cre under the promoter for 
agouti-related protein (AgRP). Neurons expressing AgRP are known to contribute to 
energy homeostasis, but their exact role in feeding behavior is unclear. In acute 
brain slices, Krashes et al. found that CNO depolarized and increased the firing rate 
of AgRP neurons that expressed hM3Dq, thereby providing independent 
confirmation of this effect of hM3Dq. In vivo, CNO increased c-fos expression in the 
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arcuate nucleus, suggesting increases in neuronal activity. Moreover intraperitoneal 
administration of CNO (0.3 mg/kg) increased feeding behavior in ad libitum fed mice 
and decreased energy expenditure for 8 h. In contrast, in mice expressing hM4Di in 
AgRP neurons, CNO hyperpolarized and decreased the firing rate of the AgRP 
neurons and reduced food intake. 
Twice-daily injections of CNO caused an increase in body weight and body fat 
in hM3Dq-expressing animals; withdrawal of CNO resulted in “compensatory” 
hypophagia and a reversal of the obesity phenotype. Importantly, CNO activation of 
hM3Dq also increased the motivation of ad libitum fed mice to work for a food 
reward, mimicking the effect of food deprivation. Indeed, when food was removed at 
the time of administration of CNO, hM3Dq-expressing mice spent hours engaging in 
food-seeking behavior; the mice did not exhibit such activity when food was present. 
Together, these findings demonstrate that AgRP neurons are necessary and 
sufficient for normal feeding and food-seeking behavior. Moreover, this study 
provides a nice example of the translational potential of DREADDs. Such studies 
should help identify the exact cell populations that obesity medications should target, 
and perhaps DREADDs might someday provide a route through which the activity of 
crucial neuronal populations can be remotely modulated for therapeutic benefit. 
 Together, these two studies show how we can use DREADDs both to better 
understand the neurobiological networks underlying obesity and the motivation to 
feed; the role of particular G protein pathways in regulating that drive; the effect on 
plasma insulin and blood glucose levels of directly stimulating pancreatic islets; and 
how activating particular cells in both the hypothalamus and the pancreas modulates 
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metabolic consequences of obesity. Thus, we can use DREADDs for both scientific 
investigation and, eventually, for human therapy. Together, research endeavors 
such as those I have just described will improve the understanding of disease 
processes, identify novel therapeutic targets, and provide new avenues of treatment. 
 
5.6 Future directions 
 
 In addition to specific future directions to more fully define the molecular and 
biochemical properties of hM3Dq signaling, particularly in relation to the native M3 
receptor (see section 5.1), I will discuss future directions for general research in the 
field of experimental manipulation of neuronal signaling. 
 
5.6.1 Functionally selective designer ligands and receptors 
As researchers gain an understanding of the importance of β-arrestinergic 
signaling, functional selectivity becomes particularly relevant (Urban et al., 2007). 
Functional selectivity refers to both the ability of a ligand, acting at a given receptor, 
to preferentially activate different intracellular signal transduction pathways (biased 
agonism) and, more broadly, the ability of a ligand, acting at a given receptor, to 
have different effects depending on the cell type and available intracellular signaling 
machinery. As an example, both Claysen et al. and Chang et al. (Chang et al., 1998; 
Claeysen et al., 2003) described functional selectivity of 5-HT4D100A receptor ligands. 
The former reported that ligands could be antagonists at the wild-type 5-HT4 
receptor but agonists at the D100A receptor, while the latter group reported that 
various ligands could direct coupling to only Gs or to Gs and Gq signaling pathways.  
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Indeed, designer GPCRs provide an ideal method of investigating such 
differential signaling. First, we can express them in distinct tissues or cell types to 
determine how activating the same G protein can have different effects, depending 
on its signaling partners. For example, we hypothesized that the underlying 
mechanism of CNO-induced seizures in mice expressing hM3Dq in the 
hippocampus is reduced stability of the membrane potential due to activation of the 
Gq-PLCβ-PIP2 hydrolysis pathway and subsequent closing of PIP2-gated KCNQ 
outwardly-rectifying potassium channels (Alexander et al., 2009). In other neuronal 
populations or even subcellular compartments that do not express KCNQ channels, 
however, activation of the same Gq-PLCβ-PIP2 hydrolysis pathway might effect 
different alterations in neuronal function. Thus, we should continue to express these 
receptors in diverse cell types in order to determine the differential roles of G 
protein-mediated signaling. 
 Furthermore, native GPCRs express in distinct subcellular compartments, 
and their downstream effects depend on local signaling machinery and scaffolds. 
The postsynaptic density is a nice example of a subcellular compartment that 
mediates signaling of postsynaptic receptors. Using trafficking signals and signal 
peptides, similar to those already in use for optogenetics (Gradinaru et al., 2007; 
Gradinaru et al., 2010), we are currently targeting DREADDs to specific cellular 
compartments to modulate different intracellular pathways and to improve our ability 
to study functional selectivity (Dong et al., 2010a). Developing such tools would 
greatly further our ability to remotely activate neuronal signaling. 
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Returning to β-arrestinergic signaling, we do not know the extent to which 
mutant GPCRs mimic the signaling properties of their wild-type templates. With 
regard to rM3/β1Ds in particular, it would be interesting to know the extent to which it 
signals through β-arrestin, as the β-arrestinergic signaling properties of the β-
adrenergic receptors are so well defined, and the intracellular loops of rM3/β1Ds are 
those of the β1-AR. Work is underway in Dr. Roth’s laboratory to answer this 
question. Then, it would be useful to develop CNO analogs or additional DREADD 
ligands that exhibit a range of efficacies for both G protein-dependent and -
independent signaling. Additionally, we can generate DREADDs with mutations or 
deletions of their intracellular loops that affect their ability to signal via these two 
mechanisms. Such avenues of research are particularly important given a recent 
report that the clinical efficacy of antipsychotic drug action might depend on G 
protein-independent signaling and that ligands that show a bias toward β-
arrestinergic signaling might have high potential as antipsychotic treatments (Masri 
et al., 2008). 
 
5.6.2 Combining designer receptors with optogenetics 
 As yet, no one has published data combining optical and GPCR-based 
approaches to remote control of neuronal signaling (although Dr. Scott Sternson’s 
group at the Howard Hughes Medical Institute has informally reported such data). 
Such combinations of approaches would answer some of the questions about 
whether the precise timing and pattern of electrical activity or the intracellular 
second-messenger pathways are more important in certain contexts. The role of 
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gamma rhythm in cortical inhibition and psychosis presents a nice example of how 
these techniques can work together, as both hM3Dq and ChR2 can stimulate 
gamma rhythm (Alexander et al., 2009; Cardin et al., 2009; Sohal et al., 2009). It 
would be interesting to use the viral self-cleaving 2A peptide sequence to equally 
express both hM3Dq and ChR2 or hM4Di and eNpHR under the parvalbumin or 
CaMKIIα promoters and to compare the effects of electrical versus pharmacological 
stimulation and inhibition of each cell type. Then, one could induce gamma rhythm 
electrically and pharmacologically in a mouse model of psychosis (e.g., 
phencyclidine-induced hyperlocomotion) and determine the direct effects of 
induction or inhibition of gamma rhythm on psychotic behaviors and whether the two 
types of stimulation have differential effects on those behaviors. In this way, one 
could truly identify different signaling components that are necessary and/or 
sufficient for generating gamma rhythm and improving psychotic symptoms. 
 The TRPV1 approach provides another opportunity for combining two 
techniques. Early papers used photocaged capsaicin to provide high spatiotemporal 
resolution (Zemelman et al., 2003; Lima and Miesenbock, 2005), while several years 
later, Arenkiel et al. (Arenkiel et al., 2008) elicited stereotypies by uncaging 
capsaicin. The stereotypies occurred within 5 to 15 min after capsaicin infusion. 
Using caged capsaicin in vivo would improve the temporal precision of this 
approach. Local infusion of capsaicin is already invasive and technically more 
demanding than peripheral drug administration, so adding photostimulation to the 
experimental design should not be prohibitively challenging. 
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5.7 Final remarks 
 
 Techniques for experimental manipulation of neuronal signaling have 
improved phenomenally in the last decade, and we now have the ability to directly 
alter neuronal activity via several different mechanisms. Other fields are taking 
similar approaches to remotely modifying particular intracellular activities such as 
calcium channel activity [via a MIST-like dimerization approach; see Chapter 1 
(Yang et al., 2007)], kinase activity, and others. In short time, researchers might be 
able to remotely control the level and/or direction of activity of many cellular proteins 
and functions. A DREADD-like receptor tyrosine kinase or a chimera of an opsin and 
a receptor tyrosine kinase would be a nice addition to the receptor toolbox. 
 This thesis has described the clinical and translational potential of these 
techniques. The therapeutic applications of DREADDs are evident in the pancreatic 
studies from Guettier et al. (Guettier et al., 2009). For optogenetics in particular, the 
retina is well suited to clinical applications because the vitreous humor is easily 
accessible for viral injections, and viral gene therapy for blindness has already 
shown success in clinical trials. The main obstacle to translation of any of these 
techniques to human therapy, however, remains the ability to safely, reliably, and 
stably express an exogenous protein in human tissue. Until such gene therapy is 
routine, it will be difficult to fully realize the potential of these techniques. 
Nonetheless, DREADDs, RASSLs, opsins, and other tools currently provide 
excellent approaches to improving our understanding of the biological basis of 
behavior. While each of these approaches has its advantages and disadvantages, 
the techniques are largely complementary. Ideally, researchers will soon begin to 
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combine multiple approaches to modulate signaling to determine the interplay 
between the targeted pathways and networks. 
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